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Abstract 
 
Lantibiotics are post-translationally modified antimicrobial peptides and are 
synthesised by a number of Gram-positive bacteria.  Lantibiotics are defined by the 
inclusion of lanthionine residues and often contain other modified amino acids within 
their structures.  Actagardine, produced by Actinoplanes garbadinensis, was 
originally discovered in 1976 and identified as a potential clinically useful antibiotic.  
In recent years, discovery of an actagardine homolog, deoxyactagardine B, 
produced by Actinoplanes liguriae has prompted further investigation into the 
biosynthesis of these lantibiotics. 
 
The biosynthetic gene clusters for actagardine and deoxyactagardine B 
biosynthesis were identified by Novacta Biosystems from cosmid libraries of the 
natural producers.  Heterologous expression of these cosmids in various 
Streptomyces hosts has confirmed that they contained all the genes required for the 
biosynthesis of these lantibiotics.  An in-depth computational analysis of the cosmid 
has allowed the identification of a number of lantibiotic-associated biosynthesis 
genes, including the unique lantibiotic monooxygenase GarO, responsible for the 
oxygen moiety on the C-terminal methylanthionine bridge of actagardine.  Using this 
information, a directed reduction in the cosmid size identified a likely set of genes 
that are essential for the biosynthesis of actagardine. 
 
With these data, a deletion series of all the putative lantibiotic biosynthesis genes 
within the actagardine gene cluster demonstrated that a number of these genes 
were essential for its biosynthesis.  It also demonstrated that the Streptomyces 
hosts are apparently able to compensate for the loss of a number of genes.  
 
Computational analysis identified the actagardine homologs michiganin A and 
gnavucin, an undiscovered lantibiotic prepropeptide.  Whilst the structural peptides 
of these four lantibiotics are very similar; they are encoded by very different putative 
biosynthetic gene clusters, requiring further investigations for an understanding of 
their biosynthesis. 
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1 Introduction 
 
The discovery of penicillin in 1928 by Alexander Fleming sparked a continuing battle 
between human infections and man‟s ability to fight them.  The identification, 
industrial scale production and wide-spread use of a variety of antibiotics have 
inevitably led to the evolution of drug-resistant pathogens.  Unfortunately, there is 
now no antibiotic in clinical use to which resistance has not developed (Weigel et 
al., 2003), and while frequently hailed as the “drug of last resort”, vancomycin is now 
ineffective against many enterococcal infections that are also resistant to other 
clinically used antibiotics.  Consequently there is a pressing need for new 
antimicrobial agents to fight infectious diseases.  Lantibiotics have the potential to 
reinforce our ability to combat bacterial infections. 
 
Lantibiotics are post-translationally modified, ribosomally synthesised antimicrobial 
peptides produced by Gram-positive bacteria and are effective against a wide 
variety of bacteria.  The term lantibiotic was first introduced in 1988 to describe 
these lanthionine (and/or methyl-lanthionine)-containing antibiotics (Schnell et al., 
1988).  The amino acid lanthionine, created from a thioether cross-link between the 
β-carbons of two alanine residues, was first isolated from sodium carbonate treated 
wool in 1941 (Horn et al., 1941).  The lanthionine and methyl-lanthionine bridges 
found in lantibiotics arise from 2,3-didehydroalanine (Dha) and (Z)-2,3-
didehydrobutyrine (Dhb), which are formed by the enzymatic dehydration of serine 
and threonine residues, respectively.  The dehydrated amino acids are then 
subjected to nucleophilic attack by SH (thiol) groups of cysteine residues located 
elsewhere in the peptide to form the characteristic lanthionine and methyl-
lanthionine ring structures (see figure 1.1) (Sahl & Bierbaum, 1998).  As well as 
these residues, lantibiotics may also contain other unusual modified amino acids 
and modifications such as lysinoalanine, S-aminovinyl-D-cysteine, ß-hydroxy-
aspartate, D-alanine, 2-oxobutyrate, 2-oxopropionate (pyruvate), 2-
hydroxypropionate (lactate), and S-aminovinyl D-methylcysteine (Chatterjee et al., 
2005).  Some of the more common post-translational modifications and 
representative lantibiotic structures found in lantibiotics are shown in figure 1.1 and 
1.2. 
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Figure 1.1:  Common lantibiotic structural motifs produced from post-translational 
modification of amino acids via lantibiotic biosynthetic enzymes.  The coloured 
pictograms are used henceforth to represent the individual modifications in 
lantibiotic structures.  Structures taken from Patton and van der Donk (2005). 
 
Figure 1.2:  Representative structures of various lantibiotics.  The common 
structural motifs and other post-translational modifications are shown in more detail 
in figure 1.1 and are represented in the same colours in the structures above.  Many 
of these structures are discussed in the subsequent text.  Figure taken from Patton 
and van der Donk (2005). 
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The unusual modifications found in lantibiotics result from the unique modification 
enzymes encoded by their respective biosynthetic gene clusters.  Lantibiotic 
biosynthetic gene clusters can be found on conjugative transposable elements 
(nisin), on the chromosome of the host (subtilin) and on plasmids (epidermin and 
lacticin 481) (Chatterjee et al., 2005).  Genes within many lantibiotic clusters are 
arranged in operons, consisting of several transcriptional units, often with a weak 
terminator structure, usually a stem-loop, in the intergenic sequence between the 
structural gene that encodes the unmodified peptide and downstream genes 
encoding the modification enzymes (McAuliffe et al., 2001).  This can be seen in 
figure 1.3 that shows a number of representative biosynthetic gene clusters. 
 
 
Figure 1.3:  The biosynthetic gene clusters of nisin, subtilin, epidermin, Pep5, 
lacticin 481, lacticin S, cinnamycin, mersacidin and lacticin 3147.  In blue are genes 
that encode functions that are common to all lantibiotic gene clusters.  The red bars 
indicate promoters for known transcriptional units.  Individual genes are discussed 
in the text below.  Figure taken from Chatterjee, Paul et al. (2005). 
17 
 
Lantibiotic biosynthetic genes have been given the generic locus symbol lan, which 
is replaced by the specific name for each lantibiotic (e.g. nis for nisin) (Patton & van 
der Donk, 2005).  The lanA gene encodes the lantibiotic precursor prepropeptide, 
LanA.  The LanA prepropeptide contains a C-terminal region, the propeptide, that 
contains the unmodified structural region which will undergo post translational 
modification by either the LanBC or LanM modification machinery and become the 
mature lantibiotic.  The LanA prepropeptide also contains the relatively long (23 to 
59 amino acids) N-terminal leader sequence (“pre”) which does not undergo 
modification and which is eventually cleaved away from the mature lantibiotic.  The 
leader sequences is thought to be responsible for substrate recognition by the 
various biosynthetic enzymes and may be involved in sequestration of the lantibiotic 
before it is exported from the cell (Patton & van der Donk, 2005, Chatterjee et al., 
2005).  It is interesting to note that while both serine and threonine residues are 
found in propeptide and leader sequences, cysteine residues are found only in 
propeptide sequences. 
 
Lantibiotics were classified as group I bacteriocins by Klaenhammer (1993) but the 
activity of many lantibiotics is much wider than that usually associated with 
bacteriocins, which generally inhibit only closely related bacteria (Klaenhammer, 
1993).  Lantibiotics can be classified based on the structure of the mature lantibiotic, 
and/or by the genes that are present within their respective cluster.  Type A 
lantibiotics are characteristically described as elongated, cationic peptides that can 
also be amphipathic and screw shaped in solution.  Type A lantibiotics are usually 
between 20 and 34 amino acids in length (Chatterjee et al., 2005, Patton & van der 
Donk, 2005).  Type AI lantibiotics have the modification enzymes LanB and LanC 
(see later for a detailed description) as two distinct enzymes, whereas the Type AII 
and B lantibiotics contain a single bifunctional LanM type modification enzyme.  
Type B lantibiotics differ from the type A class by being globular in shape, and 
generally have no net charge, or a negative charge at pH 7, and have a single LanM 
modification enzyme (Chatterjee et al., 2005).  Actagardine, the subject of this 
thesis, belongs to this group of lantibiotics.  The most studied lantibiotic to date is 
the Type AI lantibiotic nisin, produced by Lactococcus lactis.  Nisin was first 
discovered in 1928 and has been used extensively in the food industry as a 
preservative for nearly 40 years, with little development of resistance in susceptible 
organisms (Delves-Broughton et al., 1996, Rogers, 1928, Rogers & Whittier, 1928). 
18 
 
1.1 Lantibiotic Biosynthesis 
 
The biosynthesis of a particular lantibiotic is determined by the genes present in its 
corresponding gene cluster.  The gene clusters encode all of the necessary 
components to produce a fully modified, functional peptide, and the ability to resist 
the effects of the lantibiotic after it has been exported.  The gene clusters must 
include genes for the lantibiotic precursor, for the dehydration and cross-linking 
reactions, and for secretion of the modified peptide (figure 1.4) (McAuliffe et al., 
2001). 
 
1.1.1 Leader Sequence 
 
The leader sequence present at the N-terminus of the prepropeptide has many 
proposed functions, including signalling for transport, providing host immunity and 
allowing the recognition and correct modification of the pre-lantibiotic by the post-
translational modification machinery, acting as both the signal and scaffold 
(Chatterjee et al., 2005).  Unlike the N-terminal leader sequences of many secreted 
proteins, those for lantibiotics (with the possible exception of cinnamycin) do not 
contain the usual characteristics of a sec-dependent transport signal sequence and 
are not likely to be exported by general transporter complexes (Chatterjee et al., 
2005).  However lantibiotic gene clusters contain lanT and sometimes lanH genes, 
encoding LanT and LanH transporter proteins, respectively, that are responsible for 
export of the peptide.  The leader sequence is also thought to be important in 
sequestration of the lantibiotic, protecting the producing organism from the effects of 
the mature lantibiotic before it has been exported from the cell.  Studies with nisin 
(van der Meer et al., 1994, Qiao et al., 1995), subtilin (Corvey et al., 2003, Stein et 
al., 2002), lacticin 481 (Xie et al., 2004) and mutacin II (Chen et al., 2001) have 
shown that the presence of the leader sequence attached to the fully modified 
lantibiotic either abolished or severely reduced biological activity.  NMR studies 
demonstrated that the N-terminal leader sequence interfered with the interaction of 
mature nisin with the cell membrane (van den Hooven et al., 1997).  The leader 
sequence is also crucial for recognition of the prepropeptide by the modification 
machinery of the lantibiotic cluster (Chakicherla & Hansen, 1995). 
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Leader sequences often contain conserved motifs that are found only in certain 
lantibiotic classes, and this characteristic has also been used as a means of 
classification (see figure 1.4).  The class I leader sequences recognised by the 
LanB and LanC modification enzymes responsible for the dehydration and 
cyclisation reactions, respectively, contain a high proportion of highly charged amino 
acids, some of which are highly conserved, giving the leader peptide either a net 
negative or slightly positive charge.  The most notable conserved region within this 
group is the FNLDV box which is located between positions -15 and -20 (in respect 
to the cleavage site); there is also a conserved proline residue located at the -2 
position (in red in figure 1.4) (Chatterjee et al., 2005, McAuliffe et al., 2001).  Class II 
lantibiotics that are modified by a single LanM enzyme have leader sequences that 
contain the conserved motifs EL/EV and EL/EM (in red in figure 1.4) (Patton & van 
der Donk, 2005).  The class II lantibiotic leader sequences also have a GG or GA 
cleavage site (known as the double Gly motif), and typically contain an unusually 
high concentration of Asp and Glu residues that results in high negative net charge 
(Chatterjee et al., 2005, McAuliffe et al., 2001).  The existence of such conserved 
motifs in the leader sequences of both classes of lantibiotic suggests that they are 
important for leader sequence function, and many studies have focused on these 
conserved motifs in an effort to discover their role in lantibiotic biosynthesis (Patton 
et al., 2008, Neis et al., 1997, van der Meer et al., 1994). 
 
 
Figure 1.4:  Sequence alignments of a number of leader sequences and lantibiotics.  
The conserved residues discussed in the text are shown in red.  Arrows indicate 
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cleavage sites.  The residues in yellow and blue denote those involved in ring 
formation.  Figure taken from Chatterjee, Paul et al. (2005). 
 
Several lantibiotics have been shown to tolerate mutations in nearly all of the 
residues outside of the FN/DLDV box in the class I group leader sequences.  
Several amino acid substitutions were made in the leader sequence of nisin, 
including the conserved FN/DLD and P residues.  Fully modified and functional nisin 
resulted from nearly all of the amino acid substitutions that were made outside of 
the FNLD motif and the -2 position, indicating that these residues are not essential 
for lantibiotic biosynthesis.  In contrast, nisin biosynthesis was abolished when 
substitutions were made in the FNLD motif, suggesting that these conserved 
residues may be required for appropriate interaction with the  respective 
modification enzymes and therefore essential for biosynthesis (van der Meer et al., 
1994).  Chatterjee et al. (2005) suggested that that the leader sequences are 
recognised by the modification machinery as a consequence of the tertiary structure 
of the leader sequence and propeptide, rather than by recognition of specific amino 
acids in the leader sequence. 
 
Class II leader sequences are also amenable to numerous amino acid exchanges 
and appear to be just as intolerant to substitutions within the conserved motifs, 
particularly at the cleavage site (see figure 1.4).  Experiments carried out on 
mutacin demonstrated that the conversion of either one or both of the double Gly 
motif residues to Ala at the -1 and -2 positions completely abolished lantibiotic 
production (Chen et al., 2001). 
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Strain Biological activity Mutacin Prepropeptide Mutacin peptide 
Wild-type ++++ − + 
G-1A − + − 
G-2A − + − 
I-4V ++++ np np 
I-4D ++++ − − 
L-7M ++++ np np 
L-7K − − − 
E-8D ++++ np np 
E-8K +++ − + 
S-11A ++++ np np 
S-11T ++++ np np 
V-12A ++++ np np 
V-12I ++++ np np 
V-12L ++ − + 
E-13D ++++ np np 
E-13K + − − 
aThe mutacin production level of the wild-type Streptococcus mutans T8 was assigned as ++++. 
b+, signal corresponding to correct mass was identified ; −, no signal corresponding to correct mass 
was identified; 
np, not performed 
 
Figure 1.5:  Effects of amino acid substitutions within the leader sequence of 
mutacin (Chen et al., 2001). 
 
Figure 1.5 also demonstrates that the mutacin leader sequence can tolerate a large 
number of other amino acid substitutions.  Only two substitutions abolished the 
interaction of the mutacin prepropeptide with its modification enzymes: the 
conversion of Ile to Asp and Leu to Lys at -4 and -7, respectively.  Glu8 to Lys, 
Val12 to Leu and Glu13 to Lys reduced the level of mutacin production to 
approximately 75%, 50% and 10% of the wild-type level, respectively.  This 
demonstrates that while not all of the amino acids in the leader sequence are 
essential for biosynthesis of the lantibiotic, some are important for optimal 
biosynthesis (Chen et al., 2001). 
 
Further studies on the lantibiotic lacticin 481 have shown that the length of the 
prepropeptide is not crucial for correct modification (Xie et al., 2004).  C-terminally 
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truncated prepropeptide was modified and complete removal of the leader 
sequence from lacticin 481 did not  abolish dehydration by LctM (Levengood et al., 
2007).  Prepropeptides that lacked the first three, eight or eleven amino acids from 
the leader sequence were still modified correctly; though removal of the first 14 
amino acids abolished modification (Chatterjee and van der Donk unpublished data) 
(Chatterjee et al., 2005).  In lacticin 481, residues 17 to 24 (in red in figure 1.4) are 
suggested to be essential for enzyme recognition, while the GA sequence is 
essential for correct cleavage of leader peptide to yield the mature lantibiotic and 
are not required for recognition by the modification machinery (Chatterjee et al., 
2005). 
 
1.1.2 Enzymes and proteins involved in lantibiotic 
biosynthesis 
 
As mentioned previously, the lanA gene encodes the unmodified prepropeptide that 
is modified by either a LanM or LanBC modification enzymes.  Lantibiotics are 
synthesised by the dehydration and cyclisation of serine and threonine residues 
present within the sequence of the propeptide.  Lantibiotic gene clusters contain 
either a single modification gene, lanM, or two separate genes lanBC.  The first step 
in lantibiotic biosynthesis is the dehydration of serine and threonine residues, 
followed by cyclisation of the dehydrated peptides with cysteine thiols.  In type AI 
lantibiotics, dehydration is carried out by the LanB dehydratase, followed by ring 
formation mediated by the cyclase LanC.  In type AII and B clusters, both reactions 
are performed by a single LanM enzyme. 
 
Mutations in the nisin propeptide have given some insight into the organisation and 
order of lantibiotic biosynthesis.  Lubelshi et al. (2009) hypothesise that the nisin 
prepropeptide is processed from the N-terminus to the C-terminus, and that NisB 
and NisC function alternatively to dehydrate and cyclise the lantibiotic. 
 
1.1.3 LanB 
 
lanB genes encode dehydratase enzymes that are responsible for the selective 
dehydration of serine and threonine residues to Dha and Dhb, respectively 
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(Chatterjee et al., 2005, McAuliffe et al., 2001, Patton & van der Donk, 2005).  lanB 
genes generally encode large (about 1000 amino acids) generally hydrophilic 
molecules, with some hydrophobic domains, suggesting that they are membrane 
associated, as proposed for the nisin biosynthesis complex (see regulation of nisin 
biosynthesis, figure 1.10) (McAuliffe et al., 2001, Siegers et al., 1996).  There is little 
homology between the LanB proteins of different Class AI lantibiotic gene clusters 
(generally around 30% amino acid sequence identity), although when comparing 
structurally similar lantibiotics, homology can be much higher (83% in the case of 
SpaB and EriB involved in subtilin and ericin S biosynthesis, respectively (Mulders 
et al., 1991)).  LanB activity was first confirmed when dehydrated Pep5 was 
identified after deletion of pepC in a Pep5-producing strain of Staphylococcus 
epidermidis (Meyer et al., 1995).  The dehydratase activity of LanB was also 
confirmed for nisin when nisABT was placed in a non-producing strain of L. lactis, 
resulting in the production of dehydrated prenisin lacking thioether rings (Kuipers et 
al., 2004).  His-tagged nisin precursor peptides were expressed in a strain that 
lacked nisB, resulting in accumulation of unmodified prenisin.  In contrast removal of 
nisC from L. lactis resulted in the production of dehydrated peptides, providing 
further confirmation that the LanB is responsible for the dehydration of the 
prepropeptide (Okeley et al., 2003, Patton & van der Donk, 2005).  The LanB 
dehydratases perform the dehydration reaction in the same way as the LanM 
synthetases (discussed later). 
 
1.1.4 LanC 
 
The next step in modifying the lantibiotic after dehydration in the type AI lantibiotic 
biosynthetic pathway is cyclisation of the dehydrated prepropeptide to form the 
uncleaved fully processed lantibiotic.  This is performed by the LanC cyclase.  
LanCs catalyse the addition of cysteine thiols to the dehydrated serine and 
threonine residues (figure 1.6) (Relyea & van der Donk, 2006).  The amount of 
energy needed to form rings within the lantibiotic structure is thought to be less than 
that required to dehydrate the prepropeptide.  Biomimetic studies of lantibiotic 
biosynthesis have demonstrated that dehydrated peptides are able to 
spontaneously undergo cyclisation reactions in the absence of a LanC cyclase.  Not 
only were these reactions rapid, but the resulting peptides contained thioether rings 
with the correct stereochemistry; questioning the need for a dedicated cyclase 
(Burrage et al., 2000, Chatterjee et al., 2005).  In contrast, Meyer et al. (1995) 
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proposed that the PepC cyclase was essential for the correct and efficient 
cyclisation of dehydrated Pep5.  Disruption of pepC led to the production of 
dehydrated peptides with none of the lanthionine bridges formed correctly (Meyer et 
al., 1995).  Further experiments on nisin have provided additional direct evidence for 
the important role played by LanCs in lantibiotic biosynthesis.  His-tagged nisin 
precursor peptides were expressed in mutant strains of L. lactis lacking nisB or nisC 
(Koponen et al., 2002).  In the nisB deficient strain, no dehydrated or cyclised 
peptides were recovered.  In the nisC deficient strain, only dehydrated peptides 
were isolated, demonstrating that NisC was responsible for the cyclisation of 
thioether rings, or indirectly by inducing cyclisation activity in NisB (Koponen et al., 
2002, Chatterjee et al., 2005).  For both NisC and SpaC, heterologous expression 
and purification in E. coli demonstrated that these two enzymes were monomers 
and metal analysis showed that they contained zinc (Okeley et al., 2003, Patton & 
van der Donk, 2005).  It is thought that the zinc is involved in activation of the thiol 
substrates in LanC enzymes, lowering the pKa of the cysteine thiols that are added 
to the dehydrated Dha and Dhb residues (Chatterjee et al., 2005, Relyea & van der 
Donk, 2006), similar to a number of enzymes that catalyse thiol alkylation, figure 1.6 
(Matthews & Goulding, 1997, Chatterjee et al., 2005).  Generally, LanC cyclases 
share low amino acid identity (~20-30%) and only a few conserved residues.  They 
contain two conserved cysteine residues (Cys284 and Cys330, NisC numbering) 
and two histidine residues (His212 and His331) that are also conserved in the C-
terminal part of the LanM proteins and are thought to act as zinc ligands (Chatterjee 
et al., 2005, Siezen et al., 1996, Okeley et al., 2003).  Conversion of the two 
conserved cysteines to alanine in SpaC limited its ability to bind zinc and perform its 
cyclisation activity (Okeley et al., 2003).  Thus, while these enzymes are not 
essential for the cyclisation of all lantibiotics, they are responsible for the efficient 
and generally correct stereo- and regio-specific formation of lanthionine rings 
(Chatterjee et al., 2005). 
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Figure 1.6:  Cyclisation by LanC enzymes via the addition of cysteine thiols to the 
dehydrated peptides, in this case in the formation of the B-ring of subtilin and nisin.  
Figure taken from Okelely et al. (2003). 
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1.1.5 LanM 
 
In contrast to Type AI lantibiotics, Type II and B lantibiotics are processed by large 
(generally 900-1000 amino acids) bifunctional modification enzymes encoded by 
lanM genes.  These enzymes are able to carry out both the dehydration and 
cyclisation reactions (Chatterjee et al., 2005, Xie et al., 2004).  The mechanism of 
dehydration is believed to differ from that of LanBs involved in the synthesis of Type 
IA lantibiotics, and involves the addition of a phosphate group to the alcohol 
functionalities of Ser and Thr followed by the elimination of these phosphates to 
yield Dha and Dhb (figure 1.7) (Relyea & van der Donk, 2006).  In vitro studies on 
lacticin 481 demonstrated that reconstituted LctM required both Mg2+ and ATP to 
fully process the lantibiotic (Xie et al., 2004, Patton & van der Donk, 2005). 
 
 
Figure 1.7:  Schematic of LanM dehydration via the addition of a phosphate group to 
the alcohol functionalities of Ser.  Figure taken from You and van der Donk (2007). 
 
Amino acid sequence identity between the C-terminal region of LanMs and LanCs is 
around 20-27%, and there is no apparent homology between LanM and LanB 
proteins.  This suggests that lanM genes have not arisen by the fusion of lanB and 
lanC genes, and that the two modification machineries have evolved independently 
of each other (Chatterjee et al., 2005).  The homology shared with LanCs includes 
the conserved residues that are involved in binding zinc. 
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Recent studies have shown that disruption of the zinc ligands Cys781 and Cys836 
in the lacticin synthetase LctM did not affect its dehydration activity.  The mutations 
did however prevent cyclisation of full-length and truncated substrates by LctM.  
Substitution of another conserved lanC and lanM residue, His725, with Asn did not 
abolish the ability of LctM to catalyse dehydration and cyclisation reactions, but it 
decreased the level of activity compared to the wild-type enzyme (figure 1.8) (You & 
van der Donk, 2007).  You et al. (2007) proposed that the C-terminal domain of the 
peptide, containing the zinc ligands, is responsible for cyclisation and that 
dehydration takes place independently. 
 
 
Figure 1.8:  The proposed mechanism for the LctM-catalysed formation of a 
methylanthionine ring involving a number of conserved residues (discussed in the 
above text).  Figure taken from You and van der Donk (2007). 
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1.1.6 LanD 
 
There are a number of lantibiotic genes found in a number of clusters that encode 
enzymes able to perform other modifications on lantibiotic prepropeptides.  Figure 
1.1 illustrates many of the modifications performed by these enzymes, including the 
production of aminovinyl cysteine, lysinoalanine, D-alanine and ß-hydroxy aspartate 
(Patton and van der Donk, 2005).  Enzymes encoded by lanD genes are able to 
modify the lantibiotic peptides and create C-terminal S-[(Z)-aminovinyl]-D-cysteine 
(AviCys) residues.  Both EpiD and MrsD are able modify the prepropeptides of 
epidermin and mersacidin by oxidative decarboxylation of C-terminal cysteines to 
produce AviCys.  The crystal structures of these enzymes revealed that they contain 
a flavin mononucleotide (Schmid et al., 2002, Patton & van der Donk, 2005).  Unlike 
the LanBC and LanM enzymes, EpiD does not have an absolute requirement for the 
leader sequence as a substrate, and is able to decarboxylate both the EpiA 
prepropeptide and the peptide without the leader sequence (the propeptide) 
(Chatterjee et al., 2005).  The ability of EpiD to decarboxylate an even wider range 
of substrates was demonstrated by a study that used a library of heptapeptides with 
varying amino acid substitutions in the C-terminal region of EpiA.  This study 
concluded that only the C-terminal cysteine was necessary for decarboxylation.  As 
modification requires a free thiol and carboxylate for activity, it is suggested that 
oxidative decarboxylation and dehydration occur simultaneously, which is then 
followed by ring formation (Kupke et al., 1995, Schmid et al., 2002). 
 
1.1.7 Other lantibiotic modifications 
 
As mentioned previously (see figure 1.1), a number of other amino acid 
modifications are found in many lantibiotics.  Chatterjee et al. (2005) propose that 
after the removal of the leader sequence, the non-enzymatic hydrolysis of Dhb at 
position 1 of lactocin S and eplilancin K7 leads to the formation of 2-oxobutyryl and 
2-oxopropionyl groups, respectively.  In epicidin 280, the reduction of 2-
oxopropionyl to 2-hydroxypropionyl is thought to be carried out by an 
oxidoreductase, EciO, encoded by the epicidin 280 cluster, but it is not known how 
these enzymes function (Heidrich et al., 1998, van de Kamp et al., 1995, Chatterjee 
et al., 2005). 
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The lantibiotic cinnamycin contains two modifications that are unique to the 
duramycin family of lantibiotics to which it belongs.  A lysinoalanine bridge is formed 
by the dehydration of Ser to Dhb followed by the conjugate addition of Lys19.  While 
potentially analogous to lanthionine bridge formation, it is not known whether cinM 
or one of the genes of unknown function in the cin cluster is responsible for this 
unusual modification (Chatterjee et al., 2005).  Cinnamycin (and the other 
duramycins) also contain an erythro-3-hydroxy-L-aspartic acid resulting from the 
hydroxylation of L-Asp15 and is essential for recognition of its target phosphatidyl 
ethanolamine (Fredenhagen et al., 1990, Chatterjee et al., 2005).  A mammalian ß-
hydroxlase is responsible for this modification in a number of mammalian proteins, 
and it is thought that a homolog in the cinnamycin cluster may perform the same 
function (Chatterjee et al., 2005). 
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1.1.8 LanP and LanT 
 
Lantibiotics are generally transported out of the cell by a dedicated lantibiotic ATP-
dependent transporter LanT (Chatterjee et al., 2005).  NisT, the transporter encoded 
by the nisin gene cluster, is essential for extracellular transport; its deletion from L. 
lactis N8 led to the accumulation of processed nisin in the cytoplasm (Qiao & Saris, 
1996).  In other clusters, a dedicated lantibiotic transporter is not absolutely 
essential.  For example, deletion of pepT resulted in a 90% reduction in Pep5 
transport; presumably in its absence, transporter(s) encoded elsewhere in the 
genome are responsible for the residual ~10% of lantibiotic export (Meyer et al., 
1995).  Indeed, some clusters do not appear to encode a transporter at all, as is the 
case for epicidin 280 (Meyer et al., 1995, Heidrich et al., 1998).  Many lantibiotic 
transporters exhibit relaxed substrate specificity.  Fusion of the nisin leader 
sequence with unmodified forms of nisin, as well as with peptide fragments of the 
non-lantibiotic peptides enkephalin and angiotensin, were transported by NisT 
(Kuipers et al., 2004).  In another study, an alkaline phosphatase was attached to 
the subtilin leader sequence and was exported in B. subtilis.  The amount of alkaline 
phosphatase exported was increased when SpaT was present, demonstrating that 
LanT transporter systems may possess marked substrate flexibility, and that the 
leader sequence is important in substrate recognition (Izaguirre & Hansen, 1997, 
Chatterjee et al., 2005). 
 
The type AI ATP cassette (ABC) transporters represented by NisT and SpaT (for 
export of nisin and subtilin, respectively) are roughly 600 amino acids in length and 
have significant homology to haemolysin B-like ATP-dependent transport proteins 
found in a number of other organisms (Chung et al., 1992, Gentschev & Goebel, 
1992, Chatterjee et al., 2005).  They contain a hydrophobic N-terminal domain and 
a six-helix membrane-spanning domain.  They also possess a C-terminal ATP-
binding domain (Chatterjee et al., 2005). 
 
The type AII clusters contain slightly larger, 700 amino acid LanTs, such as LctT, 
and MutT (Rince et al., 1994, Chen et al., 1999).  Transporters from these clusters 
contain an additional N-terminal peptidase domain besides the C-terminal ATP-
binding and membrane-spanning domains that has been implicated in cleaving the 
leader sequences from the mature lantibiotic (Chatterjee et al., 2005).  The absence 
of a dedicated LanP protease in these gene clusters, with the exception of lactocin 
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S, which contains a truncated LanT and a LanP protease, suggests that the N-
terminal peptidase domain is responsible for the final lantibiotic processing step. 
 
Type B lantibiotic gene clusters contain two component transport systems 
consisting of a permease component and ATP-binding subunit.  These are present 
in the gene clusters of cinnamycin, actagardine, deoxyactagardine B and 
microbisporicin (Boakes et al., 2010, Boakes et al., 2009, Foulston & Bibb, 2010, 
Widdick et al., 2003).  The transporters for microbisporicin have high homology to 
those involved in cinnamycin export (Foulston & Bibb, 2010).  In cinnamycin, the 
ATP binding subunit is a member of the pfam family of ABC transporters, and has 
36% identify to MrsF (part of a putative MrsFEG immunity transporter in mersacidin) 
and the permease subunit is an integral membrane subunit and is a member of the 
pfam family of ABC-2 type transporters usually involved in drug efflux and 
resistance, or carbohydrate export (Widdick et al., 2003). 
 
The final step of lantibiotic maturation is the removal of the leader sequence from 
the fully processed lantibiotic and as implied above, this may be carried out by one 
of two lantibiotic enzymes, either by the serine-type protease LanP, or by the 
protease domain of the ATP-binding cassette LanT (Patton & van der Donk, 2005).  
Some Type B lantibiotic gene clusters (such as cinnamycin, actagardine and 
microbisporicin) contain no LanP protease and no protease domains within the 
LanT (Boakes et al., 2010, Boakes et al., 2009, Foulston & Bibb, 2010, Widdick et 
al., 2003).  Subtilin is unusual in that its gene cluster encodes both a LanT and 
LanP, neither of which is responsible for cleavage of the leader sequence from the 
lantibiotic (Patton & van der Donk, 2005).  Instead, three extracellular serine 
proteases were identified (subtilisin, WprA and Vpr) that are able to process the 
subtilin precursor peptide (Corvey et al., 2003).  Interestingly, while the nisin 
transporter NisT was able to secrete prenisin, dehydrated NisA, dehydrated and 
cyclised NisA, and the NisA leader sequence fused to non-lantibiotic peptides 
(Kuipers et al., 2004), the NisP protease would only cleave the leader peptide 
attached to fully matured nisin (Kuipers et al., 2004, Patton & van der Donk, 2005). 
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1.1.9 LanFEG / LanI 
 
Once exported from the cell and cleaved from the leader sequence, the cell must 
then protect itself from the mature lantibiotic.  To date, two systems have been 
identified that are thought to be involved in host cell immunity.  These are the 
LanFEG transporter system and LanI peptide system.  Host producers can have 
one or both of these systems.  For nisin and subtilin, both systems act 
independently to confer immunity (Chatterjee et al., 2005).  The lanFEG genes 
encode an ABC transporter which is able to remove nisin and subtilin from the 
cytoplasmic membrane and export it out into the extracellular space (Nagao et al., 
2006).  NisA and SpaI are lipoproteins which bind to and sequester their respective 
lantibiotics on the outside of the cytoplasmic membrane, preventing them from 
reaching their target.  NisI has no homology with other non-lantibiotic proteins and 
has a hydrophobic N-terminus containing a consensus lipoprotein sequence 
(Kuipers et al., 1993).  It is membrane anchored by post-translational removal of the 
first 19 amino acids as well as by lipid modification of the Cys residue at the new N-
terminus (Chatterjee et al., 2005).  The LanI lipoproteins orientate to the outside of 
the cytoplasmic membrane and sequester the lantibiotic by binding to it, but most 
are unable to provide cross-resistance against other lantibiotics (Nagao et al., 
2006).  NukH is an exception; this unique immunity protein consists of three 
transmembrane domains and is able to interact with and provide immunity towards 
both nukasin and lacticin 481, but not nisin (Nagao et al., 2006, Stein et al., 2005, 
Stein et al., 2003). 
 
Interestingly, some non-lantibiotic producing L. lactis strains are able to resist high 
levels of nisin.  These strains express a 35 kDa nisin resistance protein (NSR) that 
is able to proteolytically cleave six amino acids from the carboxyl “tail” of nisin, 
reducing its bacteriocidal activity 100-fold (Sun et al., 2009).  Listeria 
monocytogenes is also able to resist high levels of nisin.  Enhanced resistance to 
nisin and other class IIa bacteriocins was associated with the increased expression 
of three genes encoding a penicillin-binding-protein (PBP), a histidine kinase and a 
protein of unknown function (Gravesen et al., 2004). 
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1.1.10 Regulation of Lantibiotic Biosynthesis 
 
Lantibiotic production must be tightly regulated to ensure that there is an 
appropriate balance between production and resistance and that the peptides are 
produced at an appropriate time, usually during late exponential growth (Chatterjee 
et al., 2005).  To aid in tight regulation, lantibiotic biosynthetic genes are located in 
operons within their gene clusters, where a few promoters are able regulate 
biosynthesis (see figure 1.9). 
 
 
Figure 1.9:  The transcriptional operons of nisin.  The nisA promoter drives 
expression of nisABTCIP, with a transcriptional attenuator situated between the 
structural gene nisA and those encoding modification enzymes and a transporter.  
The nisR promoter drives nisRK and the nisF promoter drives nisFEG.  Figure taken 
from Kleerebezem (2004). 
 
The majority of lantibiotics studied to date use a two component regulatory system 
to regulate the production on the lantibiotic in response to extracellular signals.  The 
most studied two component regulatory systems are those of nisin and subtilin.  
There is a reported 26.6% amino acid sequence identity between NisK and SpaK, 
both of which belong to the EnvZ-like subgroup of sensor kinase proteins 
(Chatterjee et al., 2005, Kleerebezem, 2004).  These proteins are predicted to 
contain two hydrophobic transmembrane helices at their N-terminal “input” domain, 
and conserved histidine residues at the C-terminal “transmitter” domain.  The N-
terminal domains have been shown to interact with their respective lantibiotic and 
transmit the signal to the appropriate response regulator via the transmitter domain 
(Kleerebezem, 2004).  The response regulators NisR and SpaR have even higher 
homology, 41.3% amino acid identity, and belong to the OmpR-like subgroup of 
response regulators.  Both proteins contain a conserved aspartate residue that is 
targeted by sensor kinase mediated phosphotransfer in the N-terminal “receiver” 
domain.  The C-terminal “output” domain of both proteins contains a typical helix-
turn-helix motif that is involved in binding the phosphorylated response regulators to 
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their target DNA sequences (Kleerebezem, 2004).  The response regulators are 
able to bind to promoters within each lantibiotic biosynthetic gene cluster.  In the 
case of nisin, the response regulator binds to two sites, PnisA and PnisF.  The NisRK 
operon is expressed constitutively (see figure 1.9). 
 
Nisin is produced late in the exponential growth phase, similar to many other 
lantibiotics (Chatterjee et al., 2005).  Nisin is able to auto regulate its own 
transcription acting as a quorum sensor, and as little as five nisin molecules are 
sufficient to activate transcription (de Ruyter et al., 1996).  The NisK sensor kinase 
is able to bind nisin and transmit the signal to the response regulator NisR.  This is 
then able to promote the transcription of the PnisA and PnisF promoters and increase 
production of nisin (Kleerebezem, 2004).  Galactose and lactose are also able to 
stimulate nisA transcription without externally applied nisin, in a NisRK independent 
manner (Chandrapati & O'Sullivan, 1999).  An overview of the entire process can be 
seen in figure 1.10.  Transcription of the subtilin lanRK genes depends on RNA 
polymerase subunit σH, which is derepressed at the end of exponential growth 
(Stein et al., 2002). 
 
 
Figure 1.10:  Overview of nisin biosynthesis.  Extracellular changes in nisin 
concentration lead to the autophosphorylation of NisK which then transfers the 
phosphate to the Asp residue of NisR.  This induces the expression of the 
nisABTCIP and nisFEG operons.  Prepronisin is then processed by the NisBCT 
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multi-enzyme complex and exported from the cell, where the leader sequence is 
cleaved by NisP, producing mature nisin.  NisI acts to sequester nisin, while NisFEG 
removes the lantibiotic into the extracellular environment.  Figure taken from Patton 
and van der Donk (2005). 
 
Regulation of the Type B lantibiotic mersacidin is different.  While it does contain a 
two component regulatory system, MrsR2 and MrsK2, that shares homology with 
other LanRKs, it also contains an additional MrsR1 regulator (Guder et al., 2002).  
Unlike other lantibiotic two component regulatory systems, MrsRK does not regulate 
mersacidin production; instead it is responsible for the regulation of the MrsFEG 
immunity transporter.  The single regulator MrsR1 is believed to be involved in 
regulating mersacidin biosynthesis.  Currently, the stimulus for its activation is 
unknown, nor is it clear whether a thus far unidentified sensor kinase is required for 
its phosphorylation (Chatterjee et al., 2005).  Regulation of two other Type B 
lantibiotics involves a SARP (Streptomyces antibiotic regulatory protein) for 
cinnamycin production in Streptomyces cinnamoneus (Widdick et al., 2003), and an 
extracytoplasmic function σ factor–anti-σ factor complex for microbisporicin 
production in Microbispora corallina (Widdick et al., 2003, Foulston & Bibb, 2010). 
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1.2 Lantibiotic modes of action 
 
Lantibiotics commonly exert a combined set of cell killing mechanisms.  These 
generally involve either binding to the cell membrane followed by insertion, or the 
use of a receptor/docking molecule to exert a structural based activity 
(Asaduzzaman & Sonomoto, 2009).  In model membranes systems using 
cytoplasmic and artificial membrane vesicles, pore formation was determined as the 
mode of action of nisin and other cationic type AI lantibiotics (Chatterjee et al., 
2005).  The first step in nisin activity was binding of the peptide to the cell 
membrane.  In nisin, the positive charges that are found at the N- and C- termini 
attract the molecule to the membrane (Giffard et al., 1997).  The electrostatic 
differences between nisin and the membrane encourage the initial reaction 
(Asaduzzaman & Sonomoto, 2009).  The C-terminus of nisin holds a strong positive 
charge, and interacts with anionic lipids in the membrane; it is also the C-terminus 
of nisin that first translocates across the membrane (Breukink et al., 1997, van 
Kraaij et al., 1998).  Once this initial contact is made, the N-terminal rings of nisin 
bind to the disaccharide-polyphosphate of lipid II, and the C-terminus binds to the 
head-groups of the lipids within the bilayer to form a pore (Asaduzzaman & 
Sonomoto, 2009).  There are two well-established models to explain how the pores 
form within the bacterial cell membrane.  These are the barrel-stave and wedge 
models  (Asaduzzaman & Sonomoto, 2009).  In the barrel-stave model, nisin 
monomers (the stave) are bound to the cell membrane via their electrostatic charge, 
eventually forming a preaggregate.  The pores are formed when a certain 
membrane potential is reached when the nisin molecules become perpendicular to 
the membrane and a pore (the barrel) is formed (Jung & Sahl, 1991).  In the wedge 
model, surface bound nisin (in parallel) generates local strain on the lipid molecules, 
forcing the formation a pore (see figure 1.11) (Driessen et al., 1995).  The pores last 
for several hundred milliseconds, are between 0.2 to 1-2 nm in size and promote the 
breakdown of membrane potential and efflux of metabolites (Chatterjee et al., 
2005). 
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Figure 1.11:  The wedge model of nisin pore formation.  Nisin is electrostatically 
bound in parallel to the membrane, and local strain forces a pore through the cell 
wall.  Figure taken from Asaduzzaman and Sonomoto (2009). 
 
Many lantibiotics bind to the essential cell wall precursors Lipid I and Lipid II and 
interfere with peptidoglycan biosynthesis (Chatterjee et al., 2005).  This prevents the 
utilisation of these molecules by transpeptidase and transglcosylase enzymes in 
building the cross-linked network of the cell wall (Asaduzzaman & Sonomoto, 2009).  
Vancomycin is able to kill bacteria by binding to the D-ala-D-ala moiety of lipid II.  
Nisin, under normal circumstances, binds to lipid II via its disaccharides-
pyrophosphate region, making it effective against strains that are resistant to 
vancomycin (Hsu et al., 2003).  The unique ability of nisin to be effective at 
nanomolar concentrations is due to its ability to bind to lipid II and to form a pore 
using the latter as a docking molecule (Breukink et al., 1999).  Recent NMR data 
has shown that nisin interacts with lipid II using the backbone amides of rings A and 
B via 6 hydrogen bonds to the pyrophosphate moiety of lipid II (Hsu et al., 2004).  
The A and B rings of nisin are conserved in subtilin, epidermin, gallidermin and 
plantaricin C (Asaduzzaman & Sonomoto, 2009).  A schematic for this interaction is 
shown in figure 1.12.  The structure of the lantibiotic is key to its bioactivity.  For 
example, the specific substitution of the dehydro amino acid Dha from position 5 of 
nisin resulted in a complete loss of sporicidal activity although bacteriolytic activity 
remained (Pag & Sahl, 2002, Chan et al., 1996, Dodd et al., 1995). 
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Figure 1.12:  Proposed model for nisin-lipid II interaction.  The N-terminus of nisin 
binds to lipid II and forms a pore within the membrane composed of four lipid II and 
eight nisin molecules.  Figure taken from Chatterjee, Paul et al. (2005). 
 
Type B lantibiotics such as mersacidin and actagardine are also able to interact with 
Lipid II but have no structural similarity with nisin.  By binding to lipid II they are able 
to disrupt cell wall biosynthesis by blocking the transglycosylation step of 
peptidoglycan biosynthesis (Brotz et al., 1997, Boakes et al., 2010, Boakes et al., 
2009).  These compounds do not work at nanomolar concentrations because they 
do not form pores, but as mersacidin is effective against MRSA, it does have 
potential clinical applications. 
 
The two component lantibiotic lacticin 3147 works at nanomolar concentration, and 
requires a 1:1 stoichiometry of its subunits (LtnA1:LtnA2).  LtnA1 first binds to lipid II 
where it recruits LtnA2 which inhibits cell wall biosynthesis and creates pores in the 
membrane (Wiedemann et al., 2006). 
 
Cinnamycin and the duramycins are also unique among lantibiotics, exerting their 
antibacterial effect by binding to phosphatidylethanolamine (PE) and disrupting 
membrane function (Fredenhagen et al., 1990, Machaidze & Seelig, 2003).  In 
mammalian cells, and probably also in bacteria, PE is predominantly found on the 
inner leaflet of the plasma membrane.  Upon binding to PE, cinnamycin induces 
transbilayer lipid movement, flipping the PE to the outer leaflet (Makino et al., 2003).  
39 
 
Binding of cinnamycin induces reorganisation of the membrane into highly deformed 
curved structures that disrupt normal membrane function (Iwamoto et al., 2007). 
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1.3 Lantibiotic Engineering 
 
Lantibiotics have several key features that make them targets for selective 
engineering.  All lantibiotics are ribosomally synthesised, and the amino acids 
encoded by the lanA gene are directly incorporated into the lantibiotic.  
Consequently the structures of these antibiotics can be readily manipulated using 
well-understood and established DNA manipulation techniques such as site-directed 
mutagenesis, and oligonucleotide synthesis.  These approaches could be used, for 
example, in attempts to improve lantibiotic activity, stability and pharmacokinetic 
properties (Nagao et al., 2006).  In the future, the lantibiotic modification machinery 
could also be used to introduce dehydrated amino acids into other peptides and to 
generate novel cyclic peptides.  This is made possible by the relative plasticity of the 
lantibiotic synthetases, and their ability to recognise non-lantibiotic peptides 
attached to leader sequences. 
 
The generation of lantibiotic derivatives is most efficiently achieved by varying the 
sequence of the lanA gene.  The first systematic mutational analysis of a lantibiotic, 
replacing targeted amino acids with alanine residues, was performed on the two-
component lantibiotic lacticin 3147.  The results suggested that various parts of the 
lantibiotic prepropeptide were amenable to amino acid changes (Cotter et al., 2006).  
Mersacidin (figure 1.4) was the first lantibiotic to undergo systematic exchange of all 
of the amino acids in MrsA (except those involved in bridge formation) (Appleyard et 
al., 2009).  Appleyard et al. (2009) generated 228 mersacidin mutants (figure 1.13) 
of which 80 were produced at good levels.  Variants with insertions of amino acids 
into ring A and flanking regions lost all antimicrobial activity, but ring B was highly 
amenable to insertions and substitutions.  This study concluded that the geometry of 
the molecule was highly evolved to bind to lipid II.  Most of these variants did not 
improve the antimicrobial activity of mersacidin, but some did perform better against 
some Gram-positive pathogens, suggesting this method may be a useful approach 
in lantibiotic improvement programs (Appleyard et al., 2009). 
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Figure 1.13:  Mersacidin substitution library.  Circles under the mersacidin peptide 
indicate variants that were detected by LC-MS analysis.  Grey circles represent 
variants that were produced at high yield (>10% of mersacidin production) and open 
circles represent those produced at trace levels.  Da, Dha; Db, Dhb; Ab, 2-
aminobutyrate.  Figure taken from Appleyard et al. (2009). 
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1.4 Actagardine 
 
Actagardine was first isolated from Actinoplanes garbadinensis and also thought to 
be made by Actinoplanes liguriae in 1976 (Arioli et al., 1976, Coronelli et al., 1976, 
Parenti et al., 1976).  Actagardine was formerly known as gardimycin as the two 
producer strains of Actinoplanes were both isolated from garden soil samples from 
the locality of Garbady in India (hence A. garbadinensis) and the Italian region of 
Liguria (hence A. liguriae) (Parenti et al., 1976).  Actagardine was first identified as 
a peptide antibiotic because of its antimicrobial activity.  Treatment of experimental 
infections in mice using Streptococcus pneumoniae, Streptococcus haemolyticus 
and Staphylococcus aureus demonstrated that actagardine had high therapeutic 
effectiveness, as well as a low toxicity, potentially making it a good candidate for 
clinical development (Arioli et al., 1976).  Further experiments indicated that the 
frequency of S. haemolyticus mutants that were resistant to actagardine was less 
than 10-10.  When 109 cells were cultured on Brain-Heart infusion agar containing 5 
µg/ml actagardine (normal MIC is 1 µg/ml), no resistant mutants were obtained.  
Only after training (growth in Brain-Heart infusions with increasing concentrations of 
actagardine (data not shown)) were mutants resistant to 20 µg/ml actagardine 
obtained, and these exhibited no cross-resistance to penicillin, bactitracin, ristocetin, 
vancomycin, rifampicin and erythromycin (Arioli et al., 1976).  Recently, Novacta 
Biosystems have conducted further research into the genes responsible for the 
biosynthesis of actagardine (Boakes et al., 2010, Boakes et al., 2009). 
 
1.4.1 Structural characterisation and mode of action 
 
Actagardine inhibits cell wall biosynthesis, and a number of experiments were 
carried out to understand its mechanism of action.  Experiments were conducted on 
B. subtilis, where the addition of 100 µg/ml actagardine caused almost immediate 
cell lysis, which was measured by a reduction in culture absorbence (Somma et al., 
1977).  In this study, the addition of actagardine to a growing culture immediately 
suppressed the incorporation of GlcNAc, a specific precursor of peptidoglycan, into 
the cell wall of B. subtilis.  Radio-labelled alanine, used to determine whether 
actagardine disrupted peptidoglycan biosynthesis rather than GlcNac uptake or 
utilisation, was not incorporated into the cell wall; protein biosynthesis was 
unaffected, unlike tetracycline-treated controls.  The observation that actagardine 
has a bactericidal effect on actively dividing cells, but not resting cells that were not 
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actively dividing, was also consistent with inhibition of cell wall synthesis, although 
the report did not comment on the lytic ability of actagardine on stationary phase 
cells (Somma et al., 1977). 
 
The initial physicochemical characterisation of actagardine was carried out using a 
combination of infrared and U.V. spectroscopy, and acid hydrolysis.  These 
procedures identified the majority of amino acids present in the peptide and also 
detected two unknown amino acids containing sulphur moieties that presumably 
arose from two of the four lanthionine rings present in actagardine (Coronelli et al., 
1976).  The first major step forward in structurally characterising the lantibiotic took 
place in 1990 when Kettenring et al. (1990) used homonuclear 2D NMR 
spectroscopy to establish the first, but incorrect, structural model of actagardine 
(figure 1.14) (Kettenring et al., 1990). 
 
 
Figure 1.14:  The proposed sequence of actagardine based on 2D NMR.  Figure 
taken from Kettenring et al. (1990). 
 
This study correctly identified a number of the amino acids as well as the sulphur 
bridges, but was unable to assemble a complete structure.  The structure was 
eventually determined by a study carried out by Zimmermann et al. (1995), and 
further refined in a later publication (Zimmermann et al., 1995, Zimmermann & Jung, 
1997).  The complete structure of actagardine (figure 1.15) was obtained by 
combining a number of techniques including mass spectrometry, chemical 
modification, Edman degradation and NMR. 
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Figure 1.15:  The structure of actagardine.  Figure adapted from Zimmermann and 
Jung (1997). 
 
Zimmermann et al. (1997) characterised the peptide as having two distinct thioether 
ring systems, linked by a short linear segment, leading to the formation of two 
possible binding pockets.  The first pocket is lined by amide moieties built from the 
cyclisation of the C-terminal ring system.  The second consists of the N-terminal 
ring, which is perpendicular to the first, and two hydrophobic residues, Glu11 and 
Ser2, which are positioned in the centre.  This pocket is located within the region 
that shows sequence similarity with mersacidin.  The sequence of actagardine from 
Gly3 to Ala12 is very similar to the sequence of mersacidin residues Gly9 to Ah18 
(see figure 1.15).  These data supported the hypothesis that actagardine was able 
to inhibit the transfer of the disacchardic pentapeptide from the lipid carrier to the 
acceptor site which is present on the cell wall (Somma et al., 1977, Zimmermann & 
Jung, 1997).  It was also noted that the unusual structure of this molecule made it a 
good lead structure when trying to design other peptidoglycan biosynthesis 
inhibitory compounds (Zimmermann & Jung, 1997). 
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1.4.2 Actagardine derivatives 
 
To further explore the use of actagardine as an antimicrobial agent, Malabarba et al. 
(1990) produced 13 amide derivatives of actagardine using synthetic chemistry.  
They produced some monocarboxamides (2 – 10), two diamides (11 and 12) and a 
N-acyl derivative.  These derivatives were then tested against a number of different 
bacteria to test their biological activity. 
 
 
Figure 1.16:  In vitro activity of a number of amide derivatives of actagardine.  
Figure taken from Malabarba et al. (1990). 
 
Figure 1.16 shows that a number of these derivatives have lower MICs against 
some of the bacteria tested than actagardine.  Only one compound (4) was taken 
forward into a mouse model, where it did comparatively well against a number of 
different pathogens.  It would be interesting to know if the toxicity of these 
compounds was also tested. 
 
Shortly after the structural elucidation of actagardine, it was reported that A. liguriae 
ATCC 31048 produced a similar lantibiotic, Ala(0)-actagardine (Vertesy et al., 
1999).  This lantibiotic was produced when A. liguriae ATCC 31048 was cultured on 
mannitol and soya meal, and was identified by a combination of solid phase 
extraction and two-step chromatographic separation.  Ala(0)-actagardine was 
further analysed by 2D-NMR, amino acid analysis and Edman degradation, as well 
as by partial synthesis from actagardine (Vertesy et al., 1999).  Compared to 
actagardine, it has an additional N-terminal alanine residue, and was reported to 
have higher antimicrobial activity and a different spectrum of activity.  Using 
synthetic methods, Vertesy et al. were also able to produce Ala(0)-actagardine by 
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modifying actagardine, dissolving it in anhydrous dimethylformamide and treating it 
with Boc-Ala-O-N-hydroxysuccinimide.  Along with Ala(0)-actagardine, two other 
analogues were made; Lys(0)-actagardine and Ile(0)-actagardine using similar 
methods.  These new derivatives were in some cases reported to have better 
antimicrobial activity than mersacidin against Enterococci (Vertesy et al., 1999). 
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1.4.3 Actagardine homologues 
 
Homologues of actagardine produced by other bacteria have also been reported 
(figure 1.17).  The tomato pathogen Clavibacter michiganensis subsp. 
michiganensis, which is particularly effective at inhibiting the growth of a tomato 
pathogen Clavibacter michiganensis subsp. sepedonicus, produces the lantibiotic 
michiganin A (Holtsmark et al., 2006).  The structure proposed for michiganin A is 
based on and similar to the resolved structure of actagardine with a few key 
differences.  There are six amino acid differences between the two lantibiotics, 
michiganin A has one less MeLan bridge, and the C-terminal MeLan bridge lacks 
the oxygen atom present in actagardine.  However, the proposed structure may not 
be correct; the Dhb at position 8 and Cys residue at position 13 would appear to be 
amenable to Lan formation.  The study carried out by Holtsmark et al. was unable to 
find any homology of the leader sequence of michiganin A with other type B 
lantibiotics.  The similarity between the michiganin A and actagardine gene clusters 
is investigated in detail in chapter 5. 
 
 
Figure 1.17:  The structures of actagardine (A), mersacidin (B) and michiganin (C).  
Figure taken from Holtsmark et al. (2006). 
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1.4.4 Recent research 
 
In recent research articles, Novacta Biosystems have conducted a number of 
experiments on the gene clusters of actagardine and DAB, providing the 
background and parallel work to this study.  Below are the structures of the two 
lantibiotics now known to be made by the two Actinoplanes species. 
 
 
Figure 1.18:  The structures of actagardine from Actinoplanes garbadinensis (top) 
and deoxyactagardine B (DAB) from Actinoplanes liguriae (bottom) (Boakes et al., 
2010, Boakes et al., 2009). 
 
Boakes et al. (2010) reported for the first time that A. liguriae does not produce 
actagardine, but instead the related and novel compound DAB, conflicting with 
earlier reports (Vertesy et al., 1999).  DAB differs from actagardine by the 
substitution of two amino acids; Val15 to Leu and Ile16 to Val, and the lack of a 
sulfoxide between residues 14 and 19 (Boakes et al., 2010).  The DAB gene cluster 
was discovered during probing of genome libraries of both A. garbadinensis and A. 
liguriae for the biosynthetic genes involved in actagardine biosynthesis.  The probe 
hybridised to cosmid AL02, and subsequent sequencing revealed the variant lanA 
gene.  This prompted a reinvestigation of the lantibiotics produced by A. liguriae, 
and mass spectrometry and NMR analysis confirmed the presence of the DAB 
peptide in the culture supernatants of A. liguriae (Boakes et al., 2010).  Cosmids 
containing the biosynthetic gene clusters of both actagardine and DAB have been 
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sequenced and annotated (figures 1.19 and 1.20) (Boakes et al., 2010, Boakes et 
al., 2009). 
 
 
Figure 1.19:  Annotation of the AG14 cosmid from A. garbadinensis containing the 
biosynthetic genes required for actagardine biosynthesis (see chapter 3 for detailed 
description).  Figure taken from Boakes et al. (2009). 
 
Figure 1.20:  Annotation of the AL02 cosmid from A. liguriae, containing the 
biosynthetic genes required for DAB biosynthesis (see chapter 3 for detailed 
description).  Figure taken from Boakes et al. (2010). 
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The gene clusters for actagardine and DAB biosynthesis contain homologues of 
many of the previously characterised lantibiotic biosynthetic genes described above.  
There is one exception to this, garO, which appears to encode a luciferase-like 
monooxygenase that was presumed to be responsible for incorporation of the 
sulfoxide group into the C-terminal methylanthionine bridge of actagardine (Boakes 
et al., 2009).  Deletion of this gene from A. garbadinensis resulted in the production 
of deoxyactagardine A (Boakes et al., 2009).  The gene cluster of DAB also 
contains the garO homolog ligO, but DAB does not contain the sulfoxide group, 
indicating that either DAB is not a substrate for LigO, or that the monooxygenase is 
non-functional.  Expression of ligA, encoding the DAB prepropeptide, in a ∆garA 
strain of A. garbadinensis resulted in the production of the oxidised form of DAB, 
actagardine B, and the conclusion that DAB is a viable substrate for oxidation by at 
least GarO, prompting further speculation that LigO is non-functional (Boakes et al., 
2010). 
 
The main focus of Novacta Biosystem‟s research was to generate potentially 
improved versions of actagardine by variant generation.  Boakes et al. (2009) 
developed a plasmid, pAGvarX that enables the rapid generation of libraries of 
actagardine variants via mutagenesis.  This strategy does not require the creation of 
double-cross over recombinant mutants as the construct is expressed in trans in a 
∆garA mutant of A. garbadinensis.  Using this plasmid, they constructed an alanine 
scanning library and the resulting variants were analysed for improved activity; they 
were also able to assess the flexibility of the actagardine biosynthetic machinery 
(figure 1.21). 
 
 
Figure 1.21:  The results of alanine scanning of the actagardine propeptide.  Abu, 2-
aminobutyric acid.  Figure taken from Boakes et al. (2009). 
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Figure 1.21 summarises the results of the alanine scanning of actagardine.  Only 
two variants, S2A and V15A, showed any biological activity against the test 
organism, Micrococcus luteus. 
 
The eventual hope is that actagardine and/or one of its variants will be used in a 
clinical setting to tackle multidrug and vancomycin resistant infections. 
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1.5 Aims and Objectives 
 
The main aim of this study was to identify experimentally the genes required for the 
biosynthesis of actagardine and DAB. 
 
Although the gene clusters for actagardine and DAB are very similar, there are 
some notable differences that warranted further investigation.  The AL02 cosmid 
contains an additional gene, orf14 (known in this study as ligQ) (figure 1.20) that 
encodes a transport protein.  It is hypothesised that this gene may be involved in 
immunity to DAB.  An analogous role might be played by garPBP, thought to 
encode a penicillin binding protein in the AG14 cosmid and which lies next to garR 
in the actagardine gene cluster (figure 1.19).  Since homologues of garPBP have 
not been found in other lantibiotic gene clusters, its role, if any, in actagardine 
biosynthesis had to be determined experimentally.  Like mersacidin, these gene 
clusters contain three regulatory genes, lanRK and lanR1, but their direct targets for 
regulation are not known.  The role of these genes in lantibiotic production also 
required experimental verification.  These mutational studies could also be 
complemented by the construction of minimal gene sets derived from both AG14 
and AL02 to ensure that other genes within the two cosmids were not required for 
the biosynthesis of these lantibiotics. 
 
At the beginning of this work, only the AG14 cosmid has been successfully 
expressed in a heterologous host.  Attempts to express the AL02 cosmid in S. 
lividans 1326 had been unsuccessful (Novacta Biosystems, unpublished), 
warranting further attempts at heterologous expression and subsequent mutational 
analysis of the DAB gene cluster. 
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1.6 Summary of Research Aims 
 
 
 To carry out a mutational analysis of all of the potential lantibiotic regulatory 
genes carried on the AG14 cosmid. 
 
 To construct minimal gene sets for actagardine and DAB biosynthesis from 
cosmids AG14 and AL02, respectively, to identify the extent of the 
biosynthetic gene clusters. 
 
 To attempt to express the DAB gene cluster heterologously.  
 
 To use computational analysis to discover new actagardine homologs and 
gene clusters, and to carry out a bioinformatic comparison with actagardine 
and its gene cluster. 
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2 Materials and methods 
 
2.1 Bacterial strains and plasmids 
 
Table 2.1:  Plasmids and cosmids used or created in this work. 
Plasmid name Description Selection 
marker 
Reference 
SuperCos1 Cosmid library vector – 
pUCori cos 
Carb Kan Stratagene 
pIJ10702 attP int (ΦC31) oriT pUCori 
cos (pMJCOS1) 
Carb Apra (Yanai et al., 
2006) 
pSET152 attP int (ΦC31) oriT pUCori Apra (Bierman et 
al., 1992) 
pIJ10257 Expression vector - oriT 
ΦBT1 int-attB ermEp* 
Hyg (Hong et al., 
2005) 
pUZ8002 tra RP4 derivative Kan (Paget et al., 
1999) 
pIJ773 pBluescript SK+ containing 
cassette P1-FRT-oriT-
aac(3)IV-FRT-P2 
Apra (Gust et al., 
2004) 
pIJ790 λ-RED (gam bet, exo) araC 
rep101ts 
Chlor (Gust et al., 
2004) 
pIJ782 pBluscript SK+ containing 
cassette P1-FRT-tet-oriT-
FRT-P2 
Tet (Gust et al., 
2004) 
pGem Cloning vector Carb Promega 
CosAG14HEapra pIJ10702 CosAG14 Carb Apra Novacta 
Biosystems 
pIJ12201 SuperCos1 AG14 Carb Kan This work 
pIJ12202 SuperCos1 AL02 Carb Kan This work 
pIJ12203 SuperCos1 AL03 Carb Kan This work 
pIJ12204 SuperCos1 AL13 Carb Kan This work 
pIJ12205 SuperCos1 AL17 Carb Kan This work 
pIJ12206 pIJ10702 AG14 Carb Apra This work 
pIJ12207 pIJ10702 AL02 Carb Apra This work 
pIJ12208 pIJ10702 AL03 Carb Apra This work 
pIJ12209 pIJ10702 AL13 Carb Apra This work 
pIJ12210 pIJ10702 AL17 Carb Apra This work 
pIJ12211 pIJ12206∆garO::tet Carb Kan Tet This work 
pIJ12377 pIJ12201∆garA::apra Carb Kan Apra This work 
pIJ12378 pIJ12201∆garM::apra Carb Kan Apra This work 
pIJ12379 pIJ12201∆garO::apra Carb Kan Apra This work 
pIJ12380 pIJ12201∆garR1::apra Carb Kan Apra This work 
pIJ12381 pIJ12201∆garT::apra Carb Kan Apra This work 
pIJ12382 pIJ12201∆garH::apra Carb Kan Apra This work 
pIJ12383 pIJ12201∆garK::apra Carb Kan Apra This work 
pIJ12384 pIJ12201∆garR::apra Carb Kan Apra This work 
pIJ12385 pIJ12201∆garPBP::apra Carb Kan Apra This work 
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Plasmid name Description Selection 
marker 
Reference 
pIJ12386 pIJ12202∆ligQ::apra Carb Kan Apra This work 
pIJ12387 pIJ12201∆garA::scar Carb Kan This work 
pIJ12388 pIJ12201∆garM::scar Carb Kan This work 
pIJ12389 pIJ12201∆garO::scar Carb Kan This work 
pIJ12390 pIJ12201∆garR1::scar Carb Kan This work 
pIJ12391 pIJ12201∆garT::scar Carb Kan This work 
pIJ12392 pIJ12201∆garH::scar Carb Kan This work 
pIJ12393 pIJ12201∆garK::scar Carb Kan This work 
pIJ12394 pIJ12201∆garR::scar Carb Kan This work 
pIJ12395 pIJ12201∆garPBP::scar Carb Kan This work 
pIJ12396 pIJ12202∆ligQ::scar Carb Kan This work 
pIJ12397 pIJ12206∆garA::scar Carb Apra This work 
pIJ12398 pIJ12206∆garM::scar Carb Apra This work 
pIJ12399 pIJ12206∆garO::scar Carb Apra This work 
pIJ12500 pIJ12206∆garR1::scar Carb Apra This work 
pIJ12501 pIJ12206∆garT::scar Carb Apra This work 
pIJ12502 pIJ12206∆garH::scar Carb Apra This work 
pIJ12503 pIJ12206∆garK::scar Carb Apra This work 
pIJ12504 pIJ12206∆garR::scar Carb Apra This work 
pIJ12505 pIJ12206∆garPBP::scar Carb Apra This work 
pIJ12506 pIJ12207∆ligQ::scar Carb Apra This work 
pIJ12507 pIJ12201∆AG14.2-
AG14.14::tet 
Tet Carb Kan This work 
pIJ12508 pIJ12201∆AG14.2-
AG14.18::tet 
Tet Carb Kan This work 
pIJ12509 pIJ12201∆AG14.28-
AG14.30::tet 
Tet Carb Kan This work 
pIJ12510 pIJ12206∆AG14.2-
AG14.14::tet 
Tet Carb Apra This work 
pIJ12511 pIJ12206∆AG14.2-
AG14.18::tet 
Tet Carb Apra This work 
pIJ12512 pIJ12206∆AG14.28-
AG14.30::tet 
Tet Carb Apra This work 
pIJ12212  pIJ10257 ermEp* garA Hyg This work 
pIJ12213 pIJ10257 ermEp* garM Hyg This work 
pIJ12214 pIJ10257 ermEp* garO Hyg This work 
pIJ12215 pIJ10257 ermEp* garR1 Hyg This work 
pIJ12216 pIJ10257 ermEp* garK Hyg This work 
pIJ12217 pIJ10257 ermEp* garR Hyg This work 
pIJ12218 pIJ10257 ermEp* ligQ Hyg This work 
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Table 2.2:  E. coli strains used in this work. 
Strain Genotype Antibiotic resistance Reference 
DH5α recA1 endA1 gyrA96 thi-
1 hsdR17 supE44 relA1 
lac 
None (Sambrook & 
Russell, 2001) 
ET12567 dam13::Tn9 dcm6  hsdM  
hsdR recF143  
zjj201::Tn10  galK  
galT22 ara14  lacY1  
xyl5  leuB6 
 thil  tonA31  rpL136  
hisG4  tsx78 mtli glnV44  
F-
 
Chlor, Tet (MacNeil et al., 
1992) 
BW25113  (araD-araB)567 
lacZ4787(::rrnB-4)  
lacIp-4000(lacIQ) -  
rpoS369(Am) rph-1 
(rhaD-rhaB)568  
hsdR514 
None (Datsenko & 
Wanner, 2000) 
 
DH5α/BT340 As DH5α with pCP20 
(FLP+, λ ci857+, λ PR 
Repts, ApR, CmR) 
Chlor (Datsenko & 
Wanner, 2000, 
Cherepanov & 
Wackernagel, 1995) 
S17-1 recA1 pro thi hsdR  
RP4-2-Tc::Mu-Km::Tn7 
Strep, Spec 
 
(Simon et al., 1983) 
 
 
Table 2.3:  Actinomycetes used in this work. 
Species Strain Genotype Reference 
Streptomyces lividans TK24 Str-6 SLP2- SLP3- (Kieser, 2000) 
Streptomyces lividans 1326 SLP2 SLP3 (Hopwood et al., 
1983) 
Streptomyces coelicolor M1146 M145 ∆act ∆red ∆cpk ∆cda (Gomez-Escribano 
& Bibb, 2010) 
Micrococcus luteus ATCC4698  Novacta 
Biosystems 
 
 
Table 2.4:  Streptomyces lividans TK24 derivatives created in this work. 
Strain Genotype Reference 
M1201 pIJ12206 This work 
M1202 pIJ12207 This work 
M1203 pIJ12208 This work 
M1204 pIJ12209 This work 
M1205 pIJ12210 This work 
M1206 pIJ12397 This work 
M1207 pIJ12398 This work 
M1208 pIJ12399 This work 
M1209 pIJ12500 This work 
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Strain Genotype Reference 
M1210 pIJ12501 This work 
M1211 pIJ12502 This work 
M1212 pIJ12503 This work 
M1213 pIJ12504 This work 
M1214 pIJ12505 This work 
M1215 pIJ12506 This work 
M1216 pIJ10702 (empty vector control) This work 
M1278 pIJ12211 This work 
M1279 pIJ12397 in ΦC31 attB (∆garA) and pIJ12212 in ΦBT1 attB This work 
M1280 pIJ12398 in ΦC31 attB (∆garM) and pIJ12213 in ΦBT1 attB This work 
M1281 pIJ12399 in ΦC31 attB (∆garO) and pIJ12214 in ΦBT1 attB This work 
M1282 pIJ12500 in ΦC31 attB (∆garR1) and pIJ12215 in ΦBT1 attB This work 
M1283 pIJ12503 in ΦC31 attB (∆garK) and pIJ12216 in ΦBT1 attB This work 
M1284 pIJ12504 in ΦC31 attB (∆garR) and pIJ12217 in ΦBT1 attB This work 
M1285 pIJ12506 in ΦC31 attB (∆liqQ) and pIJ12218 in ΦBT1 attB This work 
 
 
Table 2.5:  Derivatives of Streptomyces coelicolor M1146 and Streptomyces lividans 
1326 created in this work. 
Strain Genotype Reference 
M1217 M1146 pIJ12206 This work 
M1218 M1146 pIJ12397 (∆garA::scar) This work 
M1219 M1146 pIJ10702 (empty vector control) This work 
M1220 1326 pIJ12206 This work 
M1276 1326 pIJ12397 (∆garA::scar) This work 
M1277 1326 pIJ10702 (empty vector control) This work 
 
 
Table 2.6:  Actinoplanes strains used in this work. 
Species Strain Genotype Reference 
Actinoplanes garbadinensis DSM 4432  (Parenti et al., 
1976) 
Actinoplanes liguriae NCIMB41362  (Boakes et al., 
2010) 
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2.2 Culture media and antibiotics 
 
Table 2.7:  Concentration of antibiotics used in this work 
Antibiotic Concentration (µg/ml) 
Apramycin (Apra) 
Carbenicillin (Carb)  
Chloramphenicol (Chlor) 
Hygromycin (Hyg) 
Kanamycin (Kan)  
Nalidixic acid (Nal) 
Spectinomycin (Spec) 
Streptomycin (Strep) 
Tetracycline (Tet) 
40 
100 
25 
40 
50 
20 
50 (E. coli)  200 (Streptomyces sp.) 
50 (E. coli)  10 (Streptomyces sp.) 
10 
 
Unless stated otherwise, the media used for the culturing actinomycetes and E. coli 
were prepared as previously described (Kieser, 2000). 
 
Table 2.8:  Agar media used in this work. 
Medium Composition  Preparation instructions 
 
L-Agar  
 
Agar 
Difco Bacto tryptone 
NaCl 
Glucose 
Distilled water 
10 g 
10 g 
5 g 
1 g 
Up to 1000 ml 
The ingredients, except 
agar, were dissolved in 
the distilled water and 
200 ml aliquots were 
dispensed into 250 ml 
Erlenmeyer flasks 
containing 2 g agar. The 
flasks were closed and 
autoclaved. 
Difco nutrient 
agar (DNA) 
 
Difco Nutrient Agar 
Distilled water 
4.6 g 
200 ml 
Difco Nutrient Agar was 
placed in each 250 ml 
Erlenmeyer flask and 
distilled water was added. 
The flasks were closed 
and autoclaved. 
Mannitol soya 
flour medium 
(MS)(SFM) 
 
Agar 
Mannitol 
Soya Flour 
Tap water 
20 g 
20 g 
20 g 
Up to 1000 ml 
The mannitol was 
dissolved in the water 
and 200 ml aliquots 
poured into 250 ml 
Erlenmeyer flasks each 
containing 2 g agar and 2 
g soya flour. The flasks 
were closed and 
autoclaved twice, with 
gentle shaking between 
the two runs. 
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Medium Composition  Preparation instructions 
 
Oatbran Medium 
(OB-N) 
Porridge Oats 
Lab M Agar 
Tap Water 
40 g 
20 g 
To 1000 ml 
The ingredients were 
mixed and dispensed into 
250 ml Erlenmeyer 
flasks. The flasks were 
closed and autoclaved 
twice, with gentle shaking 
between the two runs. 
ABB13 Soytone Peptone 
Soluble starch 
CaCO3 
MOPS 
Agar 
Distilled water 
Adjust pH to 7.0 
5 g 
5 g 
3 g 
2.1 g 
20 g 
To 1000 ml 
 
The ingredients were 
mixed and dispensed into 
250 ml Erlenmeyer 
flasks. The flasks were 
closed and autoclaved 
twice, with gentle shaking 
between the two runs. 
 
 
2.3 Liquid Media 
 
Unless stated otherwise, the media used for the culturing of actinomycetes and E. 
coli were prepared as previously described (Kieser, 2000, Sambrook & Russell, 
2001). 
 
Table 2.9:  Liquid media used in this work. 
Medium Composition  Preparation Instructions 
 
L (Lennox) 
broth (LB) 
Difco Bacto tryptone 
Difco yeast extract 
NaCl 
Glucose 
Distilled water 
10 g 
5 g 
5 g 
1 g 
Up to 1000 ml 
The ingredients were 
dissolved, in the distilled 
water and 10 ml aliquots 
were dispensed into 
universals and autoclaved. 
2 X YT 
medium 
Difco Bacto tryptone 
Difco yeast extract 
NaCl 
Distilled water 
16 g 
10 g 
5 g 
Up to 1000 ml 
The ingredients were 
dissolved, in the distilled 
water and 10 ml aliquots 
were dispensed into 
universals and autoclaved. 
SOB medium Tryptone 
Yeast extrace 
NaCl 
Distilled water 
20 g 
5 g 
0.5 g 
Up to 950 ml 
After dissolving the solutes in 
water, 10 ml 250 mM KCl 
was added and the pH was 
adjusted to pH 7 with 5 N 
NaOH. The volume was then 
made up to 1000 ml with 
deionised water and 
autoclaved. 
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Medium Composition  Preparation Instructions 
 
SOC 
medium 
  SOC medium is identical to 
SOB medium except that 
after autoclaving, 20 ml of 
sterile 1 M solution of 
glucose and 5 ml of sterile 2 
M MgCl2 were added. 
AAS seed 
medium 
Soluble starch 
Glucose 
Peptone 
Dry corn steep liquor 
Yeast extract 
Distilled water 
Adjust pH to 6.0 
10 g 
10 g 
5 g 
1 g 
2 g 
Up to 1000 ml 
The ingredients were 
dissolved in the distilled 
water and autoclaved. 
GM1 Lab Lemco meat 
extract 
Peptone 
NaCl 
Yeast extract 
Soy flour 
Glucose 
CaCO3
 
Distilled water 
Adjust pH to 7.6 
 
4 g 
4 g 
2.5 g 
1 g 
10 g 
25 g 
5 g 
Up to 1000 ml 
The ingredients were 
dissolved in the distilled 
water and autoclaved. 
TSB Tryptic soy broth 
Distilled water 
Adjust pH to 7.0 
30 g 
Up to 1000 ml 
The ingredients were 
dissolved in the distilled 
water and autoclaved. 
 
2.4 Solutions and buffers 
 
Table 2.10:  Solutions and buffers used in this study. 
Solution/buffer 
 
Compostion and instructions for preparation 
Cosmid isolation 
solution I 
Glucose 
Tris-HCl (pH 8) 
EDTA 
 
50 mM 
25 mM 
10 mM 
Cosmid isolation 
solution II 
NaOH 
SDS 
0.2 M 
1 % 
 
Cosmid isolation 
solution III 
Sodium acetate (pH 4.8) 
Acetic acid 
 
3 M 
DNA loading buffer Bromophenol blue 
Xylene-cyanol blue 
Sucrose in water 
 
0.25 % (w/v) 
0.25 % (w/v) 
40 % (w/v) 
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Solution/buffer 
 
Compostion and instructions for preparation 
Lysozyme solution 
(genomic DNA 
extractions) 
Sucrose 
Tris-HCl (pH 8) 
EDTA (pH 8) 
Lysozyme (Sigma) 
0.3 M 
25 mM 
25 mM 
2 mg/ml 
 
Phenol-chloroform- 
isoamylalcohol  
 
Phenol-chloroform-isoamylalcohol solutions were 
prepared by mixing the constituents 25:24:1. 
SDS stock solution 
 
10% (w/v) in H2O, filtered through a 0.45 m membrane. 
TAE buffer Tris 
Acetic acid 
EDTA 
40 mM 
1.142 % 
1 mM 
 
TES buffer Tris-HCl (pH 8) 
EDTA 
NaCl 
10 mM 
1 mM 
1 M 
 
2.5 Growth conditions 
 
2.5.1 Growth and storage of E. coli. 
 
E. coli was grown overnight on solid L-agar, or in liquid LB broth with shaking at 
37°C (30°C for temperature sensitive BW25113/pIJ10790).  For selection of 
plasmid- or cosmid-containing cells the appropriate antibiotics were added at the 
appropriate concentration.  For long-term storage, overnight cultures of LB broth 
cultures were mixed 40 % glycerol and stored at –80°C. 
 
2.5.2 Growth and storage of Streptomyces. 
 
Unless stated otherwise, all of the culturing methods for S. lividans or S. coelicolor 
were taken or adapted from those described by Kieser et al., (2000). 
 
For liquid culturing of S. lividans and S. coelicolor, ~108 spores were heat shocked 
at 50°C for 10 min in 5 ml TES buffer.  An equal volume of 2 x YT medium was 
added and this was incubated at 37°C for 3-4 h.  The emerging germ tubes were 
microscopically visible at this stage.  The germinated spores were recovered by 
centrifugation at 3000 x g on a benchtop centrifuge and then resuspended in 500 µl 
62 
 
of water. The cells were vortexed to disperse the clumps.  TSB liquid medium was 
inoculated to OD450 of 0.03-0.05.  Cultures were grown with shaking at 30°C until 
late stationary phase.  Mycelium was harvested by centrifugation at 3000 x g in a 
benchtop centrifuge. 
 
For manipulation and generation of spore stocks, S. lividans and S. coelicolor were 
plated onto SFM (with appropriate antibiotics) and incubated at 30°C for up to 7 
days.  Spores were collected in approximately 2 ml sterile 20% glycerol, using a 
sterile cotton pad through which the spores were filtered using a sterile 2 ml syringe 
and transferred to a cryotube.  Spore stocks were stored at -20°C.  Spore stocks 
were titred by making serial dilutions in water and plating on SFM.  Resulting 
colonies were counted from at least three dilutions and averaged. 
 
2.5.3 Growth and storage of Actinoplanes 
 
Actinoplanes strains were grown and manipulated as described in Boakes et al. 
(2009) and Boakes et al. (2010).  A. garbadinensis and A. liguriae were grown on 
OB-N or ABB13 agar for 7 to 10 days at 30°C.  For liquid growth, agar plugs taken 
from an Actinoplanes agar culture were typically placed in 250 ml baffled conical 
flasks containing 40 ml of TSB and incubated with shaking at 30°C for 6 to 7 days.  
For long-term storage, culture broth containing mycelium was dispensed into 2 ml 
cryotubes and stored at -20°C or -80°C. 
 
2.5.4 Growth and storage of M. luteus 
 
M. luteus ATCC4698 was typically grown in L broth with shaking at 250rpm or on L 
agar at 30 or 37°C.  For long-term storage, strains were grown over-night in L 
medium and cells resuspended in 20% glycerol and stored at -20°C or -80°C. 
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2.6 Genetic manipulations 
 
2.6.1 Plasmid Isolation 
 
Qiagen miniprep kits were used according to the manufacturer‟s instructions.  
Briefly, 5 ml of an overnight LB culture harbouring the plasmid of interest was 
centrifuged at 3000 g for 10 min. The cell pellet was then resuspended and 
underwent alkaline lysis.  The lysate was then neutralised and centrifuged in a 
microcentrifuge at 16000 g to remove cell debris and precipitated protein.  The 
supernatant was then applied to a silica membrane mounted in a microcentrifuge 
tube where it was washed under high salt and ethanolic buffer conditions during 
which time the DNA remains bound to the column.  DNA was eluted from the 
column in elution buffer.  Plasmid DNA was routinely stored at -20°C. 
 
2.6.2 Cosmid isolation from E. coli 
 
Cosmid isolation from E. coli was carried out by alkaline lysis as described by 
Sambrook et al. (2001).  The cell pellet from 1.5 ml of culture was resuspended by 
vortexing in 100 µl solution I.  200 µl solution II was added and the tubes inverted 
ten times.  A volume of 150 µl solution III was then added and mixed in by inverting 
the tube five times.  The tube was then centrifuged at 13000 rpm  in a 
microcentrifuge for 5 min at room temperature.  The supernatant was mixed with 
400 µl phenol/chloroform, vortexed briefly to mix and then centrifuged at 13000 rpm 
in a microcentrifuge for 5 min.  The upper phase was then transferred to a 1.5 ml 
tube, 600 µl of ice cold isopropanol was added and DNA precipitation was achieved 
by placing the tube on ice for 10 min followed by centrifuging at 13000 rpm in a 
microcentrifuge for 5 min.  The pellet was washed with 1 ml 70% ethanol and 
centrifuged at 13000 rpm in a microcentrifuge.  The pellet was dried by leaving the 
tube open for 5 min at room temperature prior to resuspension in 30 l elution 
buffer. 
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2.6.3 DNA extraction from Streptomyces 
 
2 µl of S. coelicolor spore stock was used to inoculate 10 ml SOC and grown 
overnight with shaking at 30°C.  The mycelium was recovered by centrifugation at 
3000 x g for 5 min at 4°C in a Sorvall GS3 rotor.  The mycelium was resuspended in 
500 µl of lysozyme solution.  The mycelium was incubated at 37°C for 60 min. 50 μl 
10% SDS was then added and incubation continued at 37°C for a further 15 min.  
The sample was then vortexed until the viscosity of the solution had decreased.  
300 µl phenol/chloroform/isoamyl alcohol was added and vortexed briefly until 
completely mixed.  The sample was centrifuged in a microcentrifuge on 16000 x g 
for 8 min.  Following centrifugation, the aqueous phase was removed to a fresh 
Eppendorf tube.  To decrease viscosity, 200 µl water was added to the supernatant.  
The supernatant was extracted twice with phenol/chloroform/isoamyl alcohol.  
Precipitation of the DNA was achieved by the addition of 0.1 volumes 3 M sodium 
acetate and 1 volume of ice-cold isopropanol and leaving for 10 min on ice.  The 
precipitated DNA was then recovered by centrifugation in a microcentrifuge at 
16000 x g for 5 min.  The DNA pellet was then washed with 70% ethanol before 
dissolving in 500 μl elution buffer at room temperature for 2 h.  DNAse free RNAse 
was then added to a final concentration of 40 μg/ml and the sample was incubated 
at 37°C for 30 min.  The DNA sample then underwent two 
phenol/chloroform/isoamyl alcohol extractions.  The DNA was precipitated and 
washed as before and was then dissolved in 100 μl elution buffer.  The DNA 
concentration was determined by spectrophotometry using the ND-1000 
spectrophotometer (NanoDrop®). 
 
2.6.4 Digestion of DNA using restriction enzymes 
 
Restriction enzyme digestion of cosmids, plasmids or genomic DNA was carried out 
according to the enzyme manufacturer‟s instructions.  In the case of double digests, 
an appropriate buffer was selected after consulting the manufacturer‟s literature.  
The reaction volume was typically 20 µl for analytical digests and 200 µl for 
preparative digests for use in targeting cassette construction.  Unless otherwise 
instructed, digests were typically carried out for 1 h at 37°C. 
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2.6.5 Agarose gel electrophoresis 
1% agarose gels were prepared with TAE buffer with 0.5 µg/ml ethidium bromide.  
Agarose gel electrophoresis was carried out in 1% TAE buffer at 100 V until 
completion.  Hyperladder I (Bioline) or 1 kb ladder (NEB) were used to provide size 
markers. 
 
2.6.6 Extraction of DNA from agarose gels 
 
DNA fragments separated in agarose gels were excised from the gel using a clean 
scalpel and purified using the Qiaquick gel extraction kit, following the 
manufacturer‟s instructions.  Briefly, the agarose gel slice containing the DNA 
fragment of interest was dissolved in a neutral pH, high salt buffer provided with the 
kit and applied to a silica gel membrane mounted in a microcentrifuge tube.  The 
column was washed and the DNA fragment was eluted in ultrapure water or elution 
buffer. 
 
2.6.7 Preparation and transformation of electro-
competent cells 
 
A single E. coli colony was used to inoculate 10 ml LB broth and grown overnight 
with shaking at 37°C.  100 µl of this preculture was inoculated into 10 ml SOB and 
grown at 37°C (30°C for BW25113/pIJ790) for 3-4 h with shaking at 200 rpm to an 
OD600 of ~ 0.6.  The cells were recovered by centrifugation at 3000 x g for 5 min at 
4°C in a Sorvall GS3 rotor.  After decanting the medium the pellet was resuspended 
by gentle mixing in 10 ml ice-cold 10% glycerol.  The cells were centrifuged as 
before and washed in 10 % glycerol a further two times.  After decanting the 
supernatant from the final wash, cells were resuspended in the remaining ~ 100 µl 
of 10% glycerol. 
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50 µl electro-competent cell suspension was mixed with ~ 100 ng DNA per 
transformation.  Electroporation was carried out in a 0.2 cm ice-cold electroporation 
cuvette using a GenePulser II (Bio-Rad) set to: 200 , 25 F and 2.5 kV.  The 
expected time constant is 4.5 – 4.9 ms.  After electroporation, 1 ml ice cold LB was 
immediately added to the shocked cells which were incubated with shaking for 1 h 
at 37°C (30°C for BW25113/pIJ790 transformed with cosmid).  Transformants were 
selected by spreading onto LB agar containing the appropriate antibiotic (or on DNA 
agar for selection with hygromycin). 
 
2.6.8 Transformation of chemically competent cells 
 
For transformation, 50 l of the suspension of competent cells were transferred to a 
1.5 ml microcentrifuge tube.  DNA was added (no more then 100 ng in a 10 l 
volume) and the suspension was mixed by gently swirling the tube.  The tube was 
stored on ice for 30 min.  The tube was then transferred to a water bath preheated 
to 42 C and incubated without shaking for exactly 90 s.  950 l of LB (prewarmed to 
37 C) was added to the cells and they were incubated with shaking at 37 C for 1 h.  
Transformants were selected by plating the transformation mix on to L-agar plates 
containing the appropriate antibiotics. 
 
2.6.9 FLP-mediated recombination to generate scar 
mutants 
 
E. coli DH5α/BT340 was grown in 10 ml L broth containing 25 µg/ml 
chloramphenicol overnight at 30 C with shaking at 250 rpm.  10ml L broth 
containing chloramphenicol were inoculated 1 in 20 with this overnight culture and 
incubated with shaking at 30 C for 3-4h until OD600 ~0.6.  Electrocompetent cells 
were generated from the culture as described in 2.6.7.  50 µl of the cell suspension 
were mixed with ~100 ng cosmid containing the FRT-flanked cassette to be 
removed.  Electroporation was carried out as 2.6.7.  Typically 150 μl aliquots of the 
transformation mix were plated onto L agar containing 25 µg/ml chloramphenicol 
and apramycin and incubated for 2 days at 30 C.  Approximately eight single 
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colonies were picked and streaked on to L agar without antibiotics and incubated at 
42 C overnight to promote FLP-recombination.  Single colonies from these plates 
were picked and streaked first on to L agar containing apramycin and then on to L 
agar containing antibiotics for selection of the backbone of the cosmid (carbenicillin 
and kanamycin for Supercos or carbenicillin and apramycin for pIJ10702).  The 
plates were incubated at 37 C overnight and compared to identify clones sensitive 
to the selection for the cassette used for mutagenesis but resistant to the selection 
for the cosmid backbone.  Four to eight such clones were selected and the removal 
of the cassette confirmed by PCR using flanking primers and the PCR products 
checked by Sanger sequencing. 
 
2.6.10 Ligation of DNA 
 
Fragments to be ligated were purified from solution using a Qiagen PCR purification 
kit or from an agarose gel using a Qiagen gel extraction kit.  The purifications were 
carried out according to the manufacturer‟s instructions.  The DNA was eluted in 
elution buffer.  A ligation reaction volume of 10 µl was carried out with an insert: 
vector molar ratio of 3:1.  Ligations were carried out overnight at 16 C using high 
concentration T4 DNA ligase (Promega). 
 
2.6.11 Conjugation of DNA into Streptomyces 
 
E. coli ET12567/pUZ8002 or S17-1 containing an oriT-containing vector was 
inoculated into 10 ml LB containing chloramphenicol (25 µg/ml), kanamycin (50 
µg/ml) and the appropriate antibiotic for selection of the oriT-containing vector and 
grown overnight at 37°C.  100 µl overnight culture was inoculated into 10 ml fresh 
LB plus antibiotics as above and grown for ~ 4 h at 37°C to an OD600 of 0.4 - 0.6.  
The cells were washed twice with 10 ml of LB to remove antibiotics that might inhibit 
the growth of Streptomyces, and were resuspended in 1 ml of LB.  While washing 
the E. coli cells, 10 µl (108) Streptomyces spores were added to 500 µl 2 × YT Broth 
for each conjugation, heat-shocked at 50°C for 10 min and then allowed to cool 
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slowly.  0.5 ml E. coli cell suspension was mixed with 0.5 ml heat-shocked spores 
and centrifuged briefly in a microcentrifuge.  800 l of the supernatant was poured 
off and the pellet was resuspended in 200 µl residual liquid.  A stepwise dilution 
series from 10-1 to 10-5 in a total of 200 l of water was generated.  200 l of each 
dilution was plated out on MS agar + 10 mM MgCl2 (without antibiotics) and 
incubated at 30°C for 16-20 h.  The plate was overlaid with 1 ml of water containing 
0.5 mg nalidixic acid and the appropriate plasmid selection for the isolation of 
exconjugants.  Incubation was continued at 30°C. 
 
2.7 Polymerase chain reaction (PCR) and DNA 
sequencing methods 
 
2.7.1 General PCR 
 
PCR from Streptomyces genomic DNA was typically carried out using 10 ng DNA 
as template (genomic DNA prepared according to section 2.6.3).  PCR from E. coli 
plasmid DNA was typically carried out using 1 µl of a standard plasmid or cosmid 
preparation (section 2.6.1 and 2.6.2) as template.  Primers were designed to have 
an annealing temperature between 55 and 60°C. 
 
 Reaction mixture: 
Forward primer (50 pmoles/µl)  1 µl  50 pmoles 
Reverse primer (50 pmoles/µl)  1 µl  50 pmoles 
Template DNA    x 
Buffer (10x)     5 µl  1x 
dNTPs (40 nmoles/µl)    1 µl  50 µM each 
Dimethylsulfoxide (DMSO)   2.5 µl  5 % 
DNA polymerase (2.5 U/µl)   1 µl  2.5µl 
Water to a volume of     50 µl 
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 Cycle conditions (Touchgene Gradient, Techne): 
 
 Initial denaturation:  96°C, 3 min 
 Denaturation   96°C, 30 s 
 Primer annealing  56°C, 30 s  30 cycles 
 Extension   72°C, x s 
 Final extension  72°C 10 min 
 
For all PCR reactions, an extension rate of 1 kb per minute was assumed for the 
DNA polymerase. 
 
2.7.2 E. coli colony PCR 
 
Colony PCR allows for the rapid screening of recombinant plasmids.  The PCR 
reaction mix was as in 2.7.1.  Single colonies of E. coli were picked from agar plates 
using a sterile toothpick and added to 50 µl of DMSO in a 1.5 ml Eppendorf tube.  
The tube was centrifuged briefly to pellet cell debris and 2.5 µl of the DMSO was 
added to the appropriate PCR mix in place of the DMSO and DNA template.  The 
initial denaturation time was increased by 2 minutes. 
 
2.7.3 Streptomyces colony PCR 
 
Streptomyces single colonies were patched on to DNA media containing 1% 
glucose.  Plates were incubated at 30°C overnight (20-24h).  Streptomyces 
mycelium was scraped from the plates using a sterile toothpick and added to 50 ul 
100% DMSO in a 1.5 ml Eppendorf tube.  The tube was shaken vigorously for 30-45 
mins and centrifuged briefly to pellet cell debris; 2.5 µl of the DMSO was added to 
the appropriate PCR mix in place of the DMSO and DNA template.  The initial 
denaturation time was increased by 2 minutes. 
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2.7.4 Purification of PCR products 
 
The QIAquick PCR purification kit (Qiagen) was used to remove unincorporated 
primers, dNTPs and enzymes from completed PCR reactions.  One tenth of the 
PCR reaction mixture was submitted to agarose gel electrophoresis and stained for 
visualisation.  The remaining PCR mixture was diluted 5 times in the manufacturer‟s 
high salt buffer and applied to a silica gel membrane mounted in a microcentrifuge 
tube.  The PCR products were washed free of primers, dNTPs and enzymes and 
the DNA fragment was eluted in elution buffer. 
 
2.7.5 DNA sequencing 
 
DNA sequencing was used to confirm the presence of inserts in recombinant 
plasmids and cosmids and to confirm the correct sequence of PCR amplified DNA 
fragments.  DNA sequencing was carried out using ABI BigDye 3.1 dye-terminator 
reaction mix (Applied Biosystems) with plasmid DNA template according to the 
manufacturer‟s instructions.  
 
Cycle conditions (Touchgene Gradient, Techne): 
 
 Initial denaturation 96°C, 1 min  
 Denaturation  96°C, 10 s 
 Primer annealing 50°C, 5 s  30 cycles 
 Extension  60°C, 4 min 
 
Sequence analysis was carried out by The Genome Analysis Centre at the John 
Innes Centre.  Sequence chromatograms were analysed using the chromatogram 
trace viewer software FinchTV (version 1.4; http://www.softpedia.com). 
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2.8 PCR targeting of cosmids 
 
PCR targeting was used to generate mutagenised cosmids in E. coli that could be 
subsequently transferred to Streptomyces via conjugation.  In general, the strategy 
is carried out with minor modifications to that described in REDIRECT technology:  
PCR-targeting system in Streptomyces coelicolor by Gust et al. (2004). 
 
2.8.1 PCR amplification of disruption cassettes 
 
The pIJ782 (tet) and pIJ773 (apra) templates were used to generate targeting 
cassettes for the creation of mutant cosmids.  Gene specific primers for the 
generation of each deletion mutant were designed in accordance with the criteria 
specified by (Gust et al., 2004).  These primer pairs were used in association with 
the appropriate disruption template to generate cassettes flanked by the gene-
specific 39 nt homology extensions and are listed in Table 2.11. 
 
pIJ10257 was used for the constitutive expression of genes using the ermEp* 
promoter, where the gene of interest was amplified with appropriate primers (table 
2.13) that include restriction sites.  After cloning of the PCR product into pGem 
(following manufacturer‟s instructions), PCR amplified fragments were confirmed by 
PCR (sections 2.7.4 and 2.7.5), cut from the vector with the appropriate enzymes 
and ligated with pre-digested pIJ10257 (section 2.6.10) and transferred into 
Streptomyces by conjugation (2.6.11). 
 
All PCR amplifications were performed using the Expand high fidelity PCR system 
according to the manufacturer‟s instructions (Roche).  Reaction conditions: 
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Reaction mixture: 
Forward primer (50 pmoles/µl)  1 µl  50 pmoles 
Reverse primer (50 pmoles/µl)  1 µ  50 pmoles 
Template DNA    50 ng 
Buffer (10x)     5 µl  1x 
dNTPs (40 nmoles/µl)    1 µl  50 µM each 
Dimethylsulfoxide (DMSO)   2.5 µl  5% 
DNA polymerase (2.5 U/µl)   1µl  2.5µl 
Water to a volume of     50 µl 
 
 
Cycle conditions (Touchgene Gradient, Techne): 
 
 Initial denaturation  94°C, 2 min  
 Denaturation   94°C, 45 s 
 Primer annealing  50°C, 45 s  10 cycles 
 Extension   72°C, 90 s 
 
 Denaturation   94°C, 45 s 
 Primer annealing  55°C, 45 s  15 cycles 
 Extension   72°C, 90 s 
 Final extension:  72°C, 5 min 
 
5 µl of the PCR product was used for analysis by agarose gel electrophoresis 
(section 2.6.6).  To remove enzymes, unincorporated primers and dNTPs, the 
remaining 45 µl of the PCR product was purified using the Qiagen PCR purification 
kit according to the manufacturer‟s instructions (section 2.7.4).  The PCR product 
was eluted from the column with 20 µl of water to give a DNA concentration of 
approximately 100 ng/µl. 
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Table 2.11:  Primers used for the amplification of gene-specific disruption cassettes 
in this study. 
Primer name Primer sequence (5‟  3‟) 
garA APR LFP 
SpeI forward 
ggctattcgcccgggaagtccaccgaaaggaagacacaccactagtattccggggatccgtcgacc 
 
garA APR LFP 
AvrII reverse 
gggcgggcgatgcccgccccgggccggaaacgatcgtcgacctaggtgtaggctggagctgcttc 
 
garM APR LFP 
SpeI forward 
cgcccgccccgggccatccatttcgcgcggggagcagccactagtattccggggatccgtcgacc 
 
garM APR LFP 
AvrII reverse 
agcacgctgagcacgatctcttccggcatgggctcctcccctaggtgtaggctggagctgcttc 
 
garO APR LFP 
SpeI forward 
tggcctggctgcagccgccgctgacctgaggaggagcccactagtattccggggatccgtcgacc 
 
garO APR LFP 
AvrII reverse 
gcgcgggacctacgcggagctaccgcggacctgaggccgcctaggtgtaggctggagctgcttc 
 
garR1 APR LFP 
SpeI forward 
tccgcgtaggtcccgcgcaatgccgcggacctgacggccgactagtattccggggatccgtcgacc 
 
garR1 APR LFP 
AvrII reverse 
atataagtgaagtaatgtcacgaatgcggatgcaagttgccctaggtgtaggctggagctgcttc 
 
garH APR LFP 
SpeI forward 
atttttcgcgtatagtcattaacaacacacagcgcgtcgactagtattccggggatccgtcgacc 
 
garH APR LFP 
AvrII reverse 
tcagatcctcgcggcgatggcgtcggtggcggtgtgacgcctaggtgtaggctggagctgcttc 
 
garT APR LFP 
SpeI forward 
aggcgcgcagctgggaccaggcaagcgcgaagatcatcgactagtattccggggatccgtcgacc 
 
garT APR LFP 
AvrII reverse 
agcgtgggtgcggtgacaacgcagacgacacacgccgagcctaggtgtaggctggagctgcttc 
 
garK APR LFP 
SpeI forward 
atgtctgcttaggctgggaccgtggtgcgagggaaccggactagtattccggggatccgtcgacc 
 
garK APR LFP 
AvrII reverse 
atcgtcggcgatcagcacggcgatcggtggccgcgtcatcctaggtgtaggctggagctgcttc 
 
garR APR LFP 
SpeI forward 
accacctggcccctcaccccggaaggagcgcgcgcatgaactagtattccggggatccgtcgacc 
 
garR APR LFP 
AvrII reverse 
tgccaccgtggcaccgtgtcaagggcctgagggtgcggacctaggtgtaggctggagctgcttc 
 
garPBP APR LFP 
SpeI forward 
gtttcgcctcacactggtggtggtgcggtgagttcctggactagtattccggggatccgtcgacc 
 
garPBP APR LFP 
AvrII reverse 
cacgaggcgaacgccggcgacgtctacgccgtcagccggcctaggtgtaggctggagctgcttc 
 
ligQ APR LFP 
SpeI forward 
gtcacctggctggaaccgccgcggggcacgcatgtctgaactagtattccggggatccgtcgacc 
 
ligQ APR LFP 
AvrII reverse 
cctggtccaggacactgagcatggcgtacacctcgggatcctaggtgtaggctggagctgcttc 
 
garO tet LFP 
SpeI forward 
tggcctggctgcagccgccgctgacctgaggaggagcccactagtaataggcgtatcacgaggcc 
garO tet LFP 
AvrII reverse 
gcgcgggacctacgcggagctaccgcggacctgaggccgcctaggcgccggcttc 
CosAG14.2 tet 
LFP SpeI forward 
ccgtcgggaccgaccgtgacgacgatccgaggattctccgactagtaataggcgtatcacgaggcc 
CosAG14.14 tet 
LFP AvrII reverse 
gcgagccagtacagcggagtcggccgcaagcgctgaggcgcctaggcgccggcttc 
CosAG14.18 tet 
LFP AvrII reverse 
tgcttcgcccacgggaacaagtgaaaatgggagaacaacgcctaggcgccggcttc 
CosAG14.28 tet 
LFP SpeI forward 
gtggtggtgatccaggtgagcaagggccgccggggcgcgtactagtaataggcgtatcacgaggcc 
CosAG14.30 tet 
LFP AvrII reverse 
tcgaggatgtccttcatggagacgacgggcatgccgccagcctaggcgccggcttc 
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2.8.2 Introduction of cosmids into E. coli 
BW25113/pIJ790 by electroporation 
 
E. coli BW25113 is a -RED recombination-proficient host strain and contains 
pIJ790, carrying the antibiotic resistance marker cat (chloramphenicol resistance) 
and a temperature sensitive origin of replication (replicates at 30°C, not at 37 C).  
BW25113/pIJ790 was grown overnight at 30°C in 10 ml LB containing 
chloramphenicol (25 g/ml).  100 l of the overnight culture were inoculated into 10 
ml SOB containing chloramphenicol (25 g/ml) and grown for 3-4 h at 30°C with 
shaking at 200 rpm to an OD600 of ~ 0.6.  Electrocompetent cells were generated 
from this culture and transformed with 100 ng cosmid DNA by electroporation 
(section 2.6.3).  Transformants were selected by spreading onto L-agar containing 
carbenicillin (100 g/ml), kanamycin (50 g/ml) and chloramphenicol (25 µg/ml) and 
incubating overnight at 30°C. 
 
2.8.3 PCR targeting of a cosmid 
 
10 ml SOB (without MgSO4) containing carbenicillin (100 µg/ml), kanamycin (50 
µg/ml) and chloramphenicol (25 µg/ml) were inoculated at a concentration of 1% 
with an overnight culture of E. coli BW25113/pIJ790 containing the cosmid of 
interest.  100 µl 1 M L-arabinose was added to a final concentration of 10 mM to 
induce the  RED recombination system.  The culture was grown for 3-4 h at 30°C 
with shaking at 200 rpm to an OD600 of ~ 0.6 and electrocompetent cells were 
prepared.  50 µl cell suspension was then mixed with ~ 100 ng (1-2 µl) of PCR 
product and electroporated (section 2.6.7).  Selection for gene disruption in the 
cosmid of interest was carried out on LB agar containing carbenicillin (100 µg/ml), 
kanamycin (50 µg/ml) and apramycin (50 µg/ml)/ tetracycline (10 µg/ml) overnight at 
37°C.  Correct targeting of cosmids was confirmed by PCR and restriction analysis.  
 
The targeting cassettes were subsequently removed using the FLP recombinase,  
detailed in section 2.6.9. 
 
Gene disruptions were checked using a combination of PCR (section 2.7.1, 2.7.2 
and 2.7.5) and restriction analysis (2.6.4). 
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Table 2.12:  Primers used for the confirmation of gene disruptions. 
Primer name Primer sequence (5‟  3‟) 
garA (con-3) forward cgaaatcgccgggctattcg 
garA (con-3) reverse ctgtcgcgtaccgaggtg 
garM (con-3) forward gcgagctcaccttcgag 
garM (con-3) reverse cggtggtagccgtactg 
garO (con-3) forward gcatctgccacggcgac 
garO (con-3) reverse gggtctgtccagcgacgac 
garR1 (con-3) forward gtatccgaggtggtgctcac 
garR1 (con-3) reverse gtctgacccgctgacgac 
garH (con-3) forward gatgctgaccagtgcttcg 
garH (con-3) reverse gtgaggaactgcgcagtc 
garT (con-3) forward ccggtcgccagcatcac 
garT (con-3) reverse cacggtcccagcctaagcag 
garK (con-3) forward cgccgtgttcccgcaatcg 
garK (con-3) reverse gaccatcgcgaaaccggtgc 
garR (con-3) forward cactgttcaacggcgactgc 
garR (con-3) reverse cgcaccaccaccagtgtg 
garPBP (con-3) forward ctcaggcccttgacacg 
garPBP (con-3) reverse cgttgtcgttcgagttcacg 
LigQ (con-3) forward gggacatcggcgagac 
LigQ (Con-3) reverse caccttgagcgggctg 
TcR Rev (con-1) ccaagcctatgcctacagc 
TcR Fwd (con-2) gctcaagccttcgtcactg 
10257 seq F acgtccatgcgagtgtcc 
10257 seq R ccaaacggcattgagcgtc 
 
 
Table 2.13:  Primers used for the amplification of complementation constructs. 
Primer name Primer sequence (5‟  3‟) 
garA NdeI ermE fwd aaaaacatatgtctgctctcgccatcgag 
garA HindIII ermE rev aaaaaaagctttcagcaggcgcagatc 
garM NdeI ermE fwd aaaaacatatgtcaccggttccttc 
garM HindIII ermE rev aaaaaaagctttcaggtcagcggcg 
garO NdeI ermE fwd aaaaacatatgccggaagagatcgtgctc 
garR1 NdeI ermE fwd aaaaacatatgcgttcggcggctcg 
garR1 HindIII ermE rev aaaaaaagctttcaggacaggcagacgt 
garK NdeI ermE fwd 
garK HindIII ermE rev 
aaaaacatatgctcaggatcgacgccc 
aaaaaaagctttcatgcgcgcgctc 
garR NdeI ermE fwd aaaaacatatgacgcggccaccg 
garR HindIII ermE rev aaaaaaagctttcagccgacagcgc 
garPBP NdeI ermE fwd aaaaacatatgcgccggcgcg 
garPBP HindIII ermE rev aaaaaaagctttcagcggggtggc 
ligQ NdeI ermE fwd aaaaacatatgtctgagacggccggg 
LigQ HindIII ermE rev aaaaaaagctttcaggtcagcagttgacgg 
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2.8.4 Construction of integrative cosmids 
 
The FLP mediated excision of the targeting cassette required the re-introduction of 
oriT to allow for the transfer of the cosmid into Streptomyces.  The targeted cosmids 
were transferred back into E. coli BW25113/pIJ790. 
 
E. coli BW25113/pIJ790 containing the SuperCos1 cosmid (containing the FLP 
mediated gene deletion) to be targeted was grown in 10ml L broth containing 50 
μg/ml carbenicillin, 50 μg/ml kanamycin and 25 μg/ml chloramphenicol overnight at 
30°C with shaking at 250 rpm. 10 ml SOB (minus Mg) containing carbenicillin, 
kanamycin, chloramphenicol and 10 mM L-arabinose was inoculated 1 in 20 with 
this overnight culture which was incubated with shaking at 30°C for 90 min.  An 
additional 100 μl 1 M L-arabinose were added and incubation continued at 30°C for 
an additional 60 min (until OD600 0.6).  Electrocompetent cells were generated from 
the induced culture as described in 2.6.7.  50μl of the cell suspension were mixed 
with 100 ng gel purified 5247 bp SspI fragment derived from pIJ10702 
(pMJCOS1).  Electroporation was carried out as 2.6.7.  Typically 300 μl aliquots of 
the transformation mix were plated onto two plates of L agar containing 50 μg/ml 
apramycin and 100 μg/ml carbenicillin and incubated overnight at 37°C. 
 
2.8.5 Transfer of mutant cosmids into Streptomyces 
 
Since S. coelicolor carries a methyl-specific restriction system it was necessary to 
passage the targeted cosmids containing an oriT through a non-methylating E. coli 
host.  Constructs for all Streptomyces were transferred into E. coli ET12567 
pUZ8002 so that they could be conjugated into a number of hosts.  To achieve this, 
the cosmids were introduced by transformation into the non-methylating E. coli 
ET12567 containing the RP4 derivative pUZ8002.  The cosmid was then transferred 
to Streptomyces by conjugation (section 2.6.11).  Exconjugants were selected using 
the appropriate antibiotic. 
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2.8.6 Confirmation of PCR targeted mutants in 
Streptomyces 
 
Confirmation was typically carried out using colony PCR (section 2.7.3) or PCR 
using genomic DNA (section 2.6.3 and 2.7.1). 
 
2.9 Bioassay methods 
 
2.9.1 Solid bioassay 
 
Streptomyces and Actinoplanes strains were assessed for antimicrobial activity 
using M. luteus as test organism.  2.5 ml of molten agar were poured into each of 
the 25 sections of divided square Petri plates and allowed to set.  Either 5 µl of a 
glycerol stock or 5 µl of water containing material scraped from a plate was used to 
inoculate each agar cube, and the plate incubated for 7 days at 30°C.  M. luteus 
was grown as described in section 2.5.4.  The overnight culture was diluted 1 in 25 
into 50 ml L broth and grown at 30°C with shaking until an OD600 of 0.4-0.6 was 
reached.  This culture was diluted 1 in 10 into molten L agar at 50°C and 
approximately 20 ml poured into 90 mm standard Petri dishes.  The agar plugs with 
the strains to be assessed were subsequently added to the top of the plate and 
incubated at 30°C until a halo could be seen (typically overnight). 
 
2.9.2 Liquid bioassays 
 
For liquid bioassays, agar plugs taken from Actinoplanes agar cultures were 
typically placed in 50 ml conical flasks containing 8 ml of AAS seed medium with 
appropriate antibiotics (if required) and three or four glass beads, and incubated 
with shaking at 30°C for 3-4 days.  250 µl was taken and used to inoculate a 50 ml 
flask containing 8 ml of GM1 and incubated at 30°C for a further 3-4 days.  
Streptomyces cultures were similarly incubated but using TSB medium.  1 ml 
aliquots were taken and spun at 13000 rpm in a centrifuge for 10 minutes.  The 
supernatant was either analysed by MALDI-ToF analysis or added to L agar plates 
pre-seeded with M. luteus.  For the bioassays, M. luteus was grown as described in 
section 2.5.4.  The overnight culture was diluted 1 in 25 into 50 ml L broth and 
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grown at 30°C with shaking until an OD600 of 0.4-0.6 was reached.  This culture was 
diluted 1 in 10 into molten L agar at 50°C and approximately 20 ml poured into 90 
mm standard Petri dishes.  Holes were made in the agar using an unturned sterile 
P1000 tip.  50 µl of the spun supernatant was added to the hole and allowed to dry 
before incubation at 30°C until a halo could be seen (typically overnight). 
 
2.10 MALDI-ToF analysis 
 
Culture supernatants were diluted 1 in 5 with 5% formic acid.  The diluted sample 
(ca. 0.8 µl) was spotted onto a PAC plate (Prespotted AnchorChipTM MALDI target 
plate, Bruker Daltonics, Bremen, Germany) and the spots washed briefly with 8 µl 
5% formic acid according to the manufacturer.  After drying, the samples were 
analysed by MALDI-ToF on a Bruker Ultraflex TOF/TOF.  The instrument was 
calibrated using the prespotted standards (ca. 200 laser shots).  Samples were 
analysed using a laser power of approx. 25% and spectra were summed from ca. 
20 x 20 laser shots. 
 
2.11 LC/MS analysis 
 
High performance liquid chromatography – mass spectrometry (HPLC-MS or 
LC/MS) were performed on a Hewlett Packard 1050 series HPLC system linked to a 
Micromass Platform LC (operated with MassLynx version 3.5 software) with the 
following parameters: 
 
Column:    Agilent Zorbax SB-C18 150 x 4.6 mm 5µ 
Mobile Phase A:   10% acetonitrile, 0.1% formic acid, in water 
Mobile Phase B:  90% acetonitrile, 0.1% formic acid, in water 
Flow rate:    1 ml/min 
Gradient: 
Time 0 min    100% A  0% B 
Time 10min    0% A   100% B 
Time 11min    0% A   100% B 
Time 11.2min    100% A  0% B 
Cycle time    15 min 
Wavelength:    200 – 400 nm 
79 
 
Injection volume:   10 µl 
Post column split:   1:10 
Mass spectrometer:   Micromass Platform LC 
Mode:     Electrospray positive ion 
Cone voltage:    40V 
Capillary voltage:   3.10V 
Skimmer lens offset:   5V 
Ion Energy:   1.4V 
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3 Computational analysis 
 
3.1 Introduction 
 
Bioinformatic analysis of DNA sequences has become a powerful technique that 
allows the identification and characterisation of genes and the proteins they encode 
through their homology to other characterised examples. 
 
Comparison of putative gene products against a database of previously identified 
and characterised proteins can lead to the identification and classification of 
unidentified genes of interest based on amino acid sequence homology of the 
encoded protein (Chatterjee et al., 2005).  Using this approach and computational 
analysis, this study identified a number of lantibiotic biosynthetic genes likely to be 
required for actagardine and DAB biosynthesis. 
 
The genes required for production of a particular lantibiotic are clustered together in 
the genome of the producing organism.  The clusters contain genes that encode a 
prepropeptide, at least one modification enzyme and genes for transport and 
immunity.  Most clusters also contain a regulatory gene or genes that control the 
expression of the biosynthetic genes (Chatterjee et al., 2005, Schmitz et al., 2006).  
Identification of lantibiotic biosynthesis genes can be accomplished because of the 
specialised functions that these proteins carry out, and the corresponding 
conservation of amino acid sequence across functional homologues. 
 
The complement and organisation of genes is often well conserved between 
biosynthetic gene clusters that encode similar LanA prepropeptides, for example, 
nisin and subtilin produced by Lactococcus lactis and Bacillus subtilis, respectively 
(Chatterjee et al., 2005).  Genes found within lantibiotic gene cluster that might 
perform additional functions can sometimes be identified by their absence from 
similar lantibiotic gene clusters; for example, mrsD that encodes a flavoprotein 
responsible for the creation of the unusual S-[(Z)-2-aminovinyl]-methyl-D-cysteine in 
mersacidin (Blaesse et al., 2003), and cinR1 that encodes the SARP (Streptomyces 
antibiotic regulatory protein) in the cinnamycin gene cluster, the only example of the 
presence, in a lantibiotic gene cluster, of a member of this family of regulatory 
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genes  (Blaesse et al., 2003, Widdick et al., 2003).  Analysing the composition of the 
gene cluster may also give some indications of its evolutionary origin. 
 
3.2 Computational analysis of actagardine and DAB 
biosynthesis 
 
Actagardine biosynthesis is currently being studied by Novacta Biosystems.  One of 
the main aims of their research is to produce a new clinically useful lantibiotic.  To 
achieve this aim they attempted to clone the actagardine biosynthetic gene cluster 
into a heterologous host to both manipulate the lantibiotic that the cluster produced, 
and to enable high levels of lantibiotic production.  To do this, a detailed description 
of all of the genes involved in actagardine biosynthesis was required.  To this end 
Novacta created cosmid libraries of ~35-40 kb fragments of genomic DNA from A. 
garbadinensis and A. liguriae.  The libraries were initially probed with DIG-labelled 
SBDIG-1 probe, designed based on the known amino acid sequence of 
actagardine, taking into account the codon usage of Actinoplanes.  This probe was 
used in colony hybridisation experiments and successfully identified cosmid 
pLITAG01 derived from A. garbadinensis which was subsequently sequenced.  The 
cosmid sequence was analysed and used to design a new probe designated 
SBDIG-2, ~2.3 kb in length, generated using pLITAG01 as a template.  Both probes 
were then used to screen SuperCos1 genomic libraries of both A. garbadinensis 
and A. liguriae, identifying several cosmids that hybridised to both probes.  Two 
cosmids, AG14 from A. garbadinensis and AL02 from A. liguriae, were subsequently 
fully sequenced.  Heterologous expression of AG14 in S. lividans 1326 confirmed 
that the cosmid contained all of the genes required for the production of 
actagardine.  Novacta Biosystems were unable to confirm that all of the genes 
required for DAB biosynthesis were present on AL02 since there was no production 
of DAB when the cosmid was conjugated into the same heterologous host. 
 
An initial bioinformatic analysis carried out by Novacta Biosystems was completed 
several years ago.  With the recent explosion in the amount of publicly available 
sequence information, a new analysis was performed to see if the original 
annotation could be improved.  While gene annotations describing the potential 
function of each gene product have remained mostly the same, additional data 
added to the databases has provided further and more reliable gene homology 
comparisons and more detailed information about the encoded proteins compared 
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to the original Novacta study.  In recent publications, Novacta has also updated its 
bioinformatic analyses of the biosynthetic gene clusters for both actagardine and 
DAB (Boakes et al., 2010, Boakes et al., 2009). 
 
The cosmid sequences for AG14 and AL02 used in this study were kindly provided 
by Novacta Biosystems and visualised using the Artemis program (version 8) 
available from the Sanger Institute (Rutherford et al., 2000).  Open reading frames 
(ORFs) were first identified from the raw sequence using the graphic tool “GC frame 
plot” (Bibb et al., 1984) available within the Artemis program.  This algorithm visually 
displays ORFs based on the position-specific, non-random distribution of 
nucleotides within codons, and is particularly effective with sequences of high G + C 
content.  Manual inspection of the “frame plot” allowed designation of start and stop 
codons to each individual ORF.  Both cosmid sequences were also compared using 
webACT (web-based Artemis Comparison Tool, available from the Sanger Institute), 
a tool that visualises sequence homology between two or more selected sequences. 
 
Likely protein coding sequences were extracted (in FASTA format) and submitted to 
the basic local alignment search tool database using BLASTP 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi), using default parameters (Altschul et al., 
1990).  Putative gene functions were then assigned to the ORFs that had database 
homologues with known or predicted function. 
 
Bioinformatic analysis also provided data on the presence of DNA and RNA 
secondary structures.  Using the computer program Clone Manager (version 6, Sci-
Ed Software, http://www.scied.com/index.htm), both the AG14 and AL02 cosmids 
were analysed for the presence of stem-loop structures that might act as 
transcriptional terminators or attenuators for some of the genes within the 
biosynthetic clusters. 
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3.2.1 Overview of cosmids AG14 and AL02 
 
Annotation of the sequenced cosmids identified 32 putative genes in AG14, and 31 
genes in AL02 (figure 3.1).  Table 3.1 contains the ORF number, as well as a brief 
description of the proposed function of each gene. 
 
The genes highlighted in grey in figure 3.1 are hypothesised to be involved in 
actagardine and DAB biosynthesis.  The actagardine gene cluster of AG14 is 
proposed to consist of eight genes, while the DAB gene cluster of AL02 appears to 
contain nine biosynthetic genes.  The gene clusters are very similar; all the shared 
biosynthesis genes occupy the same relative position and orientation in both 
clusters.  This high level of similarity between the two clusters is perhaps not 
surprising given that they produce very similar lantibiotics.  This high level of 
similarity may indicate a recent transfer of the cluster from one Actinoplanes species 
to the other.  However, it is also possible that both gene clusters have evolved from 
a yet unidentified common ancestor.  Analysis using webACT failed to identify any 
significant sequence similarity between the two cosmids (see section 3.5) apart from 
the shared lantibiotic biosynthesis genes, with the possible exception of four genes 
to the right of each cluster (discussed later).   
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Figure 3.1:  Schematic representation of the cloned DNA fragments present in 
cosmid AG14 from A. garbadinensis (A) and cosmid AL02 from A. liguriae (B).  
Open arrows indicate the orientation and position of each identified ORF.  Genes 
present in the proposed biosynthetic gene clusters are in grey, with the respective 
lanA genes in dark grey.  The asterisk highlights the approximate location of a stem-
loop structure. 
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Cosmid AG14 
ORF Proposed function Length 
1 Unknown 146 
2 Unknown 149 
3 ATPase involved in cell division 518 
4 Sugar hydrolase 203 
5 Endoglucanase 219 
6 Cytosine/adenine deaminase 161 
7 Unknown 413 
8 Unknown 227 
9 Pyruvate oxidase 597 
10 Hydrolase or acyltransferase 223 
11 Aldose epimerase 396 
12 ABC transport component 378 
13 ABC sugar transport permease 352 
14 ABC transport protein 253 
15 Unknown 255 
16 ABC transport permease 280 
17 ABC transport permease 301 
18 Substrate binding ABC transporter 445 
19 GarA, actagardine prepropeptide 64 
20 GarM, modification enzyme 1053 
21 GarO, monooxygenase 336 
22 GarR1, response regulator 231 
23 GarH, transporter permease 812 
24 GarT, ABC transporter 259 
25 GarK, response regulator kinase 372 
26 GarR, response regulator sensor 220 
27 Penicillin binding protein 800 
28 Methyltransferase 253 
29 Hydrolase 261 
30 Response regulator 222 
31 Fructose bisphosphate aldolase 286 
32 Hydrolase 192 
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Cosmid AL02 
ORF Proposed function  Length 
1 Secretion system protein 375 
2  Response regulator 389 
3  Unknown 266 
4. Unknown 432 
5. Response regulator ATP binding 136 
6. ABC sugar transporter 363 
7. ABC sugar transporter ATP binding 501 
8  ABC transport permease 319 
9  ABC transport permease 320 
10  Metallopeptidase 486 
11  Transcriptional regulator 286 
12  LigA, deoxyactagardine prepropeptide 64 
13  LigM, modification enzyme 1046 
14  LigQ, ABC transporter 575 
15  LigO, monooxygenase 347 
16  LigR1, response regulator 217 
17  LigH, transporter permease 814 
18  LigT, ABC transporter 240 
19  LigK, response regulator kinase 362 
20  LigR, response regulator sensor 218 
21  Putative membrane protein 301 
22  α/β hydrolase-like protein 290 
23  Transcriptional regulator 145 
24  Pyruvoyl-dependent arginine 
decarboxylase 
175 
25  Diaminopimelate decarboxylase 406 
26  Kinase 309 
27  Transcriptional regulator 367 
28  Glycosyl transferase 317 
29  Glycosyl transferase 369 
30  Dihydrolipoamide dehydrogenase 459 
31  Putative membrane protein 348 
Table 3.1:  ORFs found within cosmids AG14 and AL02 from A. garbadinensis and 
A. liguriae respectively.  Listed are the proposed functions and encoded protein 
lengths (amino acids) of each ORF. 
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3.3 Biosynthetic gene analysis 
 
Based on its predicted amino acid sequence, garA (ORF 19 of AG14) encodes the 
64 amino acid actagardine prepropeptide.  Similarly, ligA (ORF 12 of AL02) encodes 
the very similar 64 amino acid DAB prepropeptide.  The prepropeptides are 
subsequently modified by their respective biosynthetic enzymes to produce mature 
actagardine and DAB, including cleavage of the 45 amino acid long leader 
sequence from each propeptide. 
 
Both prepropeptides consist of two distinct parts, a leader sequence potentially 
involved in interacting with modification enzymes and maintaining the peptide in an 
inactive form, and the propeptide, the unmodified version of the mature lantibiotic 
(Chakicherla & Hansen, 1995, Patton et al., 2008, van der Meer et al., 1994).  The 
prepropeptides share 78% amino acid identity (figure 3.2), with reduced similarity 
towards the N-terminus, perhaps reflecting less of a role for this part of the leader 
sequence in interacting with the modification machinery. 
 
A BLASTP search using the GarA prepropeptide identified two other GarA 
homologs, ClvA from C. michiganensis and GnaA, a previously undiscovered 
actagardine-like prepropeptide encoded by a lanA gene found in Ruminococcus 
gnavus (with an identical R. gnavus gnaA also found in Blautia hansenii, see 
chapter 5 for more details).  GarA shares a high degree of propeptide homology 
with LigA, ClvA, and some with GnaA, presumably reflecting the production of 
structurally similar lantibiotics.  There is however little overall conservation of amino 
acid sequence between the leader sequences of these prepropeptides, and those of 
closely related lantibiotics (figure 3.3).  A BLASTP hit with the mersacidin 
prepropeptide MrsA was also returned, and included a conserved PAG motif in the 
leader sequence (figure 3.3; see below). 
 
The amino acid sequences of the five prepropeptides were aligned using ClustalW 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html) (figure 3.3A).  The alignment was 
adjusted manually and revealed a number of conserved residues found in all of the 
LanAs, particularly in the propeptide region (figure 3.3B).  Mersacidin showed less 
similarity, reflecting its different structural characteristics (figure 3.3). 
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All the leader sequences with the exception of that for ClvA share a number of 
conserved residues found in a number of other leader sequences (Chatterjee et al., 
2005).  In particular, the PAG motif (highlighted in red) is present in all five 
sequences (DAG in ClvA), although its function is unknown.  Both MrsA and GnaA 
share a NPA motif (part of the highly conserved PAG motif) with cinnamycin 
(Widdick et al., 2003, Chatterjee et al., 2005).  The leader sequence of GnaA is 
much shorter than the others and is missing many of the conserved residues along 
the length of the leader peptide.  This may reflect the distant evolutionary 
relationship of GnaA to the other LanA prepropeptides.  All five leader sequences 
lack amino sequence motifs, such as the FNLD motif, found in lantibiotic leader 
sequences from other rare Actinomycetes (Foulston & Bibb, 2010).  However, 
interestingly, the GarA, LigA and MrsA propeptides are all preceded by an unusual 
AA motif (figure 3.3B) that is not observed in any other lantibiotic prepropeptide 
(Chatterjee et al., 2005). 
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Figure 3.2:  The prepropeptides of GarA and LigA.  The arrow indicates the cleavage point of the leader sequence from the propeptide.  These 
two peptides share 78% amino acid identity. 
A 
GarA            -------MSALAIEKSWKDVDLRDGATSHPAGLGFGELTFEDLREDRTIYAASSGWVCTLTIECG------TVICAC-    64 
LigA            -------MSAITVETTWKNTDLREDLTAHPAGLGFGELSFEDLREDRTIYAASSGWVCTLTIECG------TLVCAC-    64 
MrsA            -------MSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMD--KLVGAGDMEAACTFTLPGGGGVCTLTSECIC-    68 
GnaA            -------------MRKFDRTNMKYN---NPAGNLLTELEAADLTSNKVDSLGSSGVVCTISVECG---SIFTLAC-C-    57 
ClvA            MNDILETETPVMVSPRWD-MLLDAGEDTSPS---VQTQIDAEFRRVVSPYMSSSGWLCTLTIECG------TIICACR    68 
                                :.      .    *:   .      ::        ..    **:::  *      *  * * 
B 
GarA    -------MSALAIEKSWKDVDLRDGATSHPAGLGFGELTFEDLREDRTIY------AA    SSGW------VCTLTIECGTVIC-AC- 64 
LigA    -------MSAITVETTWKNTDLREDLTAHPAGLGFGELSFEDLREDRTIY------AA    SSGW------VCTLTIECGTLVC-AC- 64 
MrsA    -------MSQEAIIRSWKDPFSRENSTQNPAGNPFSELKEAQMD—KLVGAGDME--AA    CTFTLPGGGGVCTLTSEC------IC- 68 
ClvA    -------MNDILETETPVMVSPRWD—MLLDAGEDTSPSVQTQIDAEFRRVVSP---YM   SSSGW------LCTLTIECGTIIC-ACR 68 
GnaA    -------MRKFDRT-NMKYN--------NPAGNLLTEL-EAADLTSNKVDS-----LG    SSGV------VCTISVECGSIFTLACC 57 
               *         *    *     ::**    **                    
 
Figure 3.3:  Alignment of the five LanAs that were returned in a BLASTP search using the GarA prepropeptide amino acid sequence as a 
query.  The top alignment (A) was returned from ClustalW, the bottom (B) is a manually edited version of A.  The PAG motif unique to these 
leader sequences is highlighted in red.  The residues shaded in blue indicate the amino acids involved in lanthionine bridge formation (those for 
GnaA and ClvA are predicted).  The red box highlights the motif likely to be involved in binding of these lantibiotics to lipid II; the arrow indicates 
the cleavage point. 
 
GarA            MSALAIEKSWKDVDLRDGATSHPAGLGFGELTFEDLREDRTIYAASSG WVCTLTIECGTVICAC 64 
LigA            MSAITVETTWKNTDLREDLTAHPAGLGFGELSFEDLREDRTIYAASSG WVCTLTIECGTLVCAC 64 
***:::*.:**:.***:. *:**********:************************** *::*** 
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All five propeptides also contain the lipid II binding motif (shown in the red box in 
figure 3.3B) that was first described and characterised in mersacidin (Brotz & Sahl, 
2000).  Presumably these eight residues also enable the other four lantibiotics to 
bind to lipid II. 
 
Not surprisingly LigA, the DAB prepropeptide, shares homology with the same 
peptides identified in the GarA BLASTP search.  However, a BLASTP search with 
LigA gave two additional hits to peptides (BSCJ1_09328 and BCSJ1_09323) from 
Bacillus cereus SJ1.  These peptides are designated as hypothetical proteins and 
are found in a cluster of three possible lanAs.  BCSJ1_09323 is identical to the third 
lanA and BCSJ1_09328 shares 76% amino acid identity with them, mainly in the 
leader sequence.  These are situated next to two putative lantibiotic modification 
(lanM) and transport genes.  The N-terminal regions of these peptides share striking 
similarity to the five lantibiotic leader sequences.  Figure 3.4 shows an alignment of 
these two peptides with the GarA, LigA, MrsA and LicA (lichenicidin; (Dischinger et 
al., 2009)) prepropeptides.  LicA was included in this alignment since a BLASTP 
searches using BSCJ1_09328 and BCSJ1_09323 as query sequences identified 
the lichenicidin prepropeptide.  The lichenicidin gene cluster also encodes multiple 
LanA peptides and LanM proteins (two of each), similar to the gene clusters 
containing BSCJ1_09328 and BCSJ1_09323.  While BSCJ1_09328 and 
BCSJ1_09323 share homology with the leader sequences of other LanA 
prepropeptides, only BSCJ1_09328 contains a Cys residue in the propeptide region.  
Since the formation of lanthionine bridges requires Cys residues, BCSJ1_09323 
and the other homologs presumably do not encode lantibiotics.  
 
Using the Clone Manager program, stem-loop structures were identified between 
the lanA and lanM genes in both AG14 and AL02, and may represent rho-
independent transcriptional terminators.  The stem-loop in the AG14 cosmid has a 
ΔG = -157.8 kJ mol-1 and starts 11 bp downstream of garA and continues for 44 bp.  
In AL02, the stem-loop has a ΔG = -131.5 kJmol-1, starting 17 bp downstream from 
the stop codon of ligA and continuing for 32 bases (Boakes et al., 2010, Boakes et 
al., 2009).  It is likely that both garAMO and ligAMQO constitute operons.  However, 
the GarA and LigA prepropeptides are required in higher amounts than the 
biosynthetic enzymes involved in their modification.  Thus these stem-loop 
structures may serve to terminate many of the transcripts initiated upstream of the 
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two lanA genes, and may also act to stabilise the mRNA transcript of the 
prepropeptide, maintaining an appropriate stoichiometry between the LanA 
prepropeptide and the modification machinery.  Similar stem-loop structures are 
observed in other lantibiotic gene clusters, and have been proposed to play similar 
roles (Altena et al., 2000, Widdick et al., 2003). 
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LigA            MSAITVETTWKNTDLR-EDLTAHPAGLGFGELSFEDLREDRTIYAASSGWVCTLTIECG- 58 
GarA            MSALAIEKSWKDVDLR-DGATSHPAGLGFGELTFEDLREDRTIYAASSGWVCTLTIECG- 58 
MrsA            MSQEAIIRSWKDPFSR-ENSTQNPAGNPFSEL--KEAQMDKLVGAGDMEAACTFTLPGGG 57 
LicA1           MSKKEMILSWKNPMYR-TESSYHPAGNILKELQ-EEEQHSIAGGTITLSTCAILSKPLGN 58 
09323           MTNEEIIVAWKNPKVRGKNMPSHPSGVGFQELSINEMAQ-VTGGAVEQRATP--ATPATP 57 
09328           MTNEEIIVAWKNPKVRGKNMPSHPSGVGFQELSINEMAQ-VTGGAVEQRATPTLATPLTP 59 
                *:   :  :**:   *    . :*:*  : **  ::        :         :      
 
LigA            -----TLVCAC------------------ 64 
GarA            -----TVICAC------------------ 64 
MrsA            G--VCTLTSECI--C-------------- 68 
LicA1           NGYLCTVTKECMPSCN------------- 74 
09323           WLIKASYVVSGAGVSFVASYITVN----- 81 
09328           HTPYATYVVSGGVVSAISGIFSNNKTCLG 88 
                     :                        
Figure 3.4:  Alignment of four lantibiotic LanA peptides with two hypothetical peptides BSCJ1_09328 and BCSJ1_09323 from B. cereus SJ1.  
Residues that are conserved throughout all the putative leader sequences are highlighted in red. 
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Downstream of garA in the AG14 cosmid lies garM, which encodes a protein 
homologous to many characterised LanM enzymes.  GarM is 1053 amino acids in 
length, slightly longer than LigM (1046 amino acids), its homologue in the AL02 
cosmid.  A BLASTP search using GarM as query revealed homology to MrsM (27 % 
amino acid identity), the modification enzyme responsible for lantibiotic ring 
formation in mersacidin biosynthesis; MrsM gave the highest level of identity after 
LigM.  There were also a large number of hits to LanC cyclases from a range of 
bacteria. 
 
LanM modification enzymes catalyse the selective dehydration of serine and 
threonine residues, and the formation of the lanthionine bridges via the conjugate 
addition of cysteine residues to the dehydrated residues.  The N-terminal regions of 
GarM and LigM share all of the conserved residues found in other LanM 
synthetases that are thought to be required for the dehydration of the serine and 
threonine residues.  Figure 3.5 is an alignment of seven LanM synthetases including 
those encoded by the actagardine, DAB, michiganin A and mersacidin gene 
clusters.  Other LanMs returned from the BLASTP search from other clusters 
include GnaM (gnavucin), CinM (cinnamycin) and LctM (lacticin 481), one the most 
intensively studied LanMs.  Dehydration involves one of two Asp residues, at 
positions 242 or 259 to accept a proton from the Ser/Thr substrate, allowing the 
deprotonated residue to attack the γ-phosphate of ATP, resulting in a 
phosphorylated peptide.  Both GarM and LigM contain the Mg2+ ligands Asn247, 
Glu261 and Glu446 (highlighted blue, figure 3.5).  They also contain Arg residues at 
positions 399 and 259, one of which is believed  to carry out deprotonation of the α-
carbon in conjunction with Lys159, resulting in elimination of the phosphate group 
from the serine and threonine residues (You & van der Donk, 2007).  The N-terminal 
regions of GarM and LigM, like all other LanM synthetases, show no detectable 
homology to LanB enzymes. 
 
The C-terminal regions of LanM enzymes share 20-27% homology to LanC 
enzymes, many of which are identified when using GarM as the query sequence in 
a BLASTP search.  These homologous sequences are responsible for the 
cyclisation reaction required for the formation of lanthionine and methyl-lanthionine 
bridges  (Chatterjee et al., 2005).  The most studied example of a LanC cyclase is 
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NisC, which catalyses the cyclisation of lanthionine rings in nisin (Li et al., 2006).  
GarM and the other LanM synthetases returned from a BLASTP search using GarM 
as query contain a number of conserved residues found in both LanC and LanM 
enzymes.  They share the conserved active site His212 residue (figure 3.6; red) and 
the ligands involved in binding zinc that are were identified in NisC and required for 
cyclisation activity (figure 3.6; blue) (Paul et al., 2007, Li et al., 2006). 
 
GarM      LVYKPRP..GGVDMHMENVIA..PIDLET..EVRYLPRPTRRYSI..IESEKR 
LigM      LVYKPRP..GAVDVHMENVIA..PIDLET..EVRYLPRPTRRYSM..IESEKR 
ClvM      LVYKPRD..GASDLHLENVIA..PIDLET..SSRHIVRATRSYSL..VEAEER 
CinM      FFYKPRS..GGSDLHFENVIV..VCDAET..TARFINWGTQIYAQ..AGREVA 
MrsM      IVYKPRS..NAVDFHMQNLIA..LVDLES..TVRQILRGTSRYAN..VNSEKE 
GnaM      ILYKPRC..EGGDIHFENLIA..IIDAET..EVRYLIRNTQQYVI..IEHEIE 
LctM      LIYKPKS..NLTDLHFENVIS..IIDLET..TCRILFRNTMEYSV..IKSEIS 
             *        * *  *       * *     *     *  *       * 
            159      242          259     399   406        446(lctM) 
Figure 3.5:  Alignment of all LanM peptides that were returned from a BLASTP 
search using GarM as query sequence.  Highlighted in red are the conserved 
Asp242/259 residues, thought to accept a proton from the Ser/Thr substrate, and 
the Mg2+ ligands Asn247, Glu261 and Glu446, all involved in dehydration of the 
prepropeptide. 
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GarM        DGLREVAAICAERLAALAVDVDG-AAGWPATPDGPLLGGFSHGAAGIAWPLHRLATE------- 879 
LigM        AGYREVAEICGRRLAGTAVDVEG-AAGWAATRTGVILGGFSHGSAGIAWALHELAAE------- 869 
ClvM        AGRHALRALAG-RLMSTAVEVEGGALVWETGAERARLGGFSHGASGVGWALARTAGV------- 879 
CinM        IEHAHRCAEHLLRHAED-DGTTLSWPPSAADETYGNLTGFSHGSGGIGWALIQLGRH------- 901 
MrsM        EQILNLITKCGNRLIQNINVMEK-GVGWKVPANPTPASGFAHGASGIIWALYEIYAI------- 882 
GnaM        PTYLQKAIQIAEQLIEDMVTDKG-KVGWKSEVVPEVLAGFAHGNSGFIEMFSRLYEV------- 840 
LctM                        RDEIDILLKSLSNKIKLKESIASYAHGNSGIATAFVHGYKV------- 740 
NisC                                 SESEMYPLGCLNMGLAHGLAGVGCILAYAHIKGYSNEAS 234 
                                                  ..:**..            
 
GarM            LGDPSLRELARRAVQFDRDLYVPAAGAWRDLRP---EMAGTDS-YPALWCHGAAGIGLSR 935 
LigM            FGDRDLRELADRAVEFDRRLYVPAAGAWRDLRP---EMAGTDG-YPALWCHGAAGIGLSR 925 
ClvM            LGDDAIADAAVRALRFDDALFDPSRRRWRDARP---EARSAAGSFPAHWCHGTAGIAMAR 936 
CinM            TGRSDYIEAGRKAFAYEDRHVDEQEKDWYDLRINNGSAVKGARHFSNAWCNGAAGIGLAR 961 
MrsM            TKQTVFKEVAEKALEFERTLFIPEKNNWADIKL---ENGQFRNDNFVAWCNGAAGIGLSR 939 
GnaM            YPQAKYLRVLSRLVEYENSLYSEKNNNWTDLRK--FPEEDQNRDQPIAWCHGAAGILLSR 898 
LctM            TKNEKYLKIFHELWNLEN--SSKLRRGWTDSRK-------VDSSYSSQWCHGASGQAIAR 791 
NisC            LSALQKIIFIYEKFELERKKQFLWKDGLVADELKKEKVIREASFIRDAWCYGGPGISLLY 294 
                           .    .              :                ** * .*  :   
 
GarM            LLIAQHDQ---------DTRLAAEATAALDLVGAHG-FGHNHSICHGDFG-ALALFDLAA 984 
LigM            LLIHRIRP---------DERLAEEARAAVALVRRHG-FGHNHSLCHGDFG-ALALLGLAD 974 
ClvM            ADAAATLD---------RPDLLELALVGARETASDA-LPSDDSLCHGTLGNLIAVRGATR 986 
CinM            ISSWAALDRS-------DEQLLRDAQQALSATLRNFPRLKNHTLCHGTSGNAELLLRFAR 1014 
MrsM            ILILPHNQ---------NELIKDEAHVAINTTLKYG-FEHDQSLCHGDLGNLDILMYAAE 989 
GnaM            LTLYNAIKNSGETA--LFQQVIKDISLAKNKLIEDG-LHAGFCLCHGNMGNLLILKRYAE 955 
LctM            MEWITVNKTARFLSNSELIKVKKELGELIDILKKEGMYTDNFCLCHGILGNLLILNTYQE 851 
NisC            LYGGLALD---------NDYFVDKAEKILESAMQRKLGIDSYMICHGYSGLIEICSLFKR 345 
                                    .                   .  :***  *           
 
Figure 3.6:  Alignment of the C-terminal regions of LanM proteins with NisC.  All members have the conserved His active site in red and metal 
ligands in blue. 
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ORF14 in the AL02 cosmid encodes a protein only found in the DAB cluster, and 
encodes a putative 575 amino acid ABC transporter designated ORF14 by Boakes 
et al. (2010) and LigQ in this study.  LigQ contains all of the conserved domains 
expected for this class of transporter: the ATP binding site (#), Walker A/P-loop 
(blue), Walker B (red) and D loops (underlined, highlighted), Q-loop lid (green) and 
H-loop/switch (light blue) (figure 3.7) (Diederichs et al., 2000, Marchler-Bauer et al., 
2009, Schneider & Hunke, 1998).  ABC transporter systems are involved in the 
uptake of a wide variety of substrates against a concentration gradient in an ATP-
dependent manner.  Many of these systems are also involved in antibacterial drug 
export and hence resistance mechanisms (Schneider & Hunke, 1998).  There were 
a number of BLASTP hits to putative multidrug export ABC transporters that hint to 
the possibility that LigQ may be part of an immunity mechanism.  Although a LigQ 
homologue is not encoded in the actagardine cluster, a potential functional 
analogue is a penicillin-binding protein (GarPBP) that could conceivably confer 
resistance to actagardine.  The biosynthetic gene cluster for michiganin A also 
encodes a likely immunity mechanism in the form of a LanFEG transport system.  It 
also has a putative membrane protein with a PASTA domain similar to those found 
in penicillin binding proteins; this is discussed further in chapter 5.  It is possible that 
three different gene clusters that produce structurally similar lantibiotics have 
evolved different mechanisms of self-resistance. 
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SSPG_04300      MSRSAMTSTQTRERPPARKTGAKNAPEPGPPAPPVRKVGLRSLFPYLQGYWPTLGIVAVL 60 
SlivT           -----MTSTQTRERPPARKTGAKNAPEPGPPAPPVRKVGLRSLFPYLQGYWPTLGIVAVL 55 
SCO3235         -----MTSTQTRERPPARKTGAKNAPEPGPPAPPVRKVGLRSLFPYLQGYWPTLGIVAVL 55 
Gobs_0007       --------MSTSAETAARAT-------------------LRQLWPLVRPHRRPLTAAAVL 33 
LigQ            -----------MSETAG------------------------LLRRSLLDHRGKLAAVAGL 25 
                             ....                         *   :  :   *  .* * 
 
SSPG_04300      SLVVTLLTLSQPVLTRDVLADIEADRPVGRLVALLIGVLVVVAVLGGVRDYLLQRAAEGL 120 
SlivT           SLVVTLLTLSQPVLTRDVLADIEADRPVGRLVALLIGVLVVVAVLGGVRDYLLQRAAEGL 115 
SCO3235         SLVVTLLTLSQPVLTRDVLADIEADRPVGRLVALLIGVLVVVAVLGGVRDYLLQRAAEGL 115 
Gobs_0007       SLVAAAGALAQPALVARVIEAVGAGRALLPVVGLLVVVLLASSALGAVQDYLLQRTAEGV 93 
LigQ            AVAGVGCQLGQPFLIRRVLTAVQSAQPYRQLALAVLAVMVVGAALGAVQQFLLQRTGEAM 85 
                ::. .   *.** *   *:  : : :.   :.  :: *::. :.**.*:::****:.*.: 
 
SSPG_04300      VLTARRRLVARLLRLPITEYDQRRTGDMLSRVGADTTMLRAVVTSGLFDTVTNVVMVGGS 180 
SlivT           VLTARRRLVARLLRLPITEYDQRRTGDMLSRVGADTTMLRAVVTSGLFDTVTNVVMVGGS 175 
SCO3235         VLTARRRLVARLLRLPITEYDQRRTGDMLSRVGADTTMLRAVVTSGLFDTVTNVVMVGGS 175 
Gobs_0007       VLSTRRTLADRLLRLPVAEYDRRRTGDLMSRVGADTTLLRATVTSGVVEVAGSAVVAVGA 153 
LigQ            VFTVRRTLVAHLLRLPVAAYDERQSGDLVSRVGADTAQVRSVITSGVVDLAGGVLLVGGS 145 
                *::.** *. :*****:: **.*::**::*******: :*:.:***:.: . ..::. *: 
 
SSPG_04300      ALMMCLIDPTLFTATALGLGLGVLAVVGLSRRVRGASRDAQDRIGEMTSAVERAISAVRT 240 
SlivT           ALMMCLIDPTLFTATALGLGLGVLAVVGLSRRVRGASRDAQDRIGEMTSAVERAISAVRT 235 
SCO3235         ALMMCLIDPTLFAATALGLGLGVLAVVGLSRRVRGASRDAQDRIGEMTSAVERAISAVRT 235 
Gobs_0007       VVAMALVDGWLLLVTVGSVAVGLAVVVSVARGVQRLSRQAQEEVGAMTAAVERALSAVRT 213 
LigQ            IAGMIIIDPVLLGVSLAPVLCGAAGVRLVGRRLRPLSSAVQESIGALTASTTRALGAIRT 205 
                   * ::*  *: .:   :  *   *  :.* ::  *  .*: :* :*::. **:.*:** 
 
SSPG_04300      IRASGAEEREGKAVDGYAQQAYHAGMRIARLQAMINPITSTTIQVAFLVVLGLGGARVAS 300 
SlivT           IRASGAEEREGKAVDGYAQQAYHAGMRIARLQAMINPITSTTIQVAFLVVLGLGGARVAS 295 
SCO3235         IRASGAEEREGKAVDGYAQQAYHAGMRIARLQAMINPITSTTIQVAFLVVLGLGGARVAS 295 
Gobs_0007       IRASGATAREVDVVAASAGRAYEAGVRVARLQALVSPAGSVAVQGAFLAVLGLGGYRVAS 273 
LigQ            IRVAGATERETALIVAEADRARAAGVRLALVAAQAGPIVRLALQGAFVAVIGFGGYRVAN 265 
                **.:**  **   : . * :*  **:*:* : *  .*    ::* **:.*:*:** ***. 
 
 
100 
 
SSPG_04300      GAIQVGDMVAFVLFLFMLWFPLGRALTAYSRLQSGLGALQRIEEMVDLPQETDAVAGPLT 360 
SlivT           GAIQVGDMVAFVLFLFMLWFPLGRALTAYSRLQSGLGALQRIEEMVDLPQETDAVAGPLT 355 
SCO3235         GAIQVGDMVAFVLFLFMLWFPLGRALTAYSRLQSGLGALQRIEEMVDLPQETDAVAGPLT 355 
Gobs_0007       GSIAVADLVAFILYLFLLVMPLGRAIGAWTQLQSGLGALARVQEVLALEPEDDARP---- 329 
LigQ            GAVSVGDLVAFTLLLFTLALPLAQLAEAATRIQTGLGALTRIEEILALPDEDSALG---- 321 
                *:: *.*:*** * ** * :**.:   * :::*:***** *::*:: *  * .*     
            ## # 
SSPG_04300      VRERTRPGTEPADAEPRPPAIEFEGVSFGYGDGETVLRDVSLAVPRGTRTALVGPSGAGK 420 
SlivT           VRERTRPGTEPADAEPRPPAIEFEGVSFGYGDGETVLRDVSLAVPRGTRTALVGPSGAGK 415 
SCO3235         VRERTRPGTEPADAEPRPPAIEFEGVSFGYGDGETVLRDVSLAVPRGTRTALVGPSGAGK 415 
Gobs_0007       ERGGAVVAVPASSPSAEVPLLELDDVSFRYPNGTDVLHGVSLSVPAGNRVALVGPSGAGK 389 
LigQ            VRART-----PATVRHDPVLLEFDHVSFRYPTGGEILRDVSFRVPAGSTTALVGPSGAGK 376 
                 *  :     .:        :*:: *** *  *  :*:.**: ** *. .********** 
                ##                                       # 
SSPG_04300      STLLSLVERFYDVTSGTVRVGGTDVRDLPRRELRGRLGYVEQSAPVLAGTVRDNLSLAAP 480 
SlivT           STLLSLVERFYDVTSGTVRVGGTDVRDLPRRELRGRLGYVEQSAPVLAGTVRDNLSLAAP 475 
SCO3235         STLLSLVERFYDVTSGTVRVGGTDVRDLPRRELRGRLGYVEQSAPVLAGTVRDNLSLAAP 475 
Gobs_0007       STVLALVEGFYPLTGGAVRWAGADVRDLPRAGLRARLGYVEQEAPVLAGSVRDNLLLAAP 449 
LigQ            STILALIARLYEVHGGRILLHGRDIRDYPLAELRAALGYVEQEAPVLAGTVRDNLTLAAP 436 
                **:*:*:  :* : .* :   * *:** *   **. ******.******:***** **** 
 
SSPG_04300      DATDDDMREVLRSVNLMGVIERAPQGLDTEVGEGGVLLSGGERQRLALARTFLAAPPIML 540 
SlivT           DATDDDMREVLRSVNLMGVIERAPQGLDTEVGEGGVLLSGGERQRLALARTFLAAPPIML 535 
SCO3235         DATDDDMREVLRSVNLMGVIERAPQGLDTEVGEGGVLLSGGERQRLALARTFLAAPPIML 535 
Gobs_0007       QATDPELWAVLADVGLTDVVQRSPRGLDVPVGDDGVLLSGGERQRLAIARSLLARPALLL 509 
LigQ            DVAEHAIRHVTASVNLDDLLARDPAGLDAPVGDGGVLFSGGERQRLAVARTLLAPGELLL 496 
                :.::  :  *  .*.* .:: * * ***. **:.***:*********:**::**   ::* 
                 ##                              # 
SSPG_04300      LDEATSNLDARNEALMREAIGTVTADRTLLVVAHRLSTVVDSDQIVVLEHGRVVAAGRHE 600 
SlivT           LDEATSNLDARNEALMREAIGTVTADRTLLVVAHRLSTVVDSDQIVVLEHGRVVAAGRHE 595 
SCO3235         LDEATSNLDARNEALMREAIGTVTADRTLLVVAHRLSTVVDSDQIVVLEHGRVVAAGRHE 595 
Gobs_0007       LDEPTASLDARNEALLRETLAAAAADRALLVVAHRLSTVLDSDRIVVLDAGRVVAAGTHE 569 
LigQ            FDEPTAHLDARNEQALQHGLTAHAAGRTLVVVAHRLATVAHADQILVIDDGRSVAAGRHE 556 
                :**.*: ******  ::. : : :*.*:*:******:** .:*:*:*:: ** **** ** 
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SSPG_04300      ELTGTSPLYRELASHQLLIQ 620 
SlivT           ELTGTSPLYRELASHQLLIQ 615 
SCO3235         ELTGTSPLYRELASHQLLIQ 615 
Gobs_0007       ELVETSPLYRELAAAQLLV- 588 
LigQ            ELLVRDPTYREFATRQLLT- 575 
                **   .* ***:*: ***   
 
Figure 3.7:  Full length alignment of the top four hits to a BLASTP search using LigQ as query sequence.  Conserved regions are highlighted: 
ATP binding site (#), Walker A/P-loop (blue), Walker B (red) and D loops (underlined, highlighted), Q-loop lid (green) and H-loop/switch (light 
blue). 
 
Transporters with the highest homology to LigQ are listed as: 
SSPG_04300 (ABC transporter):  Streptomyces  lividans TK24 
SlivT (ABC-type multidrug transport system, ATPase and permease components):  S. lividans TK24 
SCO3235 (Putative ABC transporter):  Streptomyces coelicolor A3(2) 
Gobs_007(ABC transporter related protein):  Geodermatophilus obscurus DSM 43160 
LigQ (Putative ABC transporter):  A. liguriae 
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Following garM in the actagardine gene cluster there is an ORF (garO) that encodes 
a 336 amino acid protein with homology to luciferase type monooxygenases and 
coenzyme F420-dependent enzymes.  This suggests that GarO is responsible for 
the addition of oxygen to the C-terminal methyl-lanthionine ring of actagardine 
(figure 3.8).  There are no other published examples of enzymatic oxidation of 
lanthionine bridges, and apart from LigO (see below), GarO does not share 
homology with any previously described lantibiotic-associated biosynthetic enzyme. 
 
Following ligQ in the A. liguriae biosynthetic gene cluster is ligO, which encodes a 
347 amino acid putative monooxygenase with 72% amino acid identity to GarO.  
However, the oxidised version of DAB, actagardine B, is not apparently made by A. 
liguriae (Boakes et al., 2010).  There are several possible reasons why ligO is 
unable to effect the addition of an oxygen atom to the C-terminal methyl-lanthionine 
bridge.  ligR1, a gene encoding a response regulator, runs in the opposite 
orientation to ligO, and overlaps the 3‟ end of ligO by 24 bp.  This overlap may 
interfere with the production of a full length LigO monooxygenase.  The C-terminus 
of LigO is conserved with other members of the luciferase-like monooxygenase 
protein family (figure 3.9), indicating that it is likely to be important for enzymatic 
function.  The possible insertion of ligQ (ORF14) into the DAB gene cluster may 
also have interfered with transcription of ligO.  Boakes et al. (2010) also proposed 
the presence of a stem-loop structure that might act as a transcription terminator, 
preventing ligO expression.  The stem-loop structure spans a 30 nucleotide stretch 
of high GC sequence with a ∆G = -16.10 kcal mol-1) (Boakes et al., 2010).  These 
authors proposed that this stem loop may lead to the production of a truncated and 
non-functional LigO enzyme. 
 
However, the most likely reason for the inactive ligO, discovered in this study, is the 
presence of a likely frame-shift mutation via the insertion of a G nucleotide towards 
the C-terminus of the gene.  By aligning GarO and LigO, it is possible to identify a 
likely frame-shift mutation in ligO (figure 3.9A, highlighted by the arrow), resulting in 
an overall amino acid sequence identity of 72%.  The revised LigO amino acid 
sequence was subsequently aligned with GarO, markedly increasing the overall 
level of amino acid identity to 76% (figure 3.9B).  It is possible that this putative 
frame-shift mutation has disrupted enzyme function.  This region of all of the 
luciferase-like monooxygenases enzymes that show high levels of similarity to GarO 
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(figure 3.9) is highly conserved, suggesting that is it important for enzyme function.  
It is unlikely that this is simply an error in the cosmid sequence since fermentation of 
A. liguriae yields only DAB (Boakes et al., 2010). 
 
As stated previously, there are no monooxygenase gene homologues in any 
previously described lantibiotic biosynthetic gene cluster.  This unique tailoring step 
in the production of actagardine appears to be non-essential for antibiotic activity 
since DAB appears to be just as active as actagardine.  It is possible, however, that 
this modification is important in the natural habitat of A. garbadinensis.  For 
example, this modification could reduce protease susceptibility and enhance 
solubility. 
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MSMEG_5029     3 LSVLDLVPVRTDQTTADALAATTHLAQTADRLGYHRFWVAEHHNMPAVAATSPPVLIAHLAAHTSQLRLGSGGVMLPNHA 82 
garO           7 LSVLDQVPVFRDGSPAEAVRDAVALARSAEQYGYHRFWIAEHHGSAANACAAPEVVTAAVAAATSRIRVGSGGVLLPHYS 86 
Rxyl_3089      5 LSVLDLSPVSAGSGSSRALRNTLELARLADRLGYARYWLAEHHNLPSVASPAPEVMIGHVANATARIRVGAGGIMLPNHA 84 
ABO_0676      12 FSLLELASIREGDSVGQTLANSVAYARHAESLGFQRFWLAEHHNMQGISSAATSVLVGHIAGATESIRVGSGGVMLPNHP 91 
RSc2462        9 LSILDQSPVIHGHSARDAIAATVDLAQMADALGYTRYWCAEHHGLRGVSNPAPEVMIARVASATRHLRVGSGGVMLPYYS 88 
                         90       100       110       120       130       140       150       160 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
MSMEG_5029    83 PLAVAEQFALLEAAHPGRIDLGIGRAPGSDPVTSLALRGAAgrdDRDIEAFPQYLDDVVALM---GArGVRVPlprdllr 159 
garO          87 PLKVAETFRVLAALYPGRIDLGFGRAPGGPPAMAELLNPYA---VRTDEAFLEQIGRLLGFL---GDtRT-VS------- 152 
Rxyl_3089     85 PLKVVETFRLLEALHPGRIDLGIGRAPGTDPVTAAALRRGR---GAEADDFPELFGELLAFAgegFPeGHPFA------- 154 
ABO_0676      92 PLVIAEQFGTLEILYPGRIDLGLGRAPGTDPMTSRALRRE----GLGAEQFPDDVAELQRLL---GPlDTS-Q------- 156 
RSc2462       89 PFKLAEQFRLLEALFPNRIDLGVGRAPGGDMRTAQAVAMGD---YNRGDHFPQQVQELIWHLsgtLPpDHPTH------- 158 
                        170       180       190       200       210       220       230       240 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
MSMEG_5029   160 dnyILKATPNATSVPQLWLLGSSMYSAHLAAAKGLPYVFAHHFSGHGTAEALAIYREEFQPSEAAPEPVTFLTVNAVVAE 239 
garO         153 ---RVSVTPQVEEPPVPWMLGAGTGSARMAGMLGLPFCFAQFIATEECPEAIEAYRDAFRPSPWLERPQPMLALRVLCAD 229 
Rxyl_3089    155 ---SVKAVPEDAELPPIWLLGSSGYSAKAAGEMGLGYAFASHFSPVDPAPPMLAYREHFRPSERFPEPHAILAASVVCAR 231 
ABO_0676     157 ---GVNAIPGAGTQVPIWLLGSSLYSAKLAAQRGLPYAFAGHFAPRLYREALRIYRDQFQPSAQLSKPYAMLALPAVPAD 233 
RSc2462      159 ---GVILQPEIDTRPELWMLGSSDFGGALAARLGIRFAFAHFINPHVGHIVAQQYRTDFAPGFE-PRPYSAAAVFVIAAD 234 
                        250       260       270       280       290       300       310       320 
                 ....*....|....*....|....*....|....*....|....*....|....*....|....*....|....*....| 
MSMEG_5029   240 TTEEAEALLLPQLQMM---------ARLRTGQPLNALDLVEDAQtTVLTPQGDAVVADGRRRAVVGSPTEAAEQVRALAE 310 
garO         230 SDAEAEELATCF--WMscttgwraqVQLTDDYRGGAPNLDDARR-YRLTAEDLALRESRPFLQISGTPAAVGKEIRRLQA 306 
Rxyl_3089    232 TRERAEELASSMGLAW---------VRMRTGKPGPLPSPEEALS-YPYSPAERRLLESYRSMQVVGDPASVRKRLAEMAE 301 
ABO_0676     234 SDEEAHYLTTTSYQRI---------LALFRGQPLWMKPPVQSMD-GLWNPQEEAGVKDFLGLQLLGTAASMQGQLDQLLD 303 
RSc2462      235 TEAEARRCEAAVDLRR---------VQMALGVNGPIPTIEQAEA-HRHTERDQAIIARERPRSLIGTPESVAEQMLRLKD 304 
                        330       340       350 
                 ....*....|....*....|....*....|....*.. 
MSMEG_5029   311 EFDVDEVMINPVASAHRgadprtatARDTTLELLAKE 347 
garO         307 VYGVSEVVLTTNCPGLP--------ARRRSYELLAGE 335 
Rxyl_3089    302 RTAAEEVMVTTMVYDHE--------ARLRSYELLAEA 330 
ABO_0676     304 SVEVDELMVTVDLYDPV--------KRRHALDILAsl 332 
RSc2462      305 RFVADELIVLTVAPSYR--------ARMRSYELLAQA 333 
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Figure 3.8:  Alignment of GarO with the closest members of the luciferase-like monooxygenase family (pfam00296) (Marchler-Bauer et al., 
2009). 
MSMEG_5029 = alkanal monooxygenase alpha chain (Mycobacterium smegmatis str. MC2 155) 
Rxyl_3089 = luciferase-like protein (Rubrobacter xylanophilus DSM 9941) 
ABO_0676 = hypothetical protein ABO_0676 (Alcanivorax borkumensis SK2) 
RSc2462 = hypothetical protein RSc2462 (Ralstonia solanacearum GMI1000) 
 
GarO            VLSVLDQVPVFRDGSPAEAVRDAVALARSAEQYGYHRFWIAEHHGSAANACAAPEVVTAA 60 
LigO            MLSVLDQVPVFRGDDPAEAVREAVGLARAAESLGYHRFWIAEHHGSAANACAAPEIVAAA 60 
                :***********...******:**.***:**. **********************:*:** 
 
GarO            VAAATSRIRVGSGGVLLPHYSPLKVAETFRVLAALYPGRIDLGFGRAPGGPPAMAELLNP 120 
LigO            VAGATERIRVGTGGVLLPYYSPLKVAEAFRVLAALYPGRIDLGFGRGRGGPAVMAELLNP 120 
                **.**.*****:******:********:******************. ***..******* 
 
GarO            YAVRTDEAFLEQIGRLLGFLGDTRTVSRVSVTPQVEEPPVPWMLGAGTGSARMAGMLGLP 180 
LigO            YAIATEEAYAEQVGRLLAFLGDARTVSRVSVTPAVQDPPLPWLLGSGVGSARLAGMLGVP 180 
                **: *:**: **:****.****:********** *::**:**:**:*.****:*****:* 
 
GarO            FCFAQFIATEECPEAIEAYRDAFRPSPWLERPQPMLALRVLCADSDAEAEELATCFWMSC 240 
LigO            FCFAQFIATEECPEAIAAYQESFRSSPWLDEPQAMLALRVLAAGTAEDAEELATGFWMSC 240 
                **************** **:::**.****:.**.*******.*.:  :****** ***** 
 
GarO            TTGWRAQVQLTDDYRGGAPNLDDARRYRLTAEDLALRESRPFLQISGTPAAVGKEIRRLQ 300 
LigO            TTGWRAQVRPDDDYRGGVPNLADAQRYTLTEEDLAMRASRPYLQISGTAETVGEEIRRLR 300 
                ********:  ******.*** **:** ** ****:* ***:******. :**:*****: 
 
GarO            AVYGVSEVVLTTNCPG--------LPARRRSYELLAGEFASPAA--- 336 
LigO            KVYDVAEVMLTTNCPGAAAPAPVLRAAGRRARADRAGVTRVRPARRW 347 
                 **.*:**:*******         .* **:    **     .*    
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Figure 3.9A:  Alignment of GarO and LigO, where a potential frame-shift mutation (arrow) has reduced the overall amino acid sequence identity 
to 72% 
GarO            VLSVLDQVPVFRDGSPAEAVRDAVALARSAEQYGYHRFWIAEHHGSAANACAAPEVVTAA 60 
LigO            MLSVLDQVPVFRGDDPAEAVREAVGLARAAESLGYHRFWIAEHHGSAANACAAPEIVAAA 60 
                :***********...******:**.***:**. **********************:*:** 
 
GarO            VAAATSRIRVGSGGVLLPHYSPLKVAETFRVLAALYPGRIDLGFGRAPGGPPAMAELLNP 120 
LigO            VAGATERIRVGTGGVLLPYYSPLKVAEAFRVLAALYPGRIDLGFGRGRGGPAVMAELLNP 120 
                **.**.*****:******:********:******************. ***..******* 
 
GarO            YAVRTDEAFLEQIGRLLGFLGDTRTVSRVSVTPQVEEPPVPWMLGAGTGSARMAGMLGLP 180 
LigO            YAIATEEAYAEQVGRLLAFLGDARTVSRVSVTPAVQDPPLPWLLGSGVGSARLAGMLGVP 180 
                **: *:**: **:****.****:********** *::**:**:**:*.****:*****:* 
 
GarO            FCFAQFIATEECPEAIEAYRDAFRPSPWLERPQPMLALRVLCADSDAEAEELATCFWMSC 240 
LigO            FCFAQFIATEECPEAIAAYQESFRSSPWLDEPQAMLALRVLAAGTAEDAEELATGFWMSC 240 
                **************** **:::**.****:.**.*******.*.:  :****** ***** 
 
GarO            TTGWRAQVQLTDDYRGGAPNLDDARRYRLTAEDLALRESRPFLQISGTPAAVGKEIRRLQ 300 
LigO            TTGWRAQVRPDDDYRGGVPNLADAQRYTLTEEDLAMRASRPYLQISGTAETVGEEIRRLR 300 
                ********:  ******.*** **:** ** ****:* ***:******. :**:*****: 
 
GarO            AVYGVSEVVLTTNCPGLPARRRSYELLAGEFASPAA- 336 
LigO            KVYDVAEVMLTTNCPGRPPRRRSYELLAAELGLTAPA 337 
                 **.*:**:******* *.*********.*:. .*.  
 
Figure 3.9B:  Alignment of GarO and LigO after correction of the putative frame-shift mutation in ligO.  The LigO amino acid sequence has been 
adjusted to remove the potential frame-shift mutation, increasing the overall amino acid identity between the two proteins to 76%.  Note the 
much improved alignment (shown in yellow) at the C-terminus compared to Fig. 3.9A. 
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The product of garR1 is a 231 amino acid protein with homology to response 
regulators from two-component signal transduction systems.  The N-terminus of 
GarR1 is similar to known signal receiver domains such as those of CheY, OmpR, 
NtrC and PhoB (Marchler-Bauer et al., 2009).  Figure 3.10 shows the conserved 
residues present in this domain.  GarR1 has the six residues (#) involved in 
coordination of the Mg2+ ion required for phosphorylation of the conserved aspartic 
acid residue (indicated by P) (Kern et al., 1999).  While the protein contains the 
conserved phosphorylated Asp residue (P), it is missing the Lys-Pro-Phe motif 
(black box) required for conformational change of the protein after phosphorylation.  
A similar situation is found in MrsR1 from the mersacidin cluster (Altena et al., 2000, 
Sola et al., 1999, Boakes et al., 2009).  The C-terminus of GarR1 aligns to DNA 
binding helix-turn-helix motifs and contains conserved residues for both dimerisation 
and DNA binding (Maris et al., 2002, Boakes et al., 2009).  The GarR1 homolog in 
the A. liguriae cluster, LigR1, also lacks the Lys-Pro-Phe motif and intriguingly, a 
number of other conserved residues.  It is unclear how these regulatory proteins are 
able to alter their configuration upon the presumed phosphorylation event; perhaps 
instead, the conformational change is induced by ligand binding.  It is also unclear 
what their role is in regulating the production of actagardine and DAB.  As 
mentioned previously, both GarR1 and LigR1 share homology with MrsR1, another 
orphan response regulator encoded by the mersacidin gene cluster.  Guder et al. 
(2002) demonstrated that MrsR1 was required for mersacidin production (Guder et 
al., 2002).  Both the AG14 and the AL02 gene clusters have homologues 
(garR/garK and ligR/ligK) of the other regulatory genes identified in the mersacidin 
cluster, mrsR2/K2.  It is therefore possible that the regulators in the actagardine and 
DAB gene clusters share the same functions as their homologues in the mersacidin 
gene cluster.  Thus in the AG14 cluster, garR1 may control expression of garA, and 
garRK may regulate expression of the potential immunity mechanisms, namely 
garPBP and/or the transport system encoded by garTH (an analogous situation may 
be true for the DAB gene cluster, with ligQ replacing garPBP) (Altena et al., 2000, 
Guder et al., 2002). 
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                  ##                                                          P           # 
ETR1        11 LVMDEN.[2].SRMVTKGLLV.[3].CEV     TTVS     SNEECLRVV.[3].HKVVFMDVCMP.[1].VENYQIA 69 
GarR1       15 LVVDGE.[2].VSIGIKMILE.[3].GFA     VATT.[1].RENLRSAVE.[3].PAVVLLDGHSA.[1].SDGLEVL 74 
LigR1        5 LVVAEE.[2].VSIGIKMILE.[3].GFS     VVAA.[1].RDSALAAVS.[3].PAVVLLDAHAT.[1].PESVPLL 64 
PhoB         6 LVVEDE.[2].IREMVCFVLE.[3].FQP     VEAE.[1].YDSAVNQLN.[3].PDLILLDWMLP.[1].GSGIQFI 65 
NtrC         7 WVVDDD.[2].IRWVLERALA.[3].LTC     TTFE     NGNEVLAAL.[4].PDVLLSXIRMP.[1].MDGLALL 66 
FixJ         7 HIVDDE.[2].VRKSLAFMLT.[3].FAV     KMHQ     SAEAFLAFA.[4].NGVLVTDLRMP.[1].MSGVELL 66 
 
                               #                      #   # 
ETR1        70 LRIH.[9].RPLLVALSG.[3].KSTKEKC.[3].GLDGVLLKPVS.[ 1].DNIRDVLSDLL 127 
GarR1       75 DQLR.[4].PPAIAMLTT.[4].ELVLDSL.[2].GACGFLLRDSQ.[ 1].EQLVAAVRALA 127 
LigR1       65 TRLR.[4].GPALAVLAT.[4].STVLESL.[2].GACGFLLKDSQ.[ 1] EQLVAAVRALA 117 
PhoB        66 KHLK.[6].DIPVVMLTA.[5].DRVRGLE.[1].GADDYITKPFS.[ 1].KELVARIKAVM 120 
NrtC        67 KQIK.[4].MLPVIIMTA.[3].LDAAVSA.[3].GAFDYLPKPFD.[ 1].DEAVALVERAI 119 
FixJ        67 RNLG.[4].NIPSIVITG.[3].VPMAVEA.[3].GAVDFIEKPFE.[ 1].TVIIEAIERAS 119 
 
ETR1 = Arabidopsis thaliana 
PhoB = Escherichia coli 
NrtC = Salmonella typhimurium 
FixJ = Rhizobium meliloti 
 
Figure 3.10:  Alignment of the N-termini of representatives of two component response regulator proteins.  The # symbol represents residues 
involved in Mg2+ coordination.  The black box represents the Lys-Pro-Phe motif missing from both GarR1 and LigR1, and normally involved in 
the conformational change of response regulators after phosphorylation of the Asp residue (labelled P). 
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Next to garR1 lie garH and garT, which appear to encode transport proteins.  garH 
encodes a putative 812 amino acid ABC transporter-associated permease, while 
garT encodes a putative 259 amino acid ATP binding cassette component.  GarH 
has 71% sequence identity with LigH, the homolog present in the DAB cluster, and 
some amino acid identity to the C-terminal region of LigQ (~28%), and shares a 
number of the domains conserved in both LigQ and other ABC transporters, such as 
the ATP binding site, Walker A/P-loop, Walker B and D loops, Q-loop lid and H-
loop/switch region (Diederichs et al., 2000, Marchler-Bauer et al., 2009).  In 
addition, the protein may possibly include a Walker C motif involved in ATP 
hydrolysis (Neuwald et al., 1999), differentiating it from LigQ and further highlighting 
its putative role as an ATP binding cassette of a two component transporter.  
Boakes et al. (2009) reported 57% identity of GarT to SCO4666 from S. coelicolor, a 
putative ABC-type antimicrobial peptide transporter.  Both genes show similarity to a 
number of transport genes in S. coelicolor, S. lividans, and a number of other 
Streptomyces.  GarT shows significant identity to CinT (27%) and MrsF (21%), but 
not to the other mersacidin transport components.  As mentioned previously, the 
regulatory genes within the actagardine and DAB gene clusters are very similar to 
those found in the mersacidin cluster and have the potential to share similar 
functions in the regulation of the gene clusters.  In mersacidin biosynthesis, MrsFEG 
confer immunity and are regulated by MrsR2/K2, while MrsT appears to be involved 
in mersacidin transport out of the cell.  Thus while the transport-associated 
components of the Actinoplanes and Bacillus gene clusters may not be very similar, 
the two component regulatory systems encoded by both clusters may still regulate 
immunity (Altena et al., 2000, Guder et al., 2002). 
 
There is no protease domain associated with GarH or GarT, so they are unlikely to 
cleave the leader sequence away from the mature lantibiotic.  It is likely, as is the 
case with cinnamycin, microbisporicin and haloduracin, that an extracellular 
protease is responsible for leader peptide cleavage (Cooper et al., 2008, Foulston & 
Bibb, 2010, Widdick et al., 2003). 
 
Adjacent to the garTH genes in the actagardine gene cluster are garK and garR, 
which encode proteins homologous to two-component sensory histidine kinases and 
response regulators, respectively.  GarK shares 68% sequence identity with LigK 
and 39% sequence identity with ClvK from the michiganin A gene cluster.  GarR 
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shares homology with lantibiotic two-component response regulators, including 73% 
sequence identity with LigR and 51% identity with ClvR.  Much like other response 
regulators, including GarR1, GarR contains many of the conserved residues 
involved in signal reception and DNA binding.  Interestingly, none of the actagardine 
response regulators, neither the orphan regulators nor the response regulators that 
are members of the two-component systems, have the otherwise conserved Lys-
Pro-Phe motif; this is also true for the mersacidin response regulators (black box, 
figure 3.11) (Altena et al., 2000, Marchler-Bauer et al., 2009).  In model systems 
studying the PhoB receiver domain of E. coli, Lys108 is likely to be influenced by 
phosphorylation of the conserved Asp65, changing the conformation of the protein 
and altering the complementatrity of the dimerisation surface; dimerisation is 
required for DNA binding and ultimately gene regulation (Sola et al., 1999).  As 
mentioned, GarR1 lacks the key Lys108 residue and therefore is potentially unable 
to activate its dimerisation surface.  The other actagardine response regulators 
contain the conserved Lys activation residue, so they may be able to relay the 
activation signal via a conformational change, but would have to do so using 
different residues compared to those conserved in other regulators.  
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GarR            ----MTRP--PIAVLIADDQELVRTGFAMVVDAAPDMRVVAIAASGAEAIELAAEHRPDV 54 
LigR            ----MTEP--QIDVVIADDQDLVRTGFALVVDSAPDMRVVATAADGAEVVRLAAEFRPDV 54 
ClvR            ----MTDAPAPIRVVVVDDQSLVRDGFARIVDAQPDMAAVGVCADGEQAVARVVELRPDV 56 
GarR1           MRSAARGGPIVTDVLVVDGEALVSIGIKMILESTGGFAVATTDRE--NLRSAVEQHRPAV 58 
LigR1           ----------MADVLVVAEEALVSIGIKMILETMGGFSVVAADRD--SALAAVSEHRPAV 48 
MrsR2           ------MTLEENKILMVDDDEHILNLLITCFEKE-GFSNISTAMTGSETLLKIDQELPNI 53 
                             :::.  :  :   :   .:   .:          .      :  * : 
                          P 
GarR            ILMDIRMPGTDGITATSAILAAGGERPPKIIALTTYDSSDYATRILTAGASGYLLKDATA 114 
LigR            VLMDIRMPRVDGITAARAILEGNAQ-PPKIVALTTYDNDEYASRILAAGASGYLLKDTTA 113 
ClvR            VLMDVRMPVLDGIEATRRLVEGGRAEGTRILGLTTHDTDSYAIRMLRAGAVGFLLKDSTA 116 
GarR1           VLLDGHSAQSDGLEVLDQLR--ALSSPPAIAMLTTLAPPELVLDSLRGGACGFLLRDSQP 116 
LigR1           VLLDAHATLPESVPLLTRLR--DLESGPALAVLATLAASSTVLESLRGGACGFLLKDSQP 106 
MrsR2           ILLDVMLPDTDGFTLCSKIR---SHTNVPILFLTAKTTDLDKLQGFSFGGDDYITKPFNP 110 
                :*:*   .  :..     :          :  *::          :  *. .:: :   . 
 
GarR            EGLTAAIRSAYHGGSVIAPTTTRNLVA---ARAEPPPP----------ARDPAPLDTFTA 161 
LigR            EGLTAAIRTVHRGGSVLAPSTTHRLVT---AHRQHP------------ARPSALLDSFTT 158 
ClvR            VQLVDAIRSVHNGTFAASMSTTQRLLER-LAVERTAPP----------DPDTAALDVLTD 165 
GarR1           EQLVAAVRALAEGSIVLAPEASSVVVRAGSRGSAAGAG----------SPACERVKQLSD 166 
LigR1           EQLVAAVRALASGVTVLAPEASSIMLGAACRGTPAAEN------------AVDEVKQLSD 154 
MrsR2           LEIVARVKAQLKRTTQLSSSYPLKQVYDYEYFKIDPNTGRLVVNGTRIDCPAQEMKLLIY 170 
                  :.  :::        :   .   :                            :. :   
 
GarR            RERDVFDLIVAGANNAEIAARLHLAEVTVKTHVGRVLAKLG---VRDRLNVVVWAYRNGA 218 
LigR            REREVFDLIVAGASNAEIADRLNLAEVTIKTHVGRVLAKIG---VRDRVNVVIWAYRNGA 215 
ClvR            RERVVFTRLVTGASNPEIARDLSIAEVTVKTHVGHILTKLA---VRDRVHLVIWAHRRGL 222 
GarR1           REQSILRLLGAGLTNAEISRQLFLSAATVKEHVSVILSKLG---VANRVQAAVLAYASGL 223 
LigR1           REQAVLGLIGQGLTNAEIAGRLFISDSTVKEYVSVILRKLG---VANRVQAAVLAYAAGL 211 
MrsR2           FCEHPNQILSKHQIYKDVWGEFYGGDSTVMVHVRRLREKLEEDPSRPRWIKTVRGQGYIF 230 
                  .     :       ::   :  .  *:  :*  :  *:       *   .: .      
 
GarR            VG-------- 220 
LigR            GPS------- 218 
ClvR            AA-------- 224 
GarR1           SSDDVCLS-- 231 
LigR1           TTDELA---- 217 
MrsR2           EAEPIDEDLF 240 
 
Figure 3.11:  Alignment of the response 
regulator proteins (LanR) from the actagardine, 
DAB and michiganin A gene clusters, compared 
with the orphan LanR1 proteins from the 
actagardine and mersacidin gene clusters.  
Residues highlighted in red are discussed in the 
text. 
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The final potential lantibiotic biosynthetic gene within the actagardine cluster is 
garPBP.  This gene is likely to encode a penicillin binding protein (PBP).  GarPBP 
has three domains that are commonly associated with type I PBPs, namely a 
transglycosylase domain, a transpeptidase domain, and a serine/threonine kinase 
associated domain (PASTA domain) (Yeats et al., 2002).  The N-terminal 
glycosyltransferase domain catalyses the polymerisation of the glycan component of 
Lipid II (GlcNac-MurNAc-(pentapeptide) linked via a pyrophosphate bridge to 
undecaprenyl).  The second domain has transpeptidase activity and catalyses the 
peptide cross-linking of adjacent glycan chains (Terrak et al., 2008).  This PBP also 
contains a PASTA domain at the C-terminus.  PASTA domains are associated with 
the signal-binding sensing component of protein serine/threonine kinases (PSTKs) 
that are thought to act as sensors for the presence/concentration of unlinked 
peptidoglycan and activate, directly or indirectly, the expression of cell wall 
biosynthesis genes (Yeats et al., 2002).  It is believed that the PASTA domains on 
PBPs are required for localisation of the PBP to unlinked glycan chains often found 
near the site of cell division.  They may also be part of an alternative 
sensor/signalling system, and are generally found in bacteria that do not have a 
PASTA-containing PSTK (Yeats et al., 2002, Jones & Dyson, 2006). 
 
The occurrence of garPBP adjacent to key genes for actagardine biosynthesis led to 
the hypothesis that the encoded PBP may be a resistance mechanism, functionally 
analogous to the transporter LigQ in the A. liguriae gene cluster.  It is plausible that 
GarPBP might be able to circumvent actagardine-compromised lipid II incorporation 
into peptidoglycan, and confer immunity (Somma et al., 1977).  The presence of a 
gene encoding a PASTA domain-containing protein of unknown function 
downstream of the michiganin A gene cluster is intriguing, but this has yet to be 
implicated in immunity to michiganin A. 
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3.4 Comparison of actagardine and DAB gene clusters 
 
Initial inspection of the genes within the putative actagardine and DAB biosynthetic 
gene clusters of A. garbadinensis and A. liguriae revealed a high degree of 
homology between the two.  The proposed biosynthetic gene clusters consist of a 
collection of eight genes that are common to both cosmids and that stretch from 
lanA to lanR.  The order, orientation and apparent operon structure of the 
biosynthetic genes is also conserved.  There are two notable exceptions to this 
gene conservation, ligQ and garPBP, and these are discussed later. The proposed 
minimal gene sets for the two lantibiotics extend from their respective lanAs to 
garPBP in AG14 and to ligR in AL02.  The genes outside of the proposed 
biosynthetic gene clusters differ in the two cosmid sequences, reflecting their 
different parental origins.  Boakes et al. 2010 also noted a rapid reduction in 
sequence identity outside the proposed minimal gene sets.   
 
Based on gene complement, it is difficult to predict the evolutionary relationship 
between the actagardine and DAB gene clusters, and whether one is derived from 
the other, or whether they are both derived from an ancestral cluster. 
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3.5 Discussion 
 
Several computer programs were used to analyse the ORFs found in two 
sequenced cosmids, AG14 and AL02, and identified all the genes that are thought 
to be required for the production of each lantibiotic. 
 
Computational analysis identified putative minimal gene sets for actagardine and 
DAB biosynthesis.  Nine genes may be involved in the biosynthesis of actagardine 
and DAB (figure 3.12).  This includes the genes that encode the prepropeptides of 
the lantibiotics, which also show similarity to a known actagardine homolog, 
michiganin A, and to a newly discovered putative lantibiotic, gnavucin.  All 
actagardine family members share the lipid II binding motif that links this group to 
other well characterised lantibiotics such as mersacidin.  This also suggests that the 
mode of action of this lantibiotic is the same as, or at least similar to, mersacidin, 
which  binds to and sequesters lipid II, thus inhibiting cell wall biosynthesis (Somma 
et al., 1977, Brotz et al., 1998). 
 
 
Figure 3.12:  Schematic of the minimal gene sets for actagardine (top) and DAB 
biosynthesis (bottom). 
 
The AG14 and AL02 cosmids were also found to encode typical type II modification 
enzymes encoded by garM and ligM, respectively.  Both also encode two-
component transporters (GarTH and LigTH) presumably responsible for export of 
the lantibiotic, and two-component regulatory systems (GarRK and LigRK). 
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The biosynthetic gene clusters in AG14 and AL02 also contain some unusual 
genes.  They each contain an additional atypical response regulator gene (garR1 
and ligR1).  These genes may be functionally analogous to mrsR1 of the mersacidin 
gene cluster and directly regulate expression of their respective lanA genes (Guder 
et al., 2002, Altena et al., 2000, Boakes et al., 2009).  A corresponding gene is not 
present in the michiganin and gnavucin clusters. 
 
Both gene clusters also contain a gene (garO and ligO), encoding a 
monooxygenase which has not been found in any other lantibiotic biosynthetic gene 
cluster.  This monooxygenase is likely to be responsible for the addition of an 
oxygen moiety to the C-terminal methyl-lanthionine bridge of actagardine and 
appears to be non-functional in the AL02 cluster. 
 
Neither of the two gene clusters contains a gene encoding a peptidase or peptidase 
domain that could cleave the leader sequence away from the mature peptide.  The 
absence of such a function has been noted for other actinomycete lantibiotic 
biosynthetic gene clusters i.e. cinnamycin and microbisporicin (Cooper et al., 2008, 
Foulston & Bibb, 2010, Widdick et al., 2003). 
 
By analogy to mersacidin biosynthesis, garR1 may sense when it is appropriate for 
the cell to produce actagardine, activating transcription of the likely garAMO operon.  
The two-component regulatory system garRK is likely to regulate other genes in the 
cluster, such as garTH, resulting in transport of the lantibiotic out of the cell.  Similar 
regulatory mechanisms are likely to exist in the DAB gene cluster.  It is also possible 
that an immunity response is evoked to protect the cells, mediated by expressing 
ligQ or garPBP, potentially functionally equivalent genes. 
 
While this bioinformatic analysis allows us to speculate on the function of each gene 
present in the two clusters, it does not provide direct evidence for their roles in 
lantibiotic biosynthesis.  To accomplish this, a mutational study was carried out to 
determine the minimal gene set required for actagardine biosynthesis, and to 
determine the roles of each of the genes within it. 
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3.6 Summary 
 
 All of the genes likely to be involved in actagardine and DAB biosynthesis 
were identified in cosmids AG14 and AL02, respectively, by bioinformatic 
analysis. 
 
 Bioinformatic analysis of the nucleotide sequences of the cosmids identified 
gene clusters that contain a number of lantibiotic biosynthesis-associated 
proteins. 
 
 Both gene clusters are highly homologous, with the exception of garPBP and 
ligQ. 
 
 Both gene clusters contain a monooxygenase that could be responsible for 
the addition of an oxygen moiety on the C-terminal methyl-lanthionine bridge 
of actagardine, although LigO appears to be non-functional because of a 
frame-shift mutation. 
 
 Computational analysis identified two other GarA homologs, ClvA and GnaA. 
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4 Heterologous production of 
actagardine and deoxyactagardine B 
(DAB) 
4.1 Introduction 
 
Bioinformatic identification of a number of putative lantibiotic biosynthetic genes in 
cosmids derived from the natural producers of actagardine and DAB was insufficient 
by itself to establish that these genes were indeed involved in, and necessary for, 
production of the two lantibiotics. 
 
To establish that the two cosmids contained all of the genes required for 
actagardine and DAB biosynthesis, they were initially transferred to a heterologous 
Streptomyces host and assessed for their ability to confer actagardine and DAB 
biosynthesis.  Previous studies had confirmed that the AG14 cosmid contains all of 
the genes required for the production of actagardine (Boakes et al., 2009).  
However, DAB had not been produced when the AL02 cosmid was transferred into 
the same heterologous host (Novacta Biosystems, unpublished). 
 
To determine which genes were required for the production of each lantibiotic, 
minimal gene sets (MGSs) were constructed based on earlier bioinformatic analysis.  
This would ultimately allow a mutational analysis of each gene within these minimal 
genes sets to confirm and understand its involvement in lantibiotic biosynthesis.  
 
118 
 
4.2 Rationale for the heterologous production of 
actagardine and deoxyactagardine B 
 
Actagardine, formerly known as gardimycin, was isolated from two separate soil 
isolates, Actinoplanes garbadinensis and Actinoplanes liguriae.  These organisms, 
and the lantibiotics they produce, were originally investigated in 1976 by Parenti et 
al., and included studies on the growth and preservation of the natural producers, as 
well as purification of the two compounds and analysis of the biological properties of 
actagardine (Arioli et al., 1976, Coronelli et al., 1976, Parenti et al., 1976).  Novacta 
Biosystems subsequently isolated the actagardine analogue DAB from A. liguriae.  
DAB differs from actagardine by lacking the sulfoxide present in the C-terminal 
methylanthionine bridge and by the substitution of two amino acids in the C-terminal 
part of the mature peptide (V15L and I16V) (Boakes et al., 2010). 
 
A. garbadinensis and A. liguriae grew slowly, and did not appear to sporulate when 
grown on a range of agar media.  Consequently, they had to be conserved as 
mycelial cultures, which provided variable inocula for liquid cultures.  Furthermore, 
neither strain has been characterised genetically; only A. garbadinensis has been 
genetically manipulated (Boakes et al., 2010, Boakes et al., 2009), and with some 
difficulty.  Consequently the preferred approach for characterising the lantibiotics 
that they produce was to express the respective gene clusters in a suitable 
heterologous host. 
 
In this study, two species were chosen as heterologous hosts; S. lividans (strain 
TK24 and 1326) and S. coelicolor (strain M1146) (Gomez-Escribano & Bibb, 2010, 
Flinspach et al., 2010).  Heterologous expression of lantibiotic and modified peptide 
gene clusters in Streptomyces species has been used previously to study 
cinnamycin (Widdick et al., 2003) and cypemycin (Claesen & Bibb, 2010) 
biosynthesis, and modified hosts have also been used to increase levels of 
secondary metabolite production (Flinspach et al., 2010, Komatsu et al., 2010, 
Widdick et al., 2003, Gomez-Escribano & Bibb, 2010).  The cosmid libraries of the 
natural producers led to the isolation of AG14 and AL02, which could be readily 
modified for transfer into a heterologous Streptomyces host (see below).  Many 
tools have been developed for the genetic manipulation in these hosts.  PCR-
targeting (also known as REDIRECT technology) allows the efficient replacement of 
a gene of interest in a cosmid in E. coli with a selectable antibiotic resistance 
cassette, and if required, an in-frame deletion.  The PCR reaction used to generate 
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the targeting cassettes requires 39 nt homology extensions to the gene of interest 
(Gust et al., 2003).  The λ RED recombination system (gam, bet, and exo, carried 
on plasmid pIJ790) increases the rate of recombination when using linear DNA (see 
chapter 2).  The mutant cosmid can then be transferred to a Streptomyces host to 
assess the affect of the mutation. 
 
Novacta Biosystems produced actagardine from the AG14 cosmid in S. lividans 
1326 (designated Nova263).  S. lividans TK24 is a commonly used laboratory strain 
that has been used previously for the heterologous production of polyoxin (Chen et 
al., 2009), novobiocin and clorobiocin (Eustaquio et al., 2005).  M1146 is a 
derivative of S. coelicolor M145 that has had four of its secondary metabolite gene 
clusters deleted in an effort to increase the level of production from heterologously 
expressed gene clusters by removing potential alternative sinks for carbon and 
nitrogen (Gomez-Escribano & Bibb, 2010).  These strains are also useful for 
carrying out bioassays.  Neither one produces antibiotics that are active against the 
test organism Micrococcus luteus, and therefore any antimicrobial activity that is 
observed is likely to result from the production of actagardine or DAB, or one of their 
derivatives.  The construction of specific mutants, combined with such bioassays, 
would enable the identification of genes that are essential for actagardine or DAB 
production.  A mutation that resulted in loss of antimicrobial activity can thus be 
readily attributed to loss of actagardine or DAB production, which could be 
subsequently confirmed by Matrix-Assisted Laser Desorption/Ionization – Time-of-
Flight (MALDI-ToF) mass spectrum analysis (see chapter 2). 
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4.3 Transfer of the AG14 and AL02 cosmids to 
Streptomyces lividans TK24 and product analysis 
 
AG14 and AL02 were supplied as SuperCos derivatives in E. coli DH10B by 
Novacta Biosystems.  The cosmids were PCR-targeted with an SspI restriction 
fragment from pIJ10702 that contained the Streptomyces phage ΦC31 attachment 
site attP and integrase (int).  The fragment was inserted into the neomycin 
resistance gene (neo) of AG14 and AL02 creating pIJ12206 and pIJ12207, 
respectively.  Novacta Biosystems had previously made an equivalent construct to 
pIJ12206 named CosAG14HEapra in a similar way, and this was used in this study 
as a positive control.  The cosmids were transferred to S. lividans TK24 by 
conjugation using the methylation deficient host E. coli ET12567 pUZ8002 (see 
chapter 2). 
 
Several S. lividans TK24 exconjugants from each mating were tested for the 
successful integration of the respective cosmid by colony PCR.  lanA-con3 primers 
(table 2.12, chapter 2) were used to amplify a ~1 kb PCR product that was 
sequenced, that included the entire lanA gene and short stretches of intergenic 
sequence up and downstream of the gene.  Three S. lividans TK24 exconjugants 
confirmed to contain the AG14 (M1201) and AL02 (M1202) cosmids were analysed 
in a bioassay to test for lantibiotic biosynthesis.  Cubes of OB-N agar inoculated 
with a clone containing one of the cosmids was incubated for seven days.  The 
cubes were subsequently placed on plates of L agar pre-seeded with the sensitive 
test organism M. luteus and further incubated overnight.  A halo of clearing in the M. 
luteus lawn around the cube of the S. lividans exconjugants (figure 4.1) indicated 
the production of antimicrobial activity.  Comparison of the zones of inhibition after 
seven days of incubation of M1201 and M1202 suggested that they produce 
approximately the same amount of lantibiotic as the natural producers. 
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        M1201 (AG14)         M1202 (AL02)        M1216 (pIJ10702) 
 
 
    A. garbadinensis            A. liguriae     Nova263 
 
Figure 4.1:  Cubes of OB-N agar were inoculated with the natural producers, S. 
lividans TK24 containing the targeted AG14 or AL02 cosmids (strains M1201 and 
M1202, respectively), Nova263 (S. lividans 1326/CosAG14HEapra) from Novacta 
and S. lividans TK24 containing pIJ10702 (M1216) (empty vector control) and 
incubated for seven days.  The cubes were placed on a plate of L agar seeded with 
M. luteus.  Zones of inhibition, attributable to actagardine or DAB production, can be 
seen around the natural producers and the S. lividans derivatives containing the 
cloned gene clusters, but not around the empty vector control. 
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Supernatants of 7 day old liquid cultures of three M1201 and three M1202 clones 
grown in TSB were analysed to confirm that the antimicrobial activity was the result 
of actagardine and DAB production, respectively (see section 2.9.2, chapter 2).  
This was accomplished using MALDI-ToF mass spectrometry.  All M1201 clones 
produced spectra with a mass peak of 1960 Da, the predicted mass of Ala(0)-
actagardine [M+H]+ (figure 4.2A). The M1202 clones yielded spectra with the same 
mass peak at 1960 Da, indicating production of Ala(0)-deoxyactagardine B with the 
addition of one oxygen adduct [M+O]+ (figure 4.2B).  No such peaks were observed 
in the three negative control clones of M1216 (S. lividans TK24 containing pIJ10702 
(the empty vector), figure 4.2C) or media only control (figure 4.1D).  In the expanded 
spectra of M1201 and M1202 (figure 4.1E and F), peaks corresponding to a number 
of actagardine and DAB adducts can be observed.  Both spectra show that ions of 
actagardine with a sodium adduct and DAB with an additional oxygen moiety and a 
sodium adduct are the most abundant in the two spectra (1982 Da).  Oxidation 
caused by the ionisation of the sample during analysis is probably responsible for 
the lack of a DAB peak in the M1202 spectra.  This will be discussed in detail in the 
subsequent text.  Further analysis of a ∆garO mutant using both LC-MS and 
MALDI-ToF confirmed the production of DAB by the genes present in the AL02 
cosmid (see later). 
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A:  M1201 (AG14) 
D:  GM1 (media blank) C:  M1216 (pIJ10702) 
B:  M1202 (AL02) 
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m/z Description 
 Actagardine Deoxyactagardine B 
1944 Ala(0)-deoxyactagardine + H Ala(0)-deoxyactagardine B + H 
1960 Ala(0)-actagardine + H Ala(0)-deoxyactagardine B + O 
1982 Ala(0)-actagardine + Na Ala(0)-deoxyactagardine B + O + Na 
1998 Ala(0)-actagardine + O + Na Ala(0)-deoxyactagardine B + 2O + Na 
2014 Ala(0)-actagardine + 2O + Na Ala(0)-deoxyactagardine B + 3O + Na 
2030 Ala(0)-actagardine + 3O + Na Ala(0)-deoxyactagardine + 4O + Na 
 
 
E: M1201 (AG14) expanded F: M1202 (AL02) expanded 
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Figure 4.2:  MALDI-ToF spectra of culture supernatants of M1201 (AG14 – A and E), M1202 (AL02 – B and F), M1216 (pIJ10702 (empty vector 
control – C)) and GM1 media control (D).  The masses for the labelled peaks in E and F are shown in the table above.  The mass peaks for 
actagardine and DAB [M+H]+ are only present in the clones containing either the AG14 or AL02 cosmid, and are absent from the vector or 
media only controls. 
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MALDI-ToF analysis is a rapid and robust method of identifying peptides present in 
culture supernatants (Foulston & Bibb, 2010, Claesen & Bibb, 2010).  MALDI-ToF 
analysis of supernatants containing actagardine or DAB produced many peaks, 
including those corresponding to Na adducts, and to the presence of oxidation 
products of the two lantibiotics, presumably reflecting oxidation of lanthionine 
bridges during ionisation (figure 4.2).  Highly numerous oxidation products were not 
observed in the previous electro-spray mass spectrometric analyses of actagardine 
and DAB (chapter 5, and (Boakes et al., 2010, Boakes et al., 2009)).  Such 
oxidation products were also observed upon MALDI-ToF analysis of microbisporicin 
(Foulston & Bibb, 2010).  This is problematic since such oxidation could 
compromise the subsequent analysis of the ∆garO mutant (see chapter 5).  MALDI-
ToF analysis also identified a variant of actagardine where the alanine at position -1 
(with respect to the cleavage site, but named 0 here and elsewhere) has not been 
cleaved from the mature peptide (figure 4.2).  This phenomenon was described 
previously by Boakes et al. (2009), when the AG14 cosmid was expressed in S. 
lividans 1326.  MALDI-ToF spectra of A. garbadinensis contain very small amounts 
of the ala(0)- derivative, and fewer oxidation events compared to a S. lividans 1326 
derived actagardine standard, suggesting that nearly all of the prepropeptide is 
processed correctly in the natural producer (figure 4.3).  The AG14 and AL02 
cosmids do not encode a specific protease, and it appears that the specificity of the 
protease(s) present in S. lividans that are able to remove the leader sequence from 
the modified peptide is different to those in the natural producer.  Interestingly, none 
of the thus-far sequenced actinomycete lantibiotic gene clusters encode a 
discernible protease or protease domain (Widdick et al., 2003, Foulston & Bibb, 
2010, Chatterjee et al., 2005), and other host proteases are presumably responsible 
for cleavage. 
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m/z . Description 
1873.749 [M-O]+ Deoxyactagardine 
1889.844 [M+H]+ Actagardine 
1905.820 [M+O]+ Actagardine + O 
1921.821 [M+2O]+ Actagardine + 2O 
1937.815 [M+3O]+ Actagardine + 3O 
1944.777 [M+Ala-O]+ Ala-(0)deoxyactagardine 
1960.875 [M+Ala]+ Ala(0)-actagardine 
1976.825 [M+Ala+O]+ Ala(0)-actagardine + O 
1992.852 [M+Ala+2O]+ Ala(0)-actagardine + 2O 
2008.882 [M+Ala+3O]+ Ala(0)-actagardine + 3O 
 
Figure 4.3:  MALDI-ToF spectra of culture supernatants of A. garbadinensis (A) and 
a S. lividans 1326-derived actagardine standard (B).  Note the fewer oxidation 
species of actagardine from the natural producer, as well as the absence of Ala(0)- 
derivatives  The table below the spectra lists the actagardine species that 
correspond to the highlighted masses. 
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4.4 Transfer of the AG14 cosmid to Streptomyces 
coelicolor M1146 and product analysis 
 
The AG14 cosmid was transferred to S. coelicolor M1146 and S. lividans 1326, in 
the latter case mirroring the experiment carried out by Novacta Biosystems (Boakes 
et al., 2010, Boakes et al., 2009).  M1146 is a derivative of S. coelicolor M145, a 
fully sequenced strain of S. coelicolor A3(2) that lacks the plasmids SCP1 and 
SCP2.  M1146 is deleted for four S. coelicolor A3(2) M145 secondary metabolic 
gene clusters (Gomez-Escribano & Bibb, 2010), those encoding actinorhodin, 
undecylprodigiosin, calcium-dependent antibiotic and Cpk production (CpK is a 
polyketide antibiotic (Pawlik et al., 2007, Flinspach et al., 2010)).  All of these gene 
clusters were deleted in an attempt to increase the level of production from 
heterologously expressed gene clusters.  As M1146 does not produce the more 
abundant secondary metabolites found in wild type S. coelicolor, there ought to be 
more primary metabolites available for the production of heterologous compounds.  
Another advantage of using M1146 is that it lacks antibiotic activity, thus facilitating 
subsequent bioassays on derivatives containing heterologous gene clusters.  The 
AG14 cosmid, a ∆garA mutant derivative (see chapter 5) and an empty vector 
control were conjugated into M1146 via E. coli ET12567 pUZ8002, and the resulting 
strains grown in TSB liquid medium.  Culture supernatants (50 µl) were applied to 
wells made in L agar pre-seeded with M. luteus (see chapter 2, section 2.9.2).  
Clear zones of growth inhibition of the M. luteus lawn were observed around the 
clones containing AG14, but not around the two negative controls (figure 4.4).  
Production of actagardine was confirmed by MALDI-ToF analysis (figure 4.5).  The 
M1146 clones containing the AG14 cosmid produced more lantibiotic than S. 
lividans 1326, measured by the increased zone of inhibition. 
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Figure 4.4:  Bioassays of culture supernatants of S. coelicolor M1146 and S. 
lividans 1326 containing pIJ12206, pIJ12206∆garA::scar and an empty vector 
control (pIJ10702). 
pIJ12206 
pIJ10702 
pIJ12206∆garA 
S. lividans 1326  
pIJ12206 
pIJ10702 
pIJ12206 ∆garA 
M1146 
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     M1146 pIJ12206     M1146 pIJ12206∆garA::scar          M1146 pIJ10702 
 
      S. lividans 1326 pIJ12206       S. lividans 1326 pIJ12206∆garA::scar   S. lividans 1326 pIJ10702 
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Figure 4.5:  MALDI-ToF spectra of culture supernatants of M1146 and S. lividans 
1326 clones containing pIJ12206, pIJ12206∆garA::scar or pIJ10702.  The [M+Na]+ 
ala(0)-actagardine peak is present in only the clones containing pIJ12206. 
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4.5 Determination of a minimal gene set for 
actagardine production 
 
Computational analysis predicted nine putative biosynthetic genes involved in the 
biosynthesis of both actagardine and DAB.  While computational analysis could 
identify genes in these clusters that were homologous to genes involved in the 
production of other lantibiotics, it could not discount the involvement of other genes 
present in both cosmids.  Computational analysis was limited to the two sequenced 
cosmids, AG14 and AL02, thus there was also the potential for other genes present 
in the genomes of A. garbadinensis and A. Liguriae to have roles in actagardine and 
DAB biosynthesis, respectively.  Resolution of these issues required the 
establishment of minimal gene sets (MGS) for the biosynthesis of both lantibiotics in 
a heterologous host. 
 
Novacta Biosystems previously identified a number of cosmids from the natural 
producers that hybridised to the garA probe.  Using primers that hybridise to the 
bacteriophage T3 and T7 promoters that are located at the ends of the inserts in the 
SuperCos vector, nine A. garbadinensis cosmids and ten A. liguriae cosmids were 
end-sequenced by Novacta.  One cosmid from each natural producer was fully 
sequenced (Novacta Biosystems, unpublished). 
 
Computational analyses identified sets of conserved genes located downstream of 
garA and ligA in both clusters.  As homology between the two putative lantibiotic 
gene clusters is high, it is likely that these genes would be essential for lantibiotic 
production.  By comparing the two clusters it was immediately clear that the region 
of homology extended from the lanA genes to the lanR genes.  The computational 
analysis also suggested a potential function for each identified ORF.  The regions 
upstream of lanA in the AG14 and AL02 cosmids showed no significant sequence 
similarity (Boakes et al., 2010), although both regions contain genes encoding ABC 
transporters.  There is limited homology in the downstream region, where both 
clusters have genes encoding a putative membrane protein, a putative hydrolase 
and a response regulator in the subsequent four genes, one of those being garPBP 
in the AG14 cosmid.  The relatively low level of similarity of these genes compared 
to those lying between the lanA and lanR genes suggested that they (with the 
possible exception of garPBP) were not likely to be part of the biosynthetic gene 
clusters, but this required experimental confirmation. 
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To identify the MGS for actagardine production, a tetracycline resistance cassette 
was used to replace segments of AG14 surrounding the proposed MGS.  PCR-
targeting was used to make these deletions.  Essentially, 58/59 nt primers that 
corresponded to the DNA sequence adjacent to the genes to be deleted were used 
to amplify a targeting cassette containing a tetracycline resistance gene.  Once this 
cassette was created using PCR, it was used to target cosmid DNA in E. coli 
BW25113 containing pIJ790 carrying the λ red genes that promote recombination.  
The three regions targeted are shown below (figure 4.6B, 4.6C and 4.6D).  The first 
deletion (yielding cosmid AG14.2 – AG14.14) replaced all of the upstream genes 
except for the one located at the end of the cosmid insert and the four genes 
preceding garA with the tetracycline resistance cassette.  The second deletion, 
yielding cosmid AG14.2-AG14.18, removed all upstream genes except the one 
located at the end of the cosmid insert.  The third deletion (cosmid AG14.28-14.30) 
removed three of the genes downstream of garPBP.  Each of the three deleted 
cosmids was transferred to S. lividans TK24.  Figure 4.6E shows the subsequent 
bioassays.  All deleted cosmids elicited antibiotic activity against M. luteus and were 
subsequently confirmed by MALDI-ToF to be producing actagardine (figure 4.6F).  
Thus the deleted genes were not required for actagardine production in S. lividans 
TK24, and do not appear to be part of the biosynthetic gene cluster. 
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4.6A:  Schematic of AG14 cosmid 
 
4.6B:  Schematic of cosmid AG14.2–14.14 
 
4.6C:  Schematic of cosmid AG14.2-14.18 
 
136 
 
4.6D:  Schematic of cosmid AG14.28-30 
 
Figure 4.6:  A-D. Schematics representing the replacement of genes with a 
tetracycline resistance targeting cassette.  Using a PCR based targeting approach 
(chapter 2, section 2.8), the genes 2-14, 2-18 and 28-30 on the AG14 cosmid were 
replaced with the cassette, and the resulting clones tested for actagardine 
biosynthesis via bioassays (4.6E) and MALDI-ToF (4.6F). 
 
   
   AG14.2-14.14      AG14.2-14.18 
   
   AG14.28-14.30          pIJ10702 
 
Figure 4.6E:  Bioassays of S. lividans TK24 containing deletion derivatives of the 
AG14 cosmid: AG14.2-14.14, AG14.2-14.18 and AG14.28-14.30, and a vector only 
control (pIJ10702). 
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  AG14.2-14     AG14.2-18 
 
  AG14.29-30     pIJ10702 
Figure 4.6F:  MALDI-ToF spectra of S. lividans TK24 containing either the AG14.2-
14, AG14.2-18, AG14.28-30 or pIJ10702 cosmids. 
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Since deletion of the genes upstream of garA in AG14.2-14.8 did not affect the 
production of actagardine, it appears that garA is the first essential gene in the 
actagardine biosynthetic gene cluster.  Deletion of genes 28-30, potentially 
encoding proteins with functions analogous to genes found at a similar location in 
the DAB gene cluster, appear not to be involved in actagardine biosynthesis. 
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4.6 Deduction of a minimal gene set for 
deoxyactagardine B production 
 
To deduce the minimal gene set for DAB production, cosmids from A. liguriae 
containing a different complement of genes to those found on the sequenced AL02 
cosmid were assessed for their ability to produce DAB.  Novacta Biosystems 
identified four cosmids (AL02, AL03, AL13 and AL17) by probing the A. liguriae 
genome library with a garA probe.  All four cosmids were initially analysed by end-
sequencing, using primers that anneal to the T3 and T7 bacteriophage promoters in 
SuperCos, and restriction enzyme analysis to identify a cosmid where the ligA gene 
was reasonably close the centre of the cosmid, which was then fully sequenced 
(Novacta Biosystems, unpublished).  The three remaining end-sequenced cosmids 
all include some of the genes present within the sequenced and annotated AL02 
cosmid.  Figure 4.7A shows the location of the ends of the inserts present in AL03, 
AL13 and AL17 with respect to the insert present in AL02.  The AL03 insert starts 
towards the end of ORF 9, and ends after ORF 31.  The AL13 insert starts in ORF 3 
and ends at ORF 31.  The AL17 insert starts further upstream (to the left) of the 
AL02 cosmid insert and ends within ORF 29.  AL03, AL13 and AL17 were supplied 
by Novacta Biosystems as SuperCos library clones and subsequently targeted 
using the SspI cassette (refer to chapter 2, section 2.8.4), transferred into E. coli 
ET12567 pUZ8002 and conjugated into S. lividans TK24.  The subsequent clones 
were analysed by bioassay and MALDI-ToF.  Figure 4.7B shows the results of the 
bioassay. All four cosmids elicited zones of inhibition in lawns of M. luteus and the 
production of DAB was confirmed by MALDI-ToF analysis (figure 4.7C).  The most 
important cosmid to note is AL03, whose insert starts just two genes upstream of 
ligA, demonstrating that the genes upstream of ORF 10 are not required for DAB 
biosynthesis, analogous to the situation in cosmid AG14.2-14.18 cosmid.  While this 
eliminates most of the upstream genes in the cosmid, this comparative analysis was 
not able to eliminate the involvement of genes downstream of ligR gene.  However, 
as stated above, the lack of strong sequence homology downstream of ligR when 
compared to AG14 suggested that these genes were not involved in DAB 
biosynthesis (Boakes et al., 2010). 
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Figure 4.7A:  Schematic of the AL02 cosmid showing the positions of the ends of 
the inserts cloned in AL03, AL13 and AL17. 
 
 
       M1202 (AL02)        M1203 (AL03)  M1204 (AL13) 
 
 
      M1205 (AL17)  A. liguriae        M1216 (pIJ10702) 
Figure 4.7B:  Bioassay of S. lividans TK24 containing the different A. liguriae 
cosmids.  Agar cubes inoculated with each clone were incubated for 7 days and 
then placed on a L agar plate pre-seeded with M. luteus and incubated for a further 
24 hours.  Zones of inhibition can be seen around all of the cosmid clones. 
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     M1202 (AL02) 
 
     M1203 (AL03) 
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     M1204 (AL13) 
 
     M1205 (AL17) 
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     M1216 (pIJ10702) 
Figure 4.7C:  MALDI-ToF spectra of culture supernatants of five S. lividans TK24 
clones.  M1202 (AL02), M1203 (AL03), M1204 (AL13) and M1205 (AL17) produce 
Ala(0)-deoxyactagardine B ([M+O+Na]+ = 1980), M1216 does not. 
 
Figure 4.7:  Schematic of the AL02 cosmid showing the positions of the ends of the 
inserts cloned in AL03, AL13 and AL17.  Bioassay of S. lividans TK24 containing 
the different A. liguriae cosmids coupled with MALDI-ToF analysis concluded that all 
cosmids produced Ala(0)-DAB. 
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4.7 Discussion 
 
In this chapter the limitations imposed by attempting to work with the genetically 
uncharacterised natural producers A. garbadinensis and A. liguriae were 
circumvented by expressing the actagardine and DAB biosynthetic gene clusters in 
two different Streptomyces species.  Expression of the AG14 cosmid was 
successful, confirming that this cosmid contained all of the genes required for 
actagardine biosynthesis, as also shown by Boakes et al. (2009) (Boakes et al., 
2009).  S. lividans TK24 was also used in this work to express the AL02 cosmid and 
for the first time demonstrated that this cosmid contained all of the genes required 
for DAB production.  Like the natural producer, all of the A. liguriae cosmids 
conferred production of a deoxy variant of actagardine, potentially caused by a 
defective monooxygenase. 
 
S. lividans 1326 is the heterologous host routinely used at Novacta Biosystems.  It 
and the S. lividans TK24 and S. coelicolor M1146 strains analysed in this study 
produced ala(0) variants of actagardine and DAB, unlike the natural producers 
(Boakes et al., 2010, Boakes et al., 2009).  The existence of an ala(0) variant could 
indicate that cleavage of the leader sequence occurs in a two step process.  The 
first step would remove the leader sequence up to the ala(0) position, followed by a 
second cleavage that removed this residue to leave the mature peptide.  The latter 
of these activities would be absent from the Streptomyces species used as 
heterologous hosts, resulting in production of the ala(0) variants.  Alternatively, 
cleavage of the prepropeptide in the natural producers and heterologous hosts may 
be carried out a single protease with slightly different specificity.  Given that neither 
gene cluster contains a gene encoding a protease or protease domain, cleavage of 
the leader sequences from the prepropeptides is presumably performed by 
protease(s) encoded elsewhere in the genomes of the producing species.  This is 
not without precedent in lantibiotic biosynthesis (Foulston & Bibb, 2010, Cooper et 
al., 2008). 
Heterologous expression demonstrated that the transcription and translation 
machinery of S. lividans and S. coelicolor is able to recognise the Actinoplanes 
regulatory sequences required for actagardine and DAB biosynthesis.  This had 
important consequences since it enabled the use of a genetically amenable 
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heterologous host for the subsequent mutational analysis of the actagardine 
biosynthetic gene cluster.  While in principle this could have been attempted in A. 
garbadinensis (see Boakes et al. (2009)), the two Actinoplanes species used in this 
work grow more slowly than S. lividans and S. coelicolor and are genetically less 
tractable. Moreover, the use of Streptomyces species as heterologous hosts made 
available a range of vectors and techniques that could be used to characterise 
actagardine and DAB biosynthesis. 
 
Heterologous expression of the DAB gene cluster also potentially allowed for a 
functional comparison of the two clusters to be made.  For example, deletion of the 
A. liguriae-specific gene ligQ might allow us to understand its apparently unique role 
in DAB biosynthesis.  Analysis of the apparently dysfunctional monooxygenase 
could also be undertaken. 
 
A MGS was established for the production of actagardine by deleting many of the 
genes present on the AG14 cosmid.  The first gene in the cluster is garA with the 
last being either garR or garPBP.  All other genes on the AG14 cosmid appeared to 
be non-essential for actagardine biosynthesis.  The high level of homology shared 
by many of the genes present on both the AG14 and AL02 cosmids also helps to 
define a likely MGS for DAB biosynthesis.  Comparison of the genes present in the 
different A. liguriae cosmids provided by Novacta Biosystems allowed us to 
eliminate a role for many of those carried on AL02 in DAB biosynthesis.  Further 
experimental analysis to more precisely define the MGS for DAB was not carried out 
since it appeared likely that only genes with a high level of conservation to gar 
genes were likely to be required.  Consistent with levels of amino acid sequence 
similarity, Boakes et al. (2010) noted that there is a distinct drop in nucleotide 
sequence homology between the two cosmids in the regions preceding the lanA 
and following the lanR genes.  It falls from 65% between lanA and lanR (rising to 
76% if ligQ is discounted) to 30-42% in the flanking regions (Boakes et al., 2010). 
 
Expression of AG14 in S. lividans TK24, and the establishment of a minimal gene 
set, allowed the use of PCR-targeting to create deletions in each of the proposed 
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biosynthetic genes for actagardine biosynthesis.  These studies are reported in 
chapter 5. 
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4.8 Summary 
 
 Actagardine was produced heterologously when cosmid AG14 was 
introduced into S. lividans TK24 and S. coelicolor M1146. 
 
 S. coelicolor M1146, from which four secondary metabolite gene clusters 
had been deleted, appeared to produce increased levels of actagardine 
compared with S. lividans TK24. 
 
 For the first time, this study demonstrated that all of the genes required for 
DAB biosynthesis were contained in cosmid AL02. 
 
 Deletion analysis of the AG14 cosmid was used to define a likely MGS for 
actagardine biosynthesis. 
 
 Comparison of the genes contained in three other A. liguriae cosmids that 
conferred DAB production when introduced into S. lividans TK24 identified a 
reduced gene set for DAB biosynthesis. 
 
 The experimentally defined and deduced MGSs for actagardine and DAB 
biosynthesis correspond to regions of AG14 and AL02 with high levels of 
nucleotide sequence identity that drop off significantly outside of the 
proposed MGSs. 
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5 Mutational analysis of actagardine 
biosynthesis and analysis of novel 
actagardine homologs 
 
5.1 Introduction 
 
In chapter 4, heterologous expression of both the AG14 and AL02 cosmids in 
Streptomyces hosts confirmed that they contained all of the genes required for 
production of actagardine and DAB, respectively.  Computational analysis carried 
out in chapter 3 identified a number of putative lantibiotic biosynthesis genes, based 
on their homology to known examples.  Chapter 4 also identified a MGS for the 
AG14 cosmid and confirmed that eight or nine genes encode all of the necessary 
components required for actagardine biosynthesis, including the prepropeptide, and 
enzymes involved in modification, transport, regulation and potential immunity to 
actagardine.  Nine genes were proposed to be involved in DAB biosynthesis based 
on homology to characterised lantibiotic biosynthetic genes and the high degree of 
homology shared between these genes to those in the AG14 MGS.   
 
Computational analysis identified genes that were unique to each cluster, and that 
had not been found in previously characterised lantibiotic gene clusters.  garPBP 
and ligQ have no homologs in their opposing biosynthetic gene cluster, although in 
principle they could perform a similar function in providing producer immunity 
against the corresponding lantibiotic.  The LanO monooxygenases are thought to be 
capable, in principle, of adding an oxygen moiety to the C-terminal 
methlylanthionine bridge (although ligO appears non-functional), a modification that 
has not been seen in any other lantibiotic.  Deletion of these genes would determine 
whether they were essential for biosynthesis or for the bioactivity of their respective 
lantibiotics. 
 
While computational analysis is able to assign a potential function to each of the 
ORFs, it is unable to conclusively demonstrate that the gene is essential for 
lantibiotic biosynthesis.  The role of each of these genes in the biosynthesis of 
actagardine and DAB required experimental confirmation. 
149 
 
 
Many lantibiotic gene clusters such as those for nisin, the most studied lantibiotic, 
and microbisporicin, a lantibiotic produced by an actinomycete, have undergone 
numerous gene deletion experiments to provide increased understanding of the role 
each gene plays in the biosynthesis of its respective lantibiotic (van den Berg van 
Saparoea et al., 2008, Foulston & Bibb, 2010).  To determine the role of each of the 
genes proposed to be involved in actagardine and DAB biosynthesis, attempts were 
made to delete each individually from the corresponding cosmid.  The effects of 
these gene deletions were assessed using bioassays and MALDI-ToF mass 
spectroscopy. 
 
5.2 Construction, confirmation and analysis of gene 
deletions within the biosynthetic gene clusters of 
actagardine and DAB 
 
As mentioned previously, deletion of each putative biosynthetic gene will determine 
whether the protein it encodes is essential for lantibiotic biosynthesis.  The 
computational analysis carried out in chapter 3 demonstrated that nearly all of the 
actagardine and DAB biosynthesis genes have a homolog in the other cluster and 
that the homology between them is very high (see figure 5.1).  This observation 
indicates that homologous genes found in both clusters are likely to perform the 
same function within the biosynthetic pathways of these lantibiotics. 
 
 
Figure 5.1:  A diagram of the biosynthetic gene clusters from both A. garbadinensis 
(AG14, top) and A. liguriae (AL02, bottom).  Genes that are predicted to perform the 
same function in both clusters are represented in the same colour.  Genes that are 
found in only one cluster are uniquely coloured. 
 
garA garM garO garR1 garH garT garK garR Penicillin binding protein 
ligA ligM ligQ ligO ligH ligR1 ligT ligR ligK 
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With this in mind, the results from a deletion series of all the biosynthetic genes from 
the actagardine MGS on the AG14 cosmid are highly likely to apply to the 
homologous genes present on the AL02 cosmid.  This principle, however, cannot be 
applied to genes that only appear in either one of the clusters, these being garPBP 
and ligQ.  While it is possible that these two genes play equivalent roles in host 
immunity, they encode two quite different proteins, one a transporter, the other a 
penicillin binding protein.  In this study, ligQ is the only gene within the AL02 cluster 
that was deleted; garPBP was deleted in conjunction with the other putative 
actagardine biosynthetic genes. 
 
Many of the putative biosynthetic genes in the actagardine MGS have homologues 
in the gene clusters of other Class II lantibiotics, for example garA, garM, and garTH 
(Chatterjee et al., 2005).  These were thus assumed to be essential for actagardine 
biosynthesis, and deletion of these genes would likely result in the loss of 
actagardine biosynthesis.  Computational analysis carried out in chapter 3 also 
identified genes that are only found in the two Actinoplanes clusters, and are not 
found in other Class II gene clusters.  The lanO genes, encoding putative 
monooxygenases, are unique to these clusters and have the potential to perform a 
novel lantibiotic modification; enzymatic addition of an oxygen moiety to the C-
terminal methylanthionine bridge of the lantibiotics.  However, the existence of DAB 
suggests that the LigO monooxygenase is either dysfunctional, or unable to 
recognise its peptide substrate, which differs from that of actagardine.  
 
The biosynthetic genes present in the AG14 and AL02 gene clusters appear to be 
organised into several operons, as outlined in chapter 3 (and represented again in 
figure 5.1).  These consist of garA to garO, which are likely to be translationally 
coupled, garT to garR1, and garK to garR.  Any gene deletions that are made within 
the cluster must not interfere with the expression of downstream genes or the 
results would not reflect a single gene deletion.  To accomplish this, in-frame 
deletions were made that replaced essentially all of the coding sequence of the 
targeted gene with an 81 bp scar sequence.  These scar sequences retain the 
reading frame in the deleted gene and lack stop codons, and so should not interfere 
with the expression of downstream genes (figure 5.2).  Promoters and ribosome 
binding sites are unaffected by the 81 bp insertion.  The only potential issue is that 
the deletions might affect the stability of the resulting multi-cistronic mRNA, leading 
to phenotypic effects not directly attributable to deletion of the targeted gene. 
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The deletion mutants were produced using a PCR-based targeting method (also 
known as REDIRECT) that first replaces the target gene with a selectable marker 
that is subsequently converted into an 81 bp scar (Gust et al., 2003).  Using the 
REDIRECT protocol, primers that match the chromosomal DNA sequence adjacent 
to the gene that is to be deleted were used to amplify a targeting cassette from 
pIJ799 (aac(3)IV (ApraR) + oriT) containing the apramycin resistance gene and the 
origin of transfer, both of which are flanked by FRT sites (Gust et al., 2003).  The 
FRT sites are small segments of DNA that are recognised by the yeast FLP 
recombinase encoded by the BT340 plasmid (Datsenko & Wanner, 2000).  
Incubation at 420C activates expression of the FLP recombinase that selectively 
recombines the two flanking FRT sites, leaving the 81 bp in-frame non-polar 
deletion in place of the targeting cassette (Cherepanov & Wackernagel, 1995).  This 
strategy also allows the subsequent use of the apramycin resistance gene as a 
marker on the targeted cosmid, allowing for apramycin selection when conjugating 
into Streptomyces.  This was accomplished by targeting the SuperCos backbone of 
the scarred cosmids with an SspI restriction fragment from pIJ10702 (also known as 
pMJCos1) that contained the apramycin resistance gene, oriT, ΦC31 integrase gene 
and attP attachment site. 
 
 
Figure 5.2:  Sequence of the 81 bp scar sequence remaining after FLP-mediated 
excision of the apramycin cassette.  Translation of the targeted reading frame is 
printed in bold. The 20 and 19 nt priming sites used in PCR amplification are 
underlined and printed in colour (adapted from Recombineering in Streptomyces, 
Gust et al. (2006)). 
 
All scar mutants were made in the AG14 SuperCos (pIJ12201) cosmid and 
confirmed in E. coli using both restriction digests and PCR analysis (figure 5.3).  
Confirmed clones were subsequently targeted with the SspI fragment, introduced 
into S. lividans TK24 by conjugation and validated again by colony PCR (chapter 2, 
table 2.1).  Bioassays were performed by incubating the S. lividans TK24 
exconjugants on OB-N agar plugs for seven days.  An agar plug was subsequently 
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transferred onto a pre-inoculated L agar plate and incubated for a further 24 hours.  
All phenotypes were confirmed using MALDI-ToF mass spectrum analysis of 
supernatants obtained from liquid cultures. 
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Figure 5.3:  Representative PCR confirmation of the replacement of ligQ with the apramycin resistance cassette (left), followed by the 
replacement of the cassette with the 81 bp scar (right) using the lan-con3 primers in E. coli DH5α clones.  On the left, the pIJ12202 clone 
amplified a 2158 bp fragment encompassing the wild type gene.  The smaller 1819 bp fragment demonstrated that six clones have successfully 
had the gene replaced by the cassette.  On the right, three clones have had the apramycin cassette replaced with the 81 bp scar sequence 
(513 bp). 
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Streptomyces clones that contained a deletion that resulted in the loss of production 
of actagardine (or DAB) were subsequently subjected to attempted 
complementation with an in-trans chromosomally integrated (ΦBT1 attB site) copy 
of the deleted gene using the Streptomyces constitutive ermE* promoter on 
pIJ10257 (Hong et al., 2005).  This was done in an attempt to confirm that the gene 
deletion was indeed responsible for loss of production, and that it did not reflect an 
effect on downstream genes resulting from, for example, altered transcript stability, 
or a spontaneous mutation elsewhere in the genome.  The complementation 
constructs were produced by PCR amplification.  Primers with NdeI and HindIII 
restriction sites incorporated into the 3„ ends of the forward and reverse primer 
sequences were used to amplify the gene to be complemented.  The gene was 
amplified from the ATG start codon onwards since pIJ10257 contains both promoter 
and RBS elements.  After amplification, the PCR products were cut with NdeI and 
HindIII and subsequently cloned into the pGEM T-easy vector (Promega) and 
introduced into E. coli DH5α (Invitrogen) by transformation.  The resulting constructs 
were digested with NdeI and HindIII, the amplified gene subjected to gel purification, 
and ligated with the similarly cut expression vector pIJ10257.  All constructs were 
sequenced to verify that the genes had been cloned without errors.  The constructs 
were subsequently introduced into E. coli S17-1 by transformation, conjugated into 
S. lividans TK24 and subjected to bioassay and MALDI-ToF mass spectroscopy 
analysis. 
 
Figure 5.4A contains images of all the S. lividans TK24 clones that contain a 
deletion in a single putative lantibiotic biosynthetic gene in the AG14 MGS, and in 
ligQ from the AL02 cosmid.  Lack of lantibiotic biosynthesis is indicated by loss of a 
zone of inhibition around the agar plug.  Further information on each specific gene 
deletion is detailed in the subsequent text.   
 
Figure 5.4B contains images of the bioassay results of S. lividans TK24 clones 
containing the complementation constructs of single gene deletion mutants that 
resulted in a loss of production phenotype.  The garO mutant was included even 
though the clone produced a zone of inhibition.  This complemented clone should 
revert to producing actagardine, which is detectable using MALDI-ToF mass 
spectrum analysis.  However, in the majority of cases, attempts to complement the 
deleted gene failed to restore actagardine biosynthesis.  MALDI-ToF mass 
spectroscopy of culture supernatants also failed to reveal restoration of actagardine 
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production, even when a zone of inhibition was present (i.e. the complemented garR 
mutant).   
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 AG14          AG14∆garA        AG14∆garM         AG14∆garO        AG14∆garR1 
         
      AG14∆garH          AG14∆garT         AG14∆garK         AG14∆garR     AG14∆garPBP 
   
       AL02∆ligQ           pMJCos-1 
 
 
Figure 5.4A:  Images of S. lividans TK24 clones that contain a single deletion 
of a putative lantibiotic biosynthetic gene within the AG14 and AL02 
cosmids.  Clones were incubated for seven days on OB-N agar cubes and 
subsequently placed on L agar plates pre-seeded with the sensitive test 
organism M. luteus and incubated for a further 24 hours.  Zones of inhibition 
can be seen around clones where the gene deletion has not abolished 
biosynthesis of the lantibiotic.  Clones where M. luteus has grown close to 
the agar plug demonstrate that the S. lividans derivative is no longer 
producing a lantibiotic. 
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 garA    garM    garO    garR1    garK 
 
   
 garR    ligQ 
Figure 5.4B:  Images of S. lividans TK24 clones that contain a single deletion of a putative lantibiotic biosynthetic gene within the AG14 and 
AL02 cosmids and that have been subjected to attempted complementation with an in-trans integrated copy of the gene under control of the 
ermE* promoter.  Clones were incubated for seven days on OB-N agar cubes and subsequently placed on L agar plates pre-seeded with the 
sensitive test organism M. luteus and incubated for a further 24 hours.  A zone of inhibition around the garR mutant indicated successful 
complementation (the zone has suffered from re-growth of M. luteus leading to a double ring).  Clones where M. luteus has grow close to the 
agar plug indicate that the mutant has not been complemented and that biosynthesis has not been restored.  
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The first gene in the actagardine biosynthetic gene cluster is garA that encodes the 
prepropeptide.  GarA is the precursor of mature actagardine, and is modified and 
exported by other enzymes and proteins encoded within the MGS.  Figure 5.4A 
contains an image of the S. lividans TK24 clone containing the cosmid 
pIJ12206∆garA.  This clone notably lacks a halo around the agar plug after seven 
days growth on OB-N agar, in contrast to the AG14 cosmid (positive control) that 
does have a zone of inhibition, suggesting that the AG14∆garA clone is no longer 
able to produce actagardine.  MALDI-ToF mass spectrum analysis of supernatants 
from liquid cultures of the strain failed to detect peaks corresponding in size to the 
known masses of actagardine, providing further evidence that deletion of garA, as 
expected, completely abolished actagardine biosynthesis. 
 
Actagardine, like all lantibiotics, is ribosomally synthesised.  The sequence of the 
lanA structural gene correlates directly with the peptide sequence of the mature 
lantibiotic, with the exception of the amino acids that are modified to form (methyl-) 
lanthionine bridges.  The actagardine MGS is capable of producing a number of 
variant actagardine molecules (Boakes et al., 2009).  Some lantibiotic biosynthesis 
pathways can tolerate significant amino acid substitutions and truncations within the 
prepropeptide; for example, the nisin biosynthetic machinery can produce 
hexapeptides and non-lantibiotic peptides when they are fused to the nisin leader 
sequence (Kluskens et al., 2005, Kuipers et al., 2008, Rink et al., 2007).  The nisin 
biosynthesis machinery can even tolerate lantibiotic prepropeptides from different 
lantibiotic classes, including a two-component lantibiotic from Streptococcus 
pneumoniae (Majchrzykiewicz et al., 2010).  Loss of actagardine biosynthesis, and 
the failure to detect any other modified peptides in culture supernatants of the garA 
mutant, indicates that either garA is the only lanA gene in the heterologous host that 
encodes a substrate for the actagardine biosynthetic enzymes, or that deletion of 
garA has compromised the function of other gar genes in the cluster. 
 
The garA prepropeptide has also been disrupted in the natural producer A. 
garbadinensis.  Boakes et al. (2009) disrupted garA using an apramycin resistance 
gene (from pIJ773) and observed a similar loss of actagardine production.  Although 
not attempted, deletion of ligA from either the natural producer or from the AL02 
cosmid would be similarly expected to result in the loss of DAB production. 
 
An attempt was subsequently made to complement the ∆garA mutant with 
pIJ10257-garA (figure 5.4B).  Several repeats of the bioassay and MALDI-ToF 
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analysis of culture supernatants failed to reveal complementation.  The reasons for 
this are unknown, particularly since in other studies a complementation construct 
was used to generate a number of actagardine variants in the natural producer and 
to restore limited production of actagardine in an A. garbadinensis ∆garA mutant 
(Boakes et al., 2009).  pIJ10257 containing the ermE* promoter has been used 
previously to successfully complement mutants and to over-express various genes 
in a number of Streptomyces strains (McArthur & Bibb, 2008, Claesen & Bibb, 2010, 
Hong et al., 2005).  PCR and DNA sequence analysis confirmed that the 
complementation construct used in this experiment was assembled correctly. 
 
There are several possible explanations for the lack of complementation.  Boakes et 
al. (2009) commented on the low levels of actagardine production in an A. 
garbadinensis ∆garA mutant that had been complemented with garA using its own 
promoter and inserted at the ΦC31 integration site.  Reduced levels of production of 
secondary metabolites when their corresponding gene clusters have been inserted 
at the ΦC31 integration site have been reported (Baltz, 1998, Rodriguez et al., 
2003).  Boakes et al. (2009) suggested that the low levels of complementation were 
associated with in trans expression and likely to result from instability and loss of 
integrity of mRNA transcripts.  It is therefore possible that integration of garA gene 
into the ΦBT1 attachment site used in these experiments has an even more severe 
effect, resulting in lack of restoration of detectable actagardine biosynthesis.  The 
chromosomal context of garA in the complementation clone may also have an 
adverse affect on garA expression.  For example, local “chromatin” structure may 
play a role.  There may also be regulatory elements in the region of DNA directly 
upstream of garA that are crucial for its expression and that are lacking in the 
complementation construct.  Like that of many secondary metabolites, the 
production of actagardine is regulated and occurs late in growth in liquid culture, 
and is probably coordinated with morphological differentiation in agar-grown 
cultures.  Attempting to express garA in trans might have disrupted such regulatory 
mechanisms, resulting in lack of complementation. 
 
The constitutive expression of garA from the strong ermE* promoter might also 
interfere with regulatory mechanisms.  It is conceivable that the stoichiometry 
between GarA and the biosynthetic machinery is important.  The presence of 
excess actagardine prepropeptide might down-regulate expression of the rest of the 
cluster, or disrupt its function. 
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To try to identify the cause of the lack of complementation, Reverse Transcription-
PCR (RT-PCR) was performed on RNA isolated from S. lividans TK24 clones 
containing the wild-type cosmid and a number of deletion mutants.  RNA isolated 
after 3 days growth failed to yield RT-PCR products, perhaps reflecting a temporal 
delay in gar gene expression in the heterologous host.  RNA extracted from cultures 
harvested at later time points were of poor quality, and again no RT-PCR products 
were detected.  These experiments failed to provide any useful insights into the lack 
of genetic complementation. 
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garM was identified by bioinformatic analysis to encode a biosynthetic protein 
responsible for the selective dehydration of serine and threonine residues to Dha 
and Dhb, respectively.  It is also responsible for cyclisation of the modified peptide 
by the addition of cysteine thiols to the dehydrated amino acid residues (You & van 
der Donk, 2007, Paul et al., 2007).  garM lies directly downstream of garA 
apparently in the same operon, and the two genes are separated by a stem-loop 
structure (Boakes et al., 2009).  Replacement of garM in the AG14 cosmid with the 
81 bp scar sequence abolished actagardine production, as assessed by bioassay 
and MALDI-ToF mass spectrum analysis of culture supernatants.  This suggests 
that in the heterologous host GarM is the only enzyme able to modify the 
actagardine prepropeptide. 
 
Attempts to complement the garM deletion mutant did not restore actagardine 
production when the complementation clone was analysed using both bioassay and 
MALDI-ToF mass spectrum analysis of culture supernatants.  In principle, 
reintroduction of the synthetase gene should have been sufficient to restore the 
biosynthesis of actagardine by the heterologous host.  As for the garA mutant, there 
are a number of possible reasons why complementation failed. 
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The likely last gene in the garA/garM operon is garO.  garO is thought to encode a 
novel enzyme for lantibiotic biosynthesis.  The GarO monooxygenase is thought to 
be responsible for the oxidation of the C-terminal methylanthionine bridge found in 
actagardine.  The homolog found in the A. liguriae cluster, ligO, is thought to be 
non-functional as both the natural producer and heterologous hosts containing the 
AL02 cosmid all produce DAB which lacks the oxidised methylanthionine (Boakes et 
al., 2010).  Deletion of garO did not abolish the ability of the heterologous host to 
produce a compound active against M. luteus, as demonstrated by the zone of 
inhibition surrounding the pIJ12206∆garO clone (figure 5.4A). 
 
Both the actagardine and DAB biosynthetic gene clusters contain a gene, lanO, 
encoding a putative monooxygenase that has not been observed in any other 
lantibiotic biosynthetic gene cluster.  As previously discussed in chapter 3, the ligO 
gene carried on the AL02 cosmid appears to have undergone a frame shift mutation 
towards the end of the gene that may have rendered the LigO monooxygenase non-
functional.  As also previously discussed in chapter 4, MALDI-ToF analysis 
identified Ala(0)-DAA, and a number of other oxidised actagardine derivatives, in 
culture supernatants of S. lividans TK24 clones containing the AG14 cosmid, most 
of which are likely incomplete oxidation products and oxidation artefacts caused by 
the MALDI-ToF analysis.  Along with Ala(0)-DAA, peaks were observed that 
correspond to Ala(0)-actagardine peptides with up to three additional oxygen atoms, 
as well as their corresponding sodium adducts.  The additional oxygen atoms are 
likely to be present on all of the lanthionine bridges in the lantibiotic.  While 
complicating analysis of the ∆garO mutant, MALDI-ToF analysis can still be used to 
assess the affect of deleting the monooxygenase gene.  Figure 5.5 shows a 
comparison of two MALDI-ToF spectra of culture supernatants of clones containing 
the wild type AG14 cosmid and the ∆garO mutant.  The intensity of the peaks 
corresponding to Ala(0)-DAA (1944) and its sodium adduct (1966) are markedly 
elevated in the ∆garO clone.  Note also that the distribution of peaks associated with 
MALDI-ToF associated oxidation of actagardine is shifted to the left in the garO 
mutant.  These results provide strong evidence to suggest that the GarO 
monooxygenase is indeed responsible for the addition of the oxygen moiety to the 
actagardine peptide. 
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m/z Description 
1944 Ala(0)-deoxyactagardine +H 
1960 Ala(0)-actagardine + H 
1966 Ala(0)-deoxyactagardine + Na 
1982 Ala(0)-actagardine + Na 
1998 Ala(0)-actagardine + O + Na 
2014 Ala(0)-actagardine + 2O + Na 
2030 Ala(0)-actagardine + 3O + Na 
 
Figure 5.5:  MALDI-ToF spectra of culture supernatants of two heterologously 
expressed AG14 cosmids.  The top spectrum is from the wild type AG14 cosmid.  
The bottom spectrum is from a pIJ12206∆garO::scar mutant.  The major masses 
are noted on the spectra, and summarised in the table above.  Note that the peak 
that corresponds to the Ala(0)-DAA sodium adduct (in the black box) has a higher 
relative intensity in the ∆garO clone compared to AG14, suggesting  that this gene 
is indeed able to add the oxygen moiety to the C-terminal methylanthionine bridge 
of actagardine. 
 
To confirm that the above interpretation of the MALDI-ToF spectra was correct, 
liquid chromatography/mass spectroscopy (LC-MS) analysis was conducted during 
a visit to Novacta Biosystems on a ∆garO::tet mutant, where the garO gene has 
been replaced with a tetracycline resistance marker.  Three clones of the ∆garO::tet 
mutant were grown in liquid culture for seven days, and the supernatants subjected 
to LC-MS analysis and compared to the supernatants of clones containing the wild 
type AG14 cosmid.  Figure 5.6 shows the results from this experiment.  
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Figure 5.6:  LC-MS comparison of three AG14∆garO::TcR clones and the wild type AG14 cosmid in S. lividans TK24.  The table contains a 
description of the major masses identified in the spectra.  A new peak of 973 Da is observed only in the ∆garO mutants, confirming that the 
GarO monooxygenase is responsible for enzymatic oxidation of actagardine. 
 
m/z Description 
 AG14 AG14∆garO 
1) 973  Ala(0)-deoxyactagardine 
2) 981 Ala(0)-actagardine Ala(0)-deoxyactagardine + O 
3) 989 Ala(0)-actagardine + O Ala(0)-deoxyactagardine + 2O 
4) 1001 Ala(0)-actagardine + O + Na  
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LC-MS analysis of culture supernatants from S. lividans TK24 containing the wild 
type AG14 cosmid produced a peak of 981 Da corresponding to Ala(0)-actagardine, 
and two others representing a single oxidation event (989 Da) and a single oxidation 
event with an additional sodium adduct (1001 Da).  The observed mass peaks in the 
LC-MS specra are doubly charged leading to an observed mass that is half of that 
seen in MALDI-ToF specra.  In the supernatants of the cultures containing the 
∆garO deletion mutant, a new peak (973 Da) was observed, corresponding to 
Ala(0)-DAA.  Whether the singly oxidised species observed upon LC-MS analysis of 
both the wild type and mutant cultures (compared to the numerous oxidations seen 
in MALDI-ToF spectra (Chapter 4 figure 4.2)) reflects the presence of oxidised 
actagardine in the culture supernatant, or whether it arose as a consequence of the 
analysis is not known.  Later LC-MS analysis of a pIJ12206∆garO::scar mutant 
yielded the same results as seen with the tetracycline resistance marked mutant. 
 
As for garA and garM, attempts to complement the ∆garO deletion mutant did not 
restore wild type levels of Ala(0)-actagardine production; the complementation clone 
exhibited the same profile as the garO mutant upon MALDI-ToF analysis (data not 
shown). 
 
Bioassay analysis of the pIJ12206∆garO::scar mutant failed to reveal any apparent 
decrease in bioactivity against M. luteus, although this observation may have been 
compromised by the potential presence of the spontaneously oxidised derivatives.  
Boakes et al. (2009) subsequently confirmed that deletion of garO in the natural 
producer had the same effect, using HPLC-MS to identify Ala(0)-DAA in the culture 
supernatants of the mutant.  This study also demonstrated that the antimicrobial 
activity of Ala(0)-DAA against M. luteus was slightly lower than that of actagardine, 
but not for all of the Gram-positive pathogens tested (figure 5.7). 
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 Actagardine Deoxyactagardine Vancomycin 
Enterococcus faecalis 29212 8, 8 8, 8 2, 2 
E. faecium 7131121 (VRE) 64, 64 64, 64 > 64, > 64 
E. faecium 19579 (VSE) 16, 16 32, 32 0.5, 1 
Micrococcus luteus 4698 1, 1 2, 4 1, 1 
Staphylococcus aureus R33 (EMRSA) 8, 16 8, 16 1, 1 
S. aureus SH1000 (MSSA) 8, 8 16, 32 2, 2 
Streptococcus epidermidis 11047 (MSSE) 32, 32 32, 32 1, 2 
Streptococcus pneumoniae R6 16, 32 16, 32 0.5, 0.5 
VRE, vancomycin-resistant enterococcus; VSE, vancomycin-sensitive enterococcus; 
EMRSA, epidemic methicillin-resistant S. aureus; MSSA, methicillin-sensitive S. aureus; 
MSSE, methicillin-sensitive S. epidermidis. 
 
Figure 5.7:  The antimicrobial activity of actagardine, deoxyactagardine and 
vancomycin against a range of Gram-positive microorganisms shown as minimum 
inhibitory concentrations (μg ml-1), (Boakes et al., 2009). 
 
This observation was not unexpected as S. lividans containing pIJ12207 and 
producing Ala(0)-DAB also shows clear bioactivity.  Thus it appears that 
biosynthetic oxidation of actagardine has a marginal effect on its antimicrobial 
activity.  It is possible that the oxidised methylanthionine bridge serves another 
biological purpose, possibly influencing solubility or increasing resistance to 
proteases. 
 
As mentioned previously, the LigO monooxygenase appears to have a frame-shift 
mutation towards its C-terminus, and no actagardine B or Ala(0)-actagardine B 
(Ala(0)-AB) has been identified in culture supernatants from either the natural 
producer or S. lividans derivatives expressing the cloned lig gene cluster.  
Consistent with lack of functionality of LigO, replacement of  garA with ligA in A. 
garbadinensis led to the production of actagardine B (Boakes et al., 2010).  This 
demonstrates that the minor amino acid differences between actagardine and DAB 
are unlikely to be responsible for lack of oxidation of the C-terminal 
methylanthionine bridge of DAB in A. liguriae. 
.
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Deletion of garR1, encoding an orphan response regulator, eliminated the 
production of actagardine in S. lividans TK24.  Actagardine biosynthesis was not 
detectable either by bioassay or by MALDI-ToF mass spectrum analysis.  As 
described previously in chapter 3, the garR1 response regulator and the garRK two 
component regulatory system have corresponding homologues in the mersacidin 
gene cluster (Guder et al., 2002, Boakes et al., 2009).  In the mersacidin cluster, 
MrsR1 regulates the expression of mrsA and mrsRK regulate the expression of the 
immunity transporter MrsFEG.  It is therefore possible that the garR1 response 
regulator is directly responsible for regulation of garA expression.  Its absence from 
the gene cluster would prevent synthesis of the prepropeptide and the subsequent 
expression of the other biosynthetic genes through the garRK signal transduction 
system, and hence the production of mature actagardine (Guder et al., 2002, 
Boakes et al., 2009). 
 
The loss of actagardine production in the garR1 deletion mutant was not restored 
when the gene was introduced back into the chromosome under the control of the 
constitutive Streptomyces ermE* promoter.  The possible reasons for this are as for 
the other mutants where complementation failed. 
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The two transporter proteins, GarH and GarT, appear not to be essential for 
biosynthesis and export of actagardine in S. lividans TK24, since both 
pIJ12206∆garH::scar and pIJ12206∆garT::scar yielded zones of inhibition 
comparable to the wild type cosmid (figure 5.4A), and production of Ala(0)-
actagardine was confirmed by MALDI-ToF mass spectrometry.  Due to the wealth of 
secondary metabolites produced by S. lividans, it is probable that other transporter 
systems present within the heterologous host are able to export actagardine from 
the cell.  There is evidence for some lantibiotics that a number of lantibiotic 
biosynthetic enzymes may form a complex associated with the cell membrane 
(Chatterjee et al., 2005).  The transporter complex could act as an anchor at the cell 
membrane for the biosynthetic machinery and then immediately export the modified 
propeptide from the cell.  If such a complex occurred in actagardine biosynthesis, 
deletion of garTH would be expected to reduce the level of actagardine production.  
Since this was not observed, such a complex, if it occurs in A. garbadinensis, is not 
essential for actagardine production.  
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Heterologous expression of cosmids pIJ1206∆garR::scar and pIJ12206∆garK::scar 
produced no ala(0)-actagardine that was detectable by either bioassay or by 
MALDI-ToF mass spectrum analysis.  Thus the response regular and sensor kinase 
appear to be essential for actagardine biosynthesis. 
 
Unlike the actagardine cluster, deletion of the mrsR2/K2 regulatory genes had no 
effect on the biosynthesis of mersacidin (Guder et al., 2002).  This observation may 
indicate a role for garRK that is different to that of mrsR2/K2 and may suggest that 
garRK regulate processes in the biosynthetic pathway other than the (unconfirmed) 
immunity mechanism. 
 
Attempts to complement the garK mutant again failed to restore actagardine 
biosynthesis.  Conversely, expression of garR from the ermE* promoter in the garR 
deletion mutant did appear to restore actagardine production in agar-grown cultures 
(figure 5.4B), although this could not be confirmed by MALDI-ToF mass 
spectrometry of culture supernatants from liquid-grown cultures.  As mentioned 
previously, this may reflect relatively low levels of of actagardine production in liquid 
cultures of S. lividans TK24 containing the gar gene cluster. 
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The gene encoding the penicillin-binding protein located at one end of the 
biosynthetic gene cluster has the potential to be involved in producer immunity to 
actagardine.  As mentioned previously, there is a similarly located potential analog 
in the gene cluster for michiganin A biosynthesis, annotated as an unknown protein 
with a PASTA domain (figure 5.10) (Holtsmark et al., 2006).  As discussed in 
Chapter 3, PBP and serine/threonine kinase associated domains (PASTA domains) 
are required for localisation of PBPs to unlinked glycan chains often found near the 
site of cell division (Yeats et al., 2002, Jones & Dyson, 2006).  PBPs have been 
associated with the enhanced resistance of Listeria monocytogenes to nisin.  It is 
believed that the PBP is able to shield lipid II or possibly reduce the effective 
extracellular concentration of lipid II (Gravesen et al., 2004). 
Deletion of garPBP did not affect the production of actagardine in the heterologous 
host, and thus the gene appears to be outside the minimal gene set required for 
biosynthesis.  However, it is possible that the same mutation made in the natural 
producer could influence actagardine production.  As for the transport proteins, it is 
conceivable that S. lividans TK24 may be able to compensate for the lack of 
GarPBP by providing an alternative immunity mechanism to actagardine (S. lividans 
1326 (the strain from which TK24 was derived) is naturally resistant to high 
concentrations of actagardine (up to 100 µg/ml); Novacta Biosystems, personal 
communication). 
 
Nonetheless, this result suggests that GarPBP (and most likely the protein with a 
PASTA domain associated with the michiganin A gene cluster) is not involved in 
lantibiotic immunity.  Even though S. lividans TK24 is intrinsically resistant to 
actagardine, given the likely interplay between immunity and biosynthesis, deletion 
of the PBP gene, if part of the gar gene cluster, would have been expected to have 
had some effect of actagardine biosynthesis, but none was apparent.  
 
The A. garbadinensis and A. liguriae gene clusters are highly homologous, sharing 
eight out of a total of nine genes potentially required for biosynthesis of actagardine 
and DAB.  The DAB cluster has the full complement of genes found in the 
actagardine cluster, and the function of these genes is likely to be identical to those 
found in the actagardine cluster with one exception.  The DAB gene cluster encodes 
an additional ATP binding cassette transporter (LigQ) that has 51% amino acid 
sequence identity to a putative ABC transporter from S. coelicolor, SCO3235 
(Boakes et al., 2010).  Deletion of ligQ appeared to almost abolish activity against 
172 
 
M. luteus, (figure 5.4A), although some DAB was detectable upon MALDI-ToF 
analysis of culture supernatants (figure 5.8).  Expression of ligQ using the ermE* 
promoter only marginally increased levels of Ala(0)-DAB production, but was not 
able to restore wild type levels, based on the size of the zone of inhibition, and could 
not be confirmed by MALDI-ToF analysis (as for garR previously) (figure 5.4B).  
Thus while not absolutely essential, the LigQ ABC transporter appears to play an 
important role in determining the level of Ala(0)-DAB synthesis and/or export in S. 
lividans TK24. 
 
It is possible that LigQ is performing a similar role to LanFEG immunity transporters 
found in the gene clusters for the related lantibiotics michiganin A and mersacidin 
(Guder et al., 2002, Holtsmark et al., 2006).  In the absence of LigQ-mediated 
immunity, Ala(0)-DAB synthesis could be prevented as a fail-safe mechanism to 
prevent the organism killing itself.  If LigQ does encode an immunity mechanism for 
DAB production, it is surprising that the actagardine gene cluster does not possess 
an equivalent mechanism for self-resistance. 
 
A 
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Figure 5.8:  MALDI-ToF spectra of an S. lividans clone AL02∆ligQ::scar (A) and 
vector only control M1216 (B).  The ala(0)-deoxyactagardine B ([M+Na]+ = 1966) 
peak is present in the AL02∆ligQ::scar clone and not the negative control (M1216). 
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5.3 Analysis of actagardine homologs 
 
5.3.1 Introduction  
 
The gene clusters that produce actagardine and DAB, found in A. garbadinensis 
and A. liguriae, respectively, are very similar and produce lantibiotics that differ by 
only two amino acids and one lanthionine bridge modification.  To date, two other 
lantibiotics (one characterised, one putative) have been identified that share similar 
peptide sequences to these two lantibiotics.  Michiganin A is an actagardine 
homolog that is produced by Clavibacter michiganensis (Holtsmark et al., 2006).  
Clavibacter michiganensis subsp. michiganensis is described as a plant-pathogenic 
actinomycete, infecting tomato and causing bacterial wilt and canker (Gartemann et 
al., 2003).  The gene cluster for michiganin A is however markedly different from 
those encoding actagardine and DAB despite producing a lantibiotic that is very 
similar to actagardine (figure 5.9 and 5.10).  As discussed in chapter 3, bioinformatic 
analysis identified another homolog of actagardine named in this study as gnavucin.  
The gene encoding the prepropeptide for this putative lantibiotic, gnaA, was 
identified in the genomes of two bacteria, Ruminococcus gnavus ATCC 29149 and 
Blautia hansenii DSM 20583.  R. gnavus is described as a Gram positive, non 
spore-forming obligate anaerobe found normally in the human alimentary tract (Hata 
& Smith, 2004).  The R. gnavus E1 strain is responsible for producing the lantibiotic 
ruminococcin A, which differs significantly from gnavucin, when grown in the 
presence of trypsin (Dabard et al., 2001, Gomez et al., 2002, Marcille et al., 2002).  
The structure of gnavucin was predicted from the amino acid sequence of the 
encoded peptide and modelled on the structure of actagardine.  Only one other 
putative lantibiotic biosynthetic gene was identified in close proximity to the gnaA 
gene, a lanM type synthetase gene.  It is thus possible that these two genes 
represent a remnant of an earlier lantibiotic gene cluster, and it seems unlikely that 
the predicted lantibiotic is produced by its host strain.  In contrast, in addition to the 
gnaA homologue, B. hansenii contains an intact lanM gene. 
 
All three gene clusters were analysed using the same tools and methods outlined in 
chapter 3.  The biosynthetic gene cluster of michiganin A has been submitted to the 
National Centre for Biotechnology by Holtsmark et al. (2006).  The biosynthetic 
genes for gnavucin were identified by BLAST searching using the amino acid 
sequence of GarA as query sequence.  The frame-plot algorithm could not be used 
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to identify other putative lantibiotic biosynthetic genes close to gnaA due to the low 
G-C content of the R. gnavus genome.  Instead, ORFs were identified manually by 
locating gaps in the series of stop codons using Artemis, and then searching by 
BLAST for homologues in the public database. 
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Figure 5.9:  The actual and predicted structures of actagardine and two homologs, michiganin A and gnavucin.  The structure of michiganin A 
displayed here is taken from Holksmark et al. (2006).  It is possible that a lanthionine bridge exists between Dhb9 and Cys14, which would 
result in the lantibiotic closely resembling actagardine in structure; it is unclear why the authors chose not to include it in their predicted 
structure.  The structure of gnavucin was predicted from its primary amino acid sequence using the actagardine structure as a template. 
 
21
1
Gly
Leu
Glu
Ala
Trp
S
Ser
Ala
Dhb
Leu Abu
Ile
Gly
Abu
Cys
Ala
S
Ala
Ala
Arg
S
Ser Ile
Ile
Michiganin A - predicted
177 
 
5.4 Computational analysis of the gnaA and clvA gene 
clusters 
 
 
 
Figure 5.10:  The proposed biosynthetic gene clusters of actagardine (top), DAB 
(middle) and michiganin A (bottom).  Genes highlighted in the same colour are 
predicted to be functionally analogous. 
 
As seen in figure 5.10, while the gene clusters for actagardine and DAB biosynthesis 
are very similar, that for michiganin A is quite different.  The michiganin A gene cluster 
only shares similarity with respect to the relative position of the lanA and lanM genes in 
the cluster, and lacks lanO and lanTH transporter genes.  Instead, it encodes a ClvFEG 
transporter to presumably export the peptide and to provide immunity to the lantibiotic 
(Holtsmark et al., 2006).  As mentioned previously in chapter 3 section 3.1.2, the ClvA 
prepropeptide has significant homology to GarA, sharing 29 % amino acid identity, 
which increases to 89 % when comparing the propeptide amino acid sequences.  The 
leader sequence of ClvA lacks the PAG motif found in the leader sequences of all of 
the other actagardine homologs and mersacidin (chapter 3, figure 3.4).  ClvM shares 
some homology with GarM, with 29 % amino acid identity over the length of the entire 
protein.  ClvK has higher homology to LigK than GarK, sharing 38 % amino acid 
sequence identity.  ClvR also shares higher homology with LigR than GarR, sharing 52 
% amino acid identity.  ClvFEG is likely to form an ABC transporter composed of two 
cytoplasmic ATP-binding proteins (ClvFG) and a single membrane protein (ClvE) 
clvKclvF clvR clvA clvMclvE clvGPutative peptide
ABC transporter
substrate-binding protein
Putative
acetyltransferase
Hypothetical protein
with PASTA domain
garA garM garO garR1 garH garT garK garR Penicillin binding protein 
ligA ligM ligQ ligO ligH ligR1 ligT ligR ligK 
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(Siegers & Entian, 1995).  There is also a hypothetical protein that is encoded by a 
gene downstream of clvM that has a potential PASTA domain which are also found in 
PBPs, as discussed previously. 
 
GnaA shares 33% amino acid identity to GarA.  The putative gnaM gene is split by an 
insertion element (although this could reflect an error during sequence assembly).  
Reconstitution of the gnaM gene in silico revealed 24% amino acid sequence identity to 
GarM and LigM, and 99% amino acid identity to the LanM present in B. hansenii.   
 
To determine if the prepropeptides of clvA or gnaA could act as substrates for the 
actagardine biosynthetic machinery, both genes were synthesised and placed under 
control of the ermE* promoter in constructs identical to those used in the 
complementation experiments.  These constructs were subsequently transferred into S. 
lividans TK24 containing the garA deleted cosmid.  No halos were observed upon 
bioassay of agar-grown cultures against M. luteus, and no peaks were detected 
corresponding to gnavucin or michiganin A upon MALDI-ToF analysis of liquid culture 
supernatants.  It is unclear whether these negative results are due to incompatibility 
between these prepropeptides and the actagardine biosynthetic machinery, or reflect 
the same issues observed with many of the previous failed attempts to achieve 
complementation of gar mutants, including garA. 
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5.5 Discussion 
 
In this chapter an apramycin cassette was used to introduce in-frame deletion 
mutations into all of the proposed lantibiotic biosynthesis genes within the actagardine 
biosynthetic gene cluster present on the AG14 cosmid.  The subsequent clones were 
subjected to bioassays and MALDI-ToF mass spectrum analysis.  Out of the nine 
putative biosynthetic genes (garA to garPBP), five were likely to be essential for 
actagardine biosynthesis in the heterologous host S. lividans TK24. 
 
Not surprisingly, all three of the proposed prepropeptide encoding and modification 
genes (garA, garM and garO) were likely to be essential for Ala(0)-actagardine 
biosynthesis.  Deletion of garA in the natural producer A. garbadinensis also yielded a 
non-producing phenotype (Boakes et al., 2009).  Despite the complications caused by 
spontaneous oxidation, the tailoring gene garO is likely essential for the production of 
Ala(0)-actagardine in the heterologous host.  Deletion of garO appeared to have little 
effect on antimicrobial activity against M. luteus, consistent with published data (Boakes 
et al., 2010).  MALDI-ToF mass spectrum analysis of this mutant, and subsequently the 
wild type gene cluster (both in S. lividans), detected a peak corresponding to the 
biosynthesis of a new actagardine derivative, Ala(0)-DAA.   
 
The three putative regulatory genes, garR1, garR and garK, are likely to be required for 
actagardine biosynthesis, but only garR could be confirmed (by successful 
complementation) as essential.  Based on work on mersacidin, it is possible that GarR1 
directly regulates expression of the garAMO operon.  Unlike the mersacidin cluster, 
there is no obvious resistance mechanism that is regulated by GarRK, (apart from the 
ABC transporter GarTH) , but it is conceivable that GarRK, by analogy, regulate garTH 
expression  (Guder et al., 2002).  The michiganin A gene cluster contains a lanFEG 
transporter system much like mersacidin.  These transporters have been associated 
with immunity mechanisms for a number of lantibiotics, and are likely to be regulated by 
lanRK two component regulatory systems (Guder et al., 2002, Chatterjee et al., 2005). 
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The two transporter genes garH and garT appear to be unnecessary for actagardine 
production and export in the heterologous host, and presumably transporters encoded 
elsewhere in the host‟s genome are able to compensate for the loss of the lantibiotic 
transporters.  Deletion of garPBP did not affect the biosynthesis of actagardine, while 
conversely, deletion of ligQ, encoding a putative immunity mechanism in A. liguriae, 
appeared to severely limit DAB production. 
 
Attempts to complement the mutations, with one exception (garR), failed.  This could 
reflect issues with expression levels at the ΦBT1 attachment site, or perhaps more 
likely, a complex mechanism of regulation that requires stoichiometric production of the 
various biosynthetic components. 
 
Bioinformatic analysis identified two actagardine-like peptides, michiganin A and 
gnavucin, although their gene clusters differ markedly from those of their Actinoplanes 
counterparts.  This is intriguing and raises the possibility that the actagardine “scaffold” 
is perhaps more common than had been previously recognised. 
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5.6 Summary 
 
 The actagardine prepropeptide (GarA) and modification enzymes (GarM and 
GarO) are likely to be essential for actagardine biosynthesis. 
 
 Deletion of garO, encoding a monooxygenase, resulted in the detection of a 
novel actagardine derivative, Ala(0)-deoxyactagardine; DAB was also identified 
in A. liguriae. 
 
 Of the three regulatory genes (garR1, garR and garK), garR is clearly essential 
for biosynthesis. 
 
 The putative lantibiotic transporters GarTH are not essential for actagardine 
biosynthesis and export.  S. lividans TK24 appears to be able to compensate in 
their absence. 
 
 GarPBP is also not essential for actagardine biosynthesis, and is likely not part 
of the gar gene cluster.   
 
 LigQ, a putative immunity transporter, is required for wild type levels of DAB 
biosynthesis. 
 
 Bioinformatic analysis identified two actagardine homologs, michiganin A and 
gnavucin.  The gene cluster for michiganin A is markedly different to that of 
actagardine and DAB, yet produces a very similar lantibiotic. 
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6 Discussion 
 
In this study, the actagardine and DAB biosynthetic gene clusters from A. 
garbadinensis and A. liguriae were subjected to detailed analysis.  Heterologous 
expression of two cosmids, AG14 from A. garbadinensis and AL02 from A. liguriae, 
confirmed that they contained all of the genes required for the biosynthesis of 
actagardine and DAB, respectively.  For the first time, this study confirmed that DAB 
can be synthesised by a heterologous host, S. lividans TK24.  Moreover, the 
expression of the AG14 cosmid in the modified S. coelicolor strain M1146 suggested 
that deletion of secondary metabolite pathways from the host genome considerably 
improved the yield of lantibiotic production.   
 
Analysis of the two cosmids identified a number of ORFs that encoded putative 
lantibiotic biosynthetic enzymes, many of which are also encoded by other type B 
lantibiotic gene clusters (Chatterjee et al., 2005).  This allowed the bioinformatic 
prediction of MGSs for both actagardine and DAB biosynthesis.  Deletion of genes that 
flanked the putative actagardine MGS confirmed that they were not required for 
biosynthesis, even though some of them had some functional analogy with genes 
adjacent to the putative DAB MGS.  Expression of three other A. liguriae cosmids, 
identified by Novacta Biosystems and with a centrally located ligA, also served to 
narrow down the number of potential DAB biosynthetic genes.  Combining the 
computational analysis and cosmid reduction mutations, more confident MGSs were 
predicted for both actagardine and DAB production.  To confirm the involvement of 
each gene in the actagardine MGS in lantibiotic biosynthesis, a deletion series was 
created, deleting each gene in turn and analysing its effects on actagardine production. 
 
Nine genes were initially predicted to be involved in the biosynthesis of actagardine.  
Mutational analysis of the AG14 cosmid determined that garA, encoding the 
prepropeptide, appeared essential for the biosynthesis of actagardine in the S. lividans 
TK24 heterologous host.  Deletion of garA has also been accomplished in the natural 
producer, resulting in the same loss of lantibiotic biosynthesis (Boakes et al., 2010, 
Boakes et al., 2009).  The modification gene garM also appeared essential for 
production.   
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Three putative regulatory genes, garR1, garR and garK, all appeared essential for 
actagardine biosynthesis, but only garR could be confirmed as essential for actagardine 
biosynthesis in the heterologous host by genetic complementation.  Deletion of garR1 
abolished actagardine biosynthesis, and by comparison to mersacidin and MrsR1, it 
has been suggested that GarR1 regulates the expression of garA.  Unlike mersacidin 
(Guder et al., 2002), however, the GarRK two component system does not appear to 
solely regulate the putative immunity mechanism since they are essential for the 
biosynthesis of actagardine, while the transport genes garTH are not.  The michiganin 
A gene cluster does not have a homolog of garR1, and must regulate the expression of 
clvA by another mechanism.  It does, however, have homologs of the two component 
LanRK regulators that are also encoded by the actagardine, DAB and mersacidin gene 
clusters.  Using mersacidin as a model, the actagardine and DAB two component 
LanRK may regulate expression of the immunity response to the lantibiotics that they 
produce.  As indicated above, surprisingly the two component transport system, garTH, 
was not required for actagardine export, at least not in the heterologous host, where 
alternative transporters can presumably carry out this function.  Apart from these two 
genes, the only other potential immunity gene in the actagardine cluster is garPBP.  
While deletion of garPBP appeared to have no affect on actagardine biosynthesis in the 
heterologous host, it is conceivable that any phenotypic consequence was masked by 
the intrinsic resistance of S. lividans TK24 to actagardine (up to 100 µg/ml, Novacta 
Biosystems, personal communication).  Expression of garPBP in an actagardine 
sensitive host, where its introduction provides immunity to actagardine, could confirm 
the involvement of GarPBP in self-resistance to actagardine.   
 
The michiganin A gene cluster does not possess close garTH homologues, but instead 
contains the clvFEG transporter genes thought to be involved in immunity.  However, 
there are putative ABC transporter genes in close proximity to the clv gene cluster that 
have not yet been studied in any detail.  Many lantibiotic gene clusters, for example that 
for nisin, encode transporter proteins (such as LanTH) for export of the lantibiotic and in 
some cases some immunity, and in addition a dedicated immunity transporter 
(LanFEG), providing high levels of immunity to the lantibiotic.   
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The most unusual gene within the actagardine cluster is garO, predicted to encode a 
monooxygenase enzyme that adds an oxygen moiety to the C-terminal 
methylanthionine bride of actagardine.  This gene is not essential for peptide 
production, and S. lividans TK24 clones expressing AG14∆garO produce readily 
detectable quantities of the novel compound DAA.  DAA has higher MICs against a 
number of pathogens indicating that the addition of an oxygen to the C-terminal methyl-
lanthionine bridge does increase antimicrobial potency (Boakes et al., 2009).  However, 
the lack of detectable oxidation of michiganin A, and the lack of potential 
monooxygenase genes in the clv and gna gene clusters, suggests that this modification 
is not crucial in an ecological setting. 
 
The AL02 cosmid (from A. liguriae) that encodes DAB production possesses close 
homologues of many of the genes found in the actagardine biosynthesis cluster, and 
they are likely to perform the same function in DAB biosynthesis.  Notable differences 
are the additional gene ligQ, and the absence of a garPBP homologue.  Unlike garPBP, 
ligQ is essential for wild-type levels of the heterologous production of DAB by S. 
lividans TK24 and is predicted to play a role in immunity of the producing organism to 
the lantibiotic. 
 
The biosynthetic gene clusters of actagardine and DAB are highly homologous, and 
share a significant amount of sequence identity that rapidly decreases outside of the 
predicted MGSs (Boakes et al., 2009).  The DAB cluster appears to contain a non-
functional LigO monooxygenase that is unable to oxidise the C-terminal methyl-
lanthionine bridge of the DAB peptide.  Computational analysis and comparison to 
GarO predicted a frame shift mutation towards the end of ligO that presumably 
abolished its function.  This is consistent with the results of (Boakes et al., 2010).  The 
DAB prepropeptide substrate, which differs by two amino acids to actagardine, is 
amenable to oxidation by GarO when expressed in a AG14∆garA mutant of A. 
garbadinensis, resulting in the production of a novel lantibiotic, actagardine B (Boakes 
et al., 2010). 
 
The DAB gene cluster, as mentioned, also contains the additional gene ligQ that 
encodes an ABC transporter that has no counterpart in the actagardine or michiganin A 
clusters.  It is hypothesised that this gene plays a role in immunity of the host to DAB in 
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a similar way to the presumed immunity transporter ClvFEG encoded by the michiganin 
A gene cluster.  While it cannot be directly implicated, GarPBP is a possible candidate 
for an immunity mechanism encoded by the actagardine cluster, if it has one at all.  If 
this is an immunity mechanism, then it has one clear distinction from LigQ - it is not 
essential for lantibiotic biosynthesis.   
 
BLAST searches using the GarA prepropeptide identified two actagardine homologs, 
ClvA and GnaA.  ClvA is the prepropeptide of michiganin A, a lantibiotic from the plant 
pathogen C. michiganensis, while GnaA is a thus far unidentified actagardine analogue 
encoded within the newly sequenced genomes of R. gnavus and B. hansenii 
(Holtsmark et al., 2006).  While the amino acid sequences of these peptides vary 
considerably, all still maintain an overall structure similar to actagardine.  The structure 
of the lantibiotic is key to its antimicrobial activity, perhaps more so than the amino acid 
sequence, since many peptide variants (of actagardine and mersacidin, for example) 
often retain reasonable levels of antimicrobial activity (Appleyard et al., 2009, Boakes et 
al., 2009).  The leader sequences of the lantibiotics are also very different, some 
missing motifs conserved in other members, and the leader sequences also vary in 
size, with the gnavucin leader sequence being significantly shorter than the others.  
These differences most likely reflect variation in the modification enzymes of the 
individual natural producers. 
 
Actagardine (and derivatives thereof) could potentially have a role in the clinical 
environment and the lantibiotic is currently being used as a scaffold for an antibiotic 
being developed by Novacta Biosystems.  It is therefore important to gain as much 
information as possible about the enzymes that are utilised in its biosynthesis, and the 
mechanism of regulation.  The actagardine “scaffold” has been identified in five real or 
putative lantibiotics produced by sometimes quite different biosynthetic gene clusters.  
This resembles in nature, if not extent, the lacticin 481 family of lantibiotics that has at 
least 16 members that vary in both the lantibiotic prepropeptide sequence, and gene 
cluster composition and arrangement (Dufour et al., 2007).  It is likely that we are yet to 
discover other actagardine homologs and actagardine-like gene clusters.  In the 
environment, the actagardine scaffold must have significant antimicrobial activity 
against a number of hosts for it to be made by such different microorganisms. 
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6.1 Future work - Shorter term: 
 
Complementation of deleted genes should be further pursued.  This would allow the 
unambiguous identification of genes essential for the biosynthesis of actagardine and 
DAB.  One potential host for these studies would be S. coelicolor M1146.  In this study 
S. coelicolor M1146 appeared able to produce Ala(0)-actagardine at much higher levels 
and at earlier time points than the host used in this study, S. lividans TK24.  The 
complemented genes should also be configured to be expressed from their native 
promoters to mimmick, as closely as possible, expression levels in the wild type strain.  
Analysis of agar plugs using MALDI-ToF spectroscopy could also be used to increase 
the sensitivity of detection of Ala(0)-actagardine and Ala(0)-DAB production, and hence 
complementation. 
 
To explore the actagardine homologs and their biosynthesis further, both the gnaA and 
clvA prepropeptides should be expressed in the S. lividans TK24 AG14∆garA clone 
using Novacta Biosystems‟ pAGvarX construct (Boakes et al., 2010, Boakes et al., 
2009).  These constructs could avoid the previous problems encountered using the 
ermE* promoter constructs and if expressed, could demonstrate the plasticity of the 
actagardine biosynthetic machinery.  Production of gnavucin by this method would 
demonstrate that the GnaA prepropeptide is a viable substrate for lantibiotic 
biosynthesis, and would result in the production of a novel lantibiotic peptide.  If this 
lantibiotic is produced, further experiments would be required to determine its 
antimicrobial activity and potential for clinical application.  Heterologous production of 
michiganin A and gnavucin could provide new insights into the specificity of a number 
of the actagardine biosynthetic enzymes, including GarO.  If the michiganin A or 
gnavucin peptide is oxidised, it would demonstrate the possibility of using the GarO 
monooxygenase as a general modification enzyme for actagardine-like lantibiotics with 
the prospect of improved antimicrobial activity. 
 
qRT-PCR analysis of the actagardine biosynthetic gene cluster could identify the 
relative expression levels of each gene in both the wild type, and a number of deletion 
constructs.  This work should be attempted in S. coelicolor M1146 mutants since the 
level of gar gene expression is likely to be higher, and to occur earlier in growth than in 
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S. lividans TK24.  This would clarify the role of each of the three regulators in the gene 
cluster, the GarRK two component regulatory system and GarR1, in both actagardine 
biosynthesis and immunity.  Similar experiments should be carried out with the DAB 
gene cluster, in particular to address the role of the essential LigQ. 
 
Deletions should also be made in the natural producers of all of the genes analysed in 
this study that did not appear to be necessary for actagardine biosynthesis.  The 
natural producer, where each biosynthetic protein has presumably evolved to perform a 
specific role in actagardine biosynthesis, may be less tolerant of gene deletions than 
the heterologous strain, where host-encoded functions might fortuitously compensate 
for deletions within the cluster.  This is key to understanding the role of genes such as 
garPBP, where there is no clear evidence to suggest that it is a functional component of 
actagardine biosynthesis.  Similarly, garTH should also be deleted in A. garbadinensis. 
 
6.2 Future work - longer term: 
 
The most novel gene in the actagardine biosynthesis cluster is GarO, and it should be 
studied in greater detail in the future.  This enzyme has the potential to increase the 
effectiveness of clinically useful lantibiotics.  The substrate specificity of this enzyme 
should be determined.  For example, is the enzyme limited to recognising the entire 
structure of actagardine, or can it use the (methyl) lanthionine bridges found in many 
other lantibiotics, such as michiganin A, as substrate.  The crystal structure of GarO 
should be determined, and its active site and binding pockets identified, thus aiding our 
understanding of how it functions and its ability to modify actagardine and DAB.  
Potentially, this information could lead to engineering of the enzyme, extending its 
substrate specificity, and potentially leading to improved therapeutic agents. 
 
Efforts should also be made to confirm, or otherwise, the role and mechanism of action 
of GarPBP.  If this enzyme is involved in immunity of A. garbadinensis to actagardine, it 
would be the first example of the direct involvement of a PBP in lantibiotic resistance.  If 
this is the case, the mechanism by which it exerts actagardine resistance should be 
studied in detail. 
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This study has identified three regulators that are all essential for biosynthesis of 
actagardine in S. lividans TK24.  It is essential to understand the role of each of these 
regulators as they do not fit any current model of lantibiotic regulation.  This would 
enable knowledge-based approaches to improve the level of actagardine production, 
which may be crucial for its commercial application.  
 
Further studies should also be made to confirm the mode of action of actagardine.  It 
has been suggested that the molecule is able to interact with Lipid II, but this has never 
been unambiguously established.  Understanding how actagardine binds to Lipid II 
could lead to knowledge-based optimisation of the lantibiotic.  The latter is particularly 
attractive given the ribosomal origin of lantibiotics, where prepropeptide variants can be 
generated quickly and economically by oligonucleotide synthesis. 
 
6.3 Final conclusions 
 
Actagardine and its gene cluster represent a new subgroup of lantibiotic molecules that 
have a number of defining features.  The structure of the lantibiotic is conserved in at 
least five different organisms, and may possibly be found elsewhere.  While the peptide 
structures are similar, the leader sequences that are attached to them vary markedly.  
Some of the gene clusters contain bespoke components, such as the ClvFEG 
transporter in the michiganin A gene cluster, and the LanO monooxygenase found in 
the actagardine and DAB clusters.  This study has identified and confirmed the minimal 
number of genes required to produce actagardine in a heterologous host.  It has also 
paved the way for further studies into the complex role some of the genes play in its 
biosynthesis and regulation.  The information gleaned in this study will hopefully be 
used to advance the field of actagardine research, and contribute to its use as a 
clinically useful antimicrobial agent. 
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